













































































Therapeutic  Foods  (RUTF),  to  be  also  applied  to  supplementary/complementary  feeding 
interventions. 
 






A  study  using  Linear  Programming  (LP)  designed  an  improved,  cheaper  formulation 







Based  on  a  literature  review  (28  randomized  controlled  trials  of  micronutrient 
supplementation; outcomes: increased survival and CD4 cell count, reduced viral load), 

















The  existing  evidence  for  determining  micronutrient  specifications  for  SMS‐RUTF 
posed some challenges for the development of manufacturing specifications. Twelve of 




The  proposed  set  of  methods  can  be  used  to  design  and  pre‐clinically  test 

















































































































































1.4.3  What  is the adherence to paediatric RUF  formulations when used  for older 
people?  78 
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Table  24  ‐  Micronutrient  composition  in  the  RCT  used  to  determine  SMS‐RUTFh 
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Institutional and  funding support  from: Valid  International  (via a DFID‐funded core grant 
from CONCERN). 
 
Personal:  last but not  least at all,  I also dedicate  this  thesis  to my  “life‐partner‐in‐crime” 





















In  Chapter  1,  I  present  the  background  to  this  thesis,  outlining  how  undernutrition  is  a 
current global public health issue. I also describe the evolution of the management of acute 
malnutrition, highlighting  lipid‐based, ready‐to‐use food (RUF) as a key  intervention within 
























In Chapter 7,  I collate the key  findings  from the  four studies  into a method  framework to 




The Appendices  contain other materials which are not  included  in  the main body of  the 
















included  a  six month  research  project  in Burundi,  and  consolidated during  four  years of 













of  Child Health  (UCL)  and WFP  under  the  supervision  of Dr  Andy  Seal, my  tutor  in  this 




responsibility:  the design  and production  set‐up of novel  ready‐to‐use  therapeutic  foods, 









Based on the work experience gained,  in 2006, with the support  from Valid  International, 
and  a  fund  available  from Concern World Wide,  I  conceived  the  scope of  this  thesis.  Its 
focus consists of  the development of methods  for  the design and pre‐testing of ready‐to‐
use foods to prevent and manage acute malnutrition.  
 
I  officially  enrolled  into  the UCL MPhil  programme  in November  2007  and  Prof  Tomkins 
accepted  to  become my  second  supervisor,  providing  important  guidance  on  the  latest 













The methodological approach and  the  results  in  the  fourth and  last  sub‐study,  looking at 
RUF  micronutrient  specifications,  when  requirements  are  not  available,  was  initially 











research  controlled  trial,  funded  by  the  Children  Investment  Foundation  Fund  (CIFF; 
London), looking at prevention of stunting in children under two years of age (n=150,000 in 
3.5 years will be enrolled  in the  intervention group only), and using  lipid‐based, ready‐to‐
use  complementary  foods.  The  trial  outcomes  will  shape  future  policies  in  stunting 
prevention.  Furthermore,  in  collaboration  with  other  international  agencies,  academic 

























It  is an exciting  time  to work and  research  in  the area of malnutrition.  In a  recent policy 
paper,  the WFP  suggests  that  “recent    years    have    seen    rapidly    growing    interest    in  
nutrition,   galvanized   by The Lancet   medical    journal’s   2008   series,   which describe the 






Malnutrition  is a general term, which  includes different  forms of both undernutrition and 





During  the  last  decades,  the  classifications  of  malnutrition  and  its  sub‐forms  evolved  
through  a  large  number  of  definitions7–9.  In  this  thesis,  these  are mostly  based  on  the 






The  HTP  defines  undernutrition  as  “an  insufficient  intake  of  energy,  protein  or 
micronutrients  that  in  turn  leads  to  nutritional  deficiency.  Undernutrition  encompasses 
stunting, wasting and micronutrient deficiencies”. When present, this form of malnutrition 
“weakens  the  immune  system    and  increases    the    risk    and  severity    of  infections”3. 
Overnutrition  is  defined  as  “abnormal  or  excessive  fat  accumulation  that  may  impair 
health”10. Undernutrition  is common  in  low‐income groups  in developing countries and  is 
strongly  associated with  poverty5. Many  low‐  and middle‐income  countries  are  facing  a 





































































Severe  ‐  Height‐for‐age Z‐score: < ‐3 SD  ‐  ‐ 
Moderate  ‐  Height‐for‐age Z‐score: <‐2 SD to ≥‐3 SD  ‐  ‐ 
Underweight  Severe  ‐  Weight‐for‐age Z‐score: < ‐3 SD ‐ ‐















       
Overweight 
 
‐  ‐  BMI‐for‐age Z‐score: >+1SD to  < +2SD BMI‐for‐age Z‐score: >+1SD to  < +2SD BMI: >25  to <30 kg/m2












referred  to  as  sub‐forms.  In  Table  1,  these  are  classified 
separately.  However, malnourished  people  can  also  present  





Clinical  forms  of  acute malnutrition  can  be  defined  by  the 




Marasmus  is  a  form  of  severe  undernutrition,  referred  to 
alternatively  as  non‐oedematous  malnutrition.  The 
Wellcome  Classification  associated  marasmus  with 






to  as  oedematous  malnutrition.  Kwashiorkor  is 
associated with  growth  failure  (when  compared with 
healthy children) and characterised by oedema,  loss of 
appetite, thin, sparse or discoloured hair and skin with 
discoloured  patches  that  may  crack  and  peel. 
Kwashiorkor  is  associated  with  a  pitting  oedema 
affecting both sides of  the body  (bilateral)  (see Figure 
2).  Oedema  is  defined  by  the  HTP  as  “swelling  from 
excessive  accumulation  of  watery  fluid  in  cells,  or 
tissues”.  
 
Marasmic kwashiorkor  is a  form of  severe undernutrition diagnosed by  the presence of 
Box  1  –  Use  of  Z‐scores  in 
nutritional indices 







measurement  is  from  the 
median,  or  the  average  in  a 
healthy  population.  In  2006, 
WHO    released    growth    curves  
aiming   to   set   an    international  
standard    of    how  children 
“should  grow  when  free  of 
disease,  and  when  their  care 
follows healthy practices such as  




score,  another  index  calculated 
for  an  individual,  indicates  how 
many  standard  deviation  units 
an individual’s BMI value is away 
from  the  median  for  the  same 
age  in  the  WHO  standards481. 
The  index  can  be  positive  or 
negative.  If  positive,  the  index 
suggests  that  the  BMI  is  higher 
than  the  median  value  of  an 
individual of the same age in the 
WHO  reference.  If negative,  the 








if  a  child’s  Z‐score  falls  outside 
(>+2  or  <‐2),  this  signals  a 










Risk  of  short‐term  death  is  assessed  by  the  circumference  of  the  left middle  upper  arm 
(MUAC)1415, whereas nutritional  indices referring to Z‐scores (explained  in Box 1) are more 
indicated  to define  the anthropometry of children presenting moderate  (MAM) or severe 













Children  of  the  same  age,  affected  by 
MAM,  are  identified  by  weight‐for‐













In children and adolescents  (5  to 19 years of age), SAM  is defined  respectively by a body 









However,  in  emergency‐settings,  the  diagnostic  criteria  suggested  by  Collins  et  al.  16  are 
different.  In  these  contexts,  wasted  adults  of  both  genders  should  be  admitted  to 
therapeutic  feeding  programmes  when:  their  MUAC  is  below  160  mm,  irrespective  of 
clinical signs; or their MUAC is between 161 and 185 mm in association either with bilateral 
pitting oedema, or with  inability to stand, or with apparent dehydration. According to the 













It  is  commonly  accepted5  that,  after  24 months  from  birth,  this  condition may  become 
irreversible,  and  is  likely  to  lead  to  stunted  adults with  reduced  physical  and  cognitive 
capacity.  However,  some  recent  evidence  suggest  that  stunting  is  not  an  irreversible 
condition. Prentice et al.  17  looked at early growth patterns  in children  from 54  resource‐
poor countries in Africa and Southeast Asia, and concluded that substantial height catch‐up 
occurs  between  24  months  and  midchildhood,  and  again  between  midchildhood  and 
adulthood, even in the absence of any interventions. More evidence is urgently needed.  
 
Height‐for‐age  is  the  index  used  to  identify  stunting. Moderate  stunting  is  defined  by  a 
























The  latter  are  associated with  the  loss  of  appetite20,21, which may  also  contribute  to  a 
reduction of food intake.  
 
Severe  acute malnutrition  is  an  important  risk  factor  for mortality  among  HIV‐infected 
children  living  in  resource‐limited  settings22.  Complications  like  electrolyte  disorders, 
micronutrient  deficiencies,  and  severe  infections  are  often  associated  with  SAM  in  HIV 
positive children22. 
 




However,  no  international  agreement was  found  about  BMI  or MUAC  cut‐offs  to  define 








When  treatment  is  available,  ART  side  effects  may  be  worse  in  malnourished  than  in 
individuals, who are normal from the nutrition status point of view.  This may be because of 
the documented toxicity of ART27. The  latter may affect their quality of  life and their  long‐








while  reducing  absorption  of  specific  nutrients  and  increasing,  as  a  consequence,  their 
intake  requirements5.  Poor  growth  in  under‐fives  results  not  only  from  a  deficiency  of 
protein and energy, but also  from an  inadequate  intake of vital minerals, and vitamins9,28. 
The standards for micronutrients dietary requirements according to sex and age‐group are 
available  from  the  US  Institute  of  Medicine,  the  WHO,  the  FAO,  and  the  European 





documented  for  years,  especially  in  refugee  camps  where  they  were  most  frequently 
assessed.  For  these  specific  contexts,  the  authors  suggest  methods  to  monitor  the 


















age  reference  for  children, with  less  than  five years,  for  the diagnosis of overweight and 
obesity were  set as  the 97th and  the 99th per centile,  respectively. For  those aged  five  to 
nineteen years, overweight  is defined as a BMI‐for‐age value over +1 SD and obesity as a 
BMI‐for‐age value equal to or over +2 SD. Adults, whose BMI is greater than or equal to 25 
kg/m2, are considered overweight, while  if their BMI  is at  least equivalent to 30, they are 
considered obese10. 
 




last  two decades,  for  instance, UNICEF  reports  that,  in developing  countries,  the  relative 
reduction  of  stunting was  28  per  cent.  However,  due  to  population  growth,  the  overall 







and  consequences  of  these  problems  for  human  and  economic  development”.  This was 
already  reflected  in universal  recent policies  such  as  the Millennium Development Goals 









sector. The  initiative called Scaling Up Nutrition,  is currently engaged  in  raising an annual 




hungry  and  undernourished  people  in  the world.  About  1  billion    are    undernourished,  
while  2  billion  suffer  from  micronutrient  deficiencies”3. Among  children  under  5,  127  
million   are   underweight41 and   56   million   suffer    from wasting1.   WFP reports also that 
“the 195 million stunted children are at higher risk of mortality and of suffering irreversible, 





In  2008,  in  a  special  issue  of  the medical  journal  The  Lancet,  Black  et  al.  1  confirm  the 
dramatic size of undernutrition and the related consequences. The data were based on 388 
national surveys from 139 countries1. The global prevalence of underweight, stunting, and 
wasting  among  children  below  5  years  of  age,  were  based  on  the WHO  Child  Growth 
Standards released in 2006. Of the 556 million children under 5 years of age in low‐income 





underlying  cause of  3.5 million deaths  every  year, 35 per  cent of  the disease  burden  in 
children younger than 5 years and 11 per cent of  total global disability‐adjusted  life‐years 
(DALY)1. The DALY is a measure of overall disease burden, expressed as the number of years 














Human  immunodeficiency  virus  contributes  to  increase mortality  among undernourished 
children. A systematic review and meta‐analysis43 explored HIV prevalence and mortality in 
children undergoing treatment for SAM in sub‐Saharan Africa. In this study, among children 





Sub‐Saharan Africa,  in  spite of  the  increasing access  to ART. Uthman et al.  44  report  that 
demographic and health surveys from 11 sub‐Saharan African countries estimated that 10.3 
per  cent  of  HIV  infected  women  (aged  15‐49  years)  had  BMI  lower  than  18.5  kg/m2. 













1.1.2.2 Prevalence of undernutrition  in presence of overnutrition:  the 
double burden effect 





The same WHO document  reports  that many  low‐ and middle‐income countries are now 
facing  a  "double  burden" of disease.  Infections  and undernutrition  co‐exist with  a  rapid 
upsurge  in  “non‐communicable  disease  risk  factors”,  as  obesity  and  overweight  are 
currently called. Initially, this seemed particularly true in urban settings10. However, recent 
evidence  shows  that  rural  areas  are  also  increasingly  affected52.  Therefore,  finding 
undernutrition  and  obesity  existing  side‐by‐side  within  the  same  country,  the  same 
community, and the same household has become less uncommon.  
 
















of undernutrition as a “graded process of  increasing  levels of  intervention”. These  include 
“improving  energy  and  nutrient  intake  from  ordinary  foods;  fortifying  the  energy  and 
nutrient  intake  of  food  and  other  forms  of  supplementation;  enteral  nutrition;  and 
parenteral nutrition”. These approaches are routinely applied in high‐resources settings.  
 
Undernutrition  tends  to  be  more  common  in  low‐resources  settings.  But  here,  its 
management  is  often more  challenging.  For  this  reason,  food‐based  programmes  were 









a  flow  chart  to help policy makers  and donors  in  taking more  informed decisions  about 
programmes and choice of  food‐products. The  flow chart, available  in Figure 4, describes 
how  the  “non‐emergency/development”  and  “chronic  emergency”  contexts  rely  on 
programs  using  food  “primarily  for  explicit  nutritional”  or  “non‐nutritional  purposes”. 
Emergency  contexts  may  require  general  or  selective  distribution  according  to  local 
availability of food aid items, wasting prevalence, timing issues and logistic constraints. 
 

















Prevention of Stunting / Wasting
Prevention of Stunting




Children U5: CSB+ oil or RUSF
PLW, Children 6-24months: CSB+ or RUSF
Children 6-24 months: CSB+ oil or RUSF
PLW: CSB+ or RUSF (for 6 months post-birth)
Household: Grain, Oil, and Pulse (protective ration)
Adults and children: CSB+ oil or RUSF or RUTF
PLW and Children U5 (<-2 SD): CSB+ oil or RUSF
Children U5: CSB+ oil or RUSF











Pay in the context
 of deficiency
Oil + Pulse + Grain (amount based on prevailing wage rates)
Options:
(1) Oil + Pulse + SFG/SFB/SFCM; (2) Oil + Pulse + Fortified flour/meal






(1) Oil + Pulse + SFG/SFB/SFCM; (2) Oil + Pulse + Fortified flour/meal;
(3) Oil + Pulse + Grain + MNP







Options: (1) take home: Grain or Oil;
(2) On-site: HEB or Oil + Pulse + Grain
Options: (1) HEB; (2) Oil + Pulse + SFG/SFB/SFCM;
(3) Oil + Pulse + Fortified Cereal; (4) Oil + Pulse + Grain + MNP














no Grain, Oil, Pulse, HF and (1) CSB + Oil, or (2) RUSF for U2s
Grain, SFG/SFB/SFCM, Oil, Pulse, and
(1) CSB + Oil, or (2) RUSF for U2s
Fortified flour/meal, Oil, Pulse, and
(1) CSB + Oil, or (2) RUSF for U2s
Prevalence of wasting:
(<-2 SD) > 15% or 10-14% with aggravating factors
Prevalence of wasting:
(-3/-2 SD) >?* (screened adults or children)
Prevalence of wasting:














CSB + Oil or RUSF














on  the  availability  of  food  products  and  prevailing  nutrition  situation  (general  food 
distribution and selective feeding).  
 
The choice of the food‐items  is relatively  large, and  includes processed and non‐processed 
commodities. The programmes designed with explicit nutritional purposes (Figure 4) mainly 




first  fortified with micronutrients,  then  cooked  into  a  porridge.  The  second  category  of 
products includes “safe, palatable foods with a high energy content and adequate amounts 
of vitamins and minerals”55. Therefore,  it can be argued that the convenience  in the  latter 
group may often be higher than in the former. 
 
For  this  reason,  some  of  them  are  increasingly  used  in  therapeutic,  or  supplementary 
feeding  programmes.  The  following  sections  of  this  thesis  explore  in  detail  their 
importance.  However,  the  current  methods  and  protocols  stand  on  the  shoulders  of 
previous pioneering research and their applications,  including their successes and failures. 












Figure  6  ‐  The  first 







The  original  captions  of 
photo  (a)  and  (b)  report 





Undernutrition  is  as  old  as  history  itself.  Its  descriptions  fill  an 
undocumented number of pages  in  the  literature of mankind. And 
yet,  in  the  era  of  modern  medicine,  its  management  has  had  a 
relatively short, but interesting evolution.  
 
The  Jamaican  paediatrician  Cecily 
Williams  is probably among the first ones 
to  describe,  in  a  peer‐reviewed  journal 




“There  is  a  well‐marked  syndrome,  not  uncommonly  found 
among  the  children  of  the Gold  Coast  Colony  (Ghana), which  I 
have not found described. 
 



















Two  years  later,  from  the  pages  of  The  Lancet  journal,  Williams  names  this  disease 
“kwashiorkor”.  In the Ga  language, coastal Ghana, the term means "the sickness the baby 
gets  when  the  new  baby  comes".  From  the  perspective  of  the  local  population,  the 
















described Kwashiorkor  in Africa, which was also  found  later  (1954)  in Latin America60. But 
already  in 1950, Keys described  the  link between  the disappearance of  famines with  the 





“attributable  principally  to  dietary  deficiencies  and  therefore  it  could  be  prevented  or 














1959  “the  dark  ages”.  In  that  year,  for  the  first  time,  Scrimshaw,  Taylor  and  Gordon63 
describe  the  “powerful  pathway”  of  “the  cyclical  interactions  between malnutrition  and 
infection”.  This  consisted  of  a  “cycle  of  malnutrition‐infection,  more  nutritional 
deterioration‐more  infection”58.  From  this  perspective,  improving  nutritional  intake  was 
insufficient to fully reverse this cycle. That was due to the presence of repeated exposure to 
infections,  highly  prevalent  in  developing  countries.    Keusch  highlights  how  only  then  it 





































































































































for  the  recognition  that,  in SAM,  child  recovery based on  large protein  intakes  remained 








abnormal  insulin  secretion86–88.  While  the  causes  remained  undisclosed,  the  wording 





from  high‐protein,  high‐energy  feeding  interventions  around  the world,  found  that  “the 




In  a  personal  communication  (September,  2012),  Tomkins  suggested  that  at  that  time, 




However,  the disillusion about  the poor  results, derived  from  the PEM approach,  led  the 
decision  makers  to  focus  on  two  aspects:  the  clinical  aetiology  as  primary  cause  of 
malnutrition,  reinforcing  the  role  of  the  infections,  and  the  theory  that  “mothers  are 
ignorant and that education is the main intervention required”9.  
 



















was  found  to  be  “particularly  disturbed  with  livery  dysfunction  during  the  metabolic 
response to  infections”65, but, most of all, by the deficiency of certain essential nutrients9. 














merged  into  the  theory of “type  I and  II nutrients”. This  theory,  formulated, systematized 












The theory proposed by Golden suggests that nutrients called type  I  (see their  list  in  foot 
note number1) are “needed for particular biochemical functions  in the body”28. Deficiency 
of these nutrients does not generally  lead to growth  failure28. On the other hand, “type  II 
nutrients (foot note2) are likely to become limiting in the diet before the protein”9.  “If the 
diet  is poor,  then when weight  is  lost  from an  infection,  there will be  insufficient  type  II 
nutrient density  to  allow  for  catch‐up  growth during  convalescence”9. The  resurgence of 
appetite is an indicator that the type II nutrient balance has been re‐established. 
 
The  theory was  soon  applied.  In  1989,  the  type  I  and  II  nutrients  theory was  behind  a 








1  Namely:  calcium,  iron,  copper,  selenium,  iodine,  vitamin  B1,  B2,  B12,  C,  E,  A,  and  K,  niacin, 











functionality  of  the  metabolism,  resulting  in  the  re‐appearance  of  appetite.  Once  the 











“it  can  be  used  exclusively  in    health    facilities    to    prevent   misuse”9.  Because  of  this 
reasons,  the  life of  large numbers of starving people,  living  far  from clinic  facilities, could 
not be  saved. Golden  recognizes  that  “in many  settings  it  is not possible  for mothers  to 
leave  their  families  for  extended  periods,  or  to  travel  long  distances”9.  Other  authors62 
suggested  that  “this was  especially    the    case    in    open    situations    amongst  dispersed  
communities    living    in    chronic    poverty, where    often    specialized    inpatient    feeding  
centres were not accessible. In their absence, children had to be  referred  to  overcrowded  
paediatric    or    general wards    ill‐equipped    to    give    adequate    care    to malnourished 




1996,  Schofield  and  Ashworth93  reported  that  “the median  case  fatality  from  SAM  has 
remained unchanged” (20 to 30 per cent), “with the highest levels (50 to 60 per cent) being 






is  not maintained  in  function,  and  the  hygienic  conditions  are  limited  by  overcrowded 
wards.  The  same  authors  conclude  that,  in  such  contexts,  rigorously  implementing  the 
WHO 1999 protocol proved to be challenging93. 
 







home,  whenever  there  was  no medical  complication. Mobile  clinics  provided  a  weekly 
medical  check‐up  for  the  child,  and  supplied  the  mother  with  RUTF,  counselling  and 




vitamins  and  minerals.  The  brand  name  of  the  first  RUTF  was  Plumpy’Nut,  and  was 
produced  initially  in France by  the manufacturer of F100, called Nutriset. Since  then,  the 




The evidence behind RUTF effectiveness was  robust.  In 2003,  in  a RCT  conducted under 
strict  direct  observation  in  a  Senegalese  health  facility71,  children  with  SAM  showed  a 
significantly higher daily energy intake, faster weight gain, and a shorter treatment duration 











Malnutrition”  (CMAM)55.  In  the  following years, CMAM becomes a mainstream activity  in 





agencies  and  25  national  governments  had  formally  adopted  this  new model”.  In  2010, 
“approximately one million cases of SAM were treated annually, with programs expanding 










The  previous  and  the  new models  to  treat  acute malnutrition  are  complementary.  The 
previously  described  model  to  treat  SAM,  based  on  F75/F100,  becomes  one  of  the 
components of the new model (CMAM), which  includes also the use of RUTF. The criteria 
based on medical complications and appetite determine the admission to one of the two 
programme  approaches.  Children  with  medical  complications  and  little  appetite  are 
referred  to  in‐patient  programmes97  which  follow  the  WHO  1999  protocol  and  where 
therapeutic  formula  milks  are  used.  With  the  successful  treatment  of  the  medical 
complications, and the return of their appetite, children are discharged from the in‐patient 













performance,  and  in  this  new  phase  of  the  management  of  SAM,  the  concept  of 
programme  coverage  received  emphasis  like  never  before.  The  Sphere  Project99  defines 
coverage  as  the  number  of  “individuals  who  need  treatment,  against  those  actually 
receiving    treatment”.  Coverage  can  be  affected  by  the  “location  and  accessibility  of 
programme sites”.  In  the current guidelines  for  feeding programmes coverage  is expected  







In  2007,  a  study  in Malawi72,  comparing  two  interventions,  the  first  based  on  F75/F100 




In  the  first map  (Mchinji district),  the protocol  to manage  SAM was based on WHO 1999.  In  the  second map  (Dowa 
district), the protocol was based on Community‐based Management of Acute Malnutrition 2007 guidelines. The “x” and 





“enabled  higher  impact  on  severe malnutrition  in  this  population”.  The  first  programme 
reported 24.5 per  cent and  the  second 73.6 per  cent of  the  children  in need enrolled  in 
each  of  the  two  programmes.  Figure  7  compares  the  differences  between  the  spatial 
distributions of coverage for the two programmes. 
 
In  the  following  year,  further  evidence  confirmed  the  efficacy,  the  safety  and  the  cost‐




and default  in  treatment with RUTF were 88.3, 0.7 and 3.6 per  cent,  respectively with a 
mean weight gain of 3.2 g/kg/day.  In Lusaka, Bachman102 found that the use of RUTF  in a 
“Community‐based Therapeutic Care  for SAM appears highly  cost effective”. The primary 





western  Africa,  MSF  tentatively  extended  the  use  of  RUF  to  moderately  malnourished 
children.  The  intervertion  reported high  cure  and  low default  rates,  compared  to  results 
typically  obtained  with  the  standard  treatment  of moderate malnutrition  with  fortified 
blended  flours103,104. The use of RUTF  for moderately malnourished children  flattened  the 
typical seasonal rise of admissions in SAM feeding interventions.  
 
Cost  is often a  limiting  factor  in humanitarian  interventions based on  selective  targeting. 
This  is  because  the  latter  is  more  resources  intensive.  Blanket  supplementary  feeding 






product,  and  “the  incidence  of  severe  acute malnutrition  (MUAC<110 mm)  remained  at 
















The  latter  issue was  supported  by  little  evidence.  The  following  year,  in  the Democratic 
Republic of Congo, one RCT study106 assessed “the breast‐milk  intake of 9 to 10 month old 
infants given either a  ready‐to‐use complementary  food  (RUCF) paste or a standard corn‐
soy blend porridge” commonly used  in  the complementary  feeding phase. The  technique 
used was based on  a  “deuterium‐dose‐to‐the‐mother dilution”. No  differences  in breast‐
milk  intake were  observed 
between  infants 
consuming  either  RUCF  or 
the porridge. A second RCT 
study107,  in  rural  Malawi, 
found  similar  results.  In 




























At  the  end  of  the  first  decade  of  the  third millennium,  the  use  of  RUTF  is  increasing 
exponentially (Figure 8). At the same time, this and novel formulations are being tested for 
the treatment of other  forms of malnutrition. This section describes the scaling‐up of the 
demand of RUF  and  summarizes which other  forms of malnutrition RUF  are  increasingly 
used for. 
 In  2009,  Ashworth  and  Ferguson110  reported  that  beside  MSF,  the  NGO  GOAL  also 
















has not been  able  to  keep pace with  rising demand”  (Figure  8).  In  2010,  Yach  et al.  120 
confirmed  that global  “demand  for a high‐quality,  safe, and nutritious RUTF  is not being 
met”. 
In 2008, UNICEF  released one of  its  first call of proposals  for “sustainable and affordable 
supply” of RUTF for the years 2008 to 2010121. The document solicits 20,000 metric tonnes, 
and  reports  that  “RUTF  is  considered  to  be  a  key  tool  to  achieve  the  Millennium 
Development  Goals  (MDGs)”.  Interestingly,  the  solicited  forecasted  procurement  was 
limited to only twenty‐two per cent of the countries where SAM was reported (data from 
UNICEF  (2012)41), probably on  the basis of priority  ranking  versus  their  SAM prevalence 
rates (see Table 5).  
 
Ready‐to‐use  therapeutic  food  spreads were  used  to  treat  and  prevent  other  forms  of 
malnutrition, for example wasting associated to HIV and/or TB  infections. In this case, the 
results were  conflicting.  This  type  of wasting,  an  example  of  secondary malnutrition,  is 
challenging  to  treat,  because  has  “clinical  characteristics  and  implications  for  treatment 
different from those better known in primary malnutrition”. To what extent this is true is an 








a  control  group122–126.  For  this  reason,  their  evidence  is  less  robust.  Few  other  more 
convincing  trials125–128  and  a  recent  review  study129  supported,  evidence‐based,  the 
introduction of RUTF  into HIV programmes  for wasted adults.  In 2011,  treatment  for  the 
latter was reported to be available, at 23 per cent of the HIV treatment and care African 
programmes,  supported  by  the  President’s  Emergency  Plan  for  AIDS  Relief  (PEPFAR)130. 





mostly  in  the  form of paste and  trialled against a variety of  forms of undernutrition,  in a 
range of age‐groups, for supplementary and therapeutic purposes. 
 
Recently,  research  and  international  humanitarian  agencies  have  shifted  their  focus  to 
prevention and treatment of children affected by MAM. In a three‐arm RCT131, moderately 
wasted Malawian  children  (WHZ >‐3 and <‐2)  receiving a RUF based on  soy and peanut, 
called ready‐to‐use supplementary food (RUSF), which  is cheaper than RUTF, had a similar 
recovery rate to those receiving a fortified, more expensive RUSF. The  latter was based on 
soy  and milk. The  children  in either RUSF  group were more  likely  to  recover  than  those 
receiving porridge made from CSB. In 2008, in a UN conference on dietary management of 
MAM, Golden proposed nutrient  requirements  to  rehabilitate  children  from  this  form of 
malnutrition,  and  published  them  the  following  year  on  the  UN  Food  and  Nutrition 
Bulletin28.  
 
In  the  same  years,  in  Ghana,  a  placebo‐RCT132  tested  the  “hypothesis  that  multiple 
micronutrients added to home‐prepared complementary foods would increase growth and 
that  the  effect would  be  greatest  in  the  presence  of  added  energy  from  fat”.  The  three 
complementary  foods  were  a  micronutrient  powder  (brand:  Sprinkles),  a  crushable 
micronutrient tablet (Nutritabs), or a micronutrient fortified RUSF spread (Nutributter). All 












In  spite  of  their  increasing  importance,  RUF  classification  is  insufficiently  developed. 
Referring to RUF, USAID suggests that “the most significant change  in  food aid during the 
21st  century has been  the arrival of a new  family of products  in  the  form of  lipid‐based 
spreads”54.  WFP  also  argues  that  “the  development  of  RUF  have    revolutionized    the  
treatment  of  severe acute  malnutrition,  and  catalyzed  the  development  of other food‐
based  commodities  for  treating  and  preventing  less  severe  as  well  as  other  forms  of 
undernutrition”133.  In  spite  of  their  success,  a  general  classification,  internationally 






Although  not  internationally  accepted,  some  definitions were  proposed  for  lipid‐based, 
paste‐alike,  ready‐to‐use  foods. The  following sections  first  report  their definitions  in  the 














RUF  is  a  general  term.  Therefore, 
researchers  from  the  iLiNS  Project135 
suggested  the  term  lipid‐base  nutrient 
supplement (LNS), should be defined as 
“a  family  of  products  designed  to 
deliver nutrients  to vulnerable people”.  
Lipid‐based  supplements  provide  “a 
range  of  vitamins  and  minerals,  but 
unlike  most  other  multiple 
micronutrient supplements”,  because  energy,  protein,  and  essential  fatty  acids  are  also 




for  therapeutic nutrition  interventions, RUTF  is not  a  supplement, because  it  is used  for 
exclusive  feeding  until  recovery.  For  this  reason,  the  form  RUF  will  be  preferred  and 























Altered products  A  food  from  which  a  deleterious  component  has 
been  removed,  reduced  or  replaced  with  another 
substance with beneficial effects 
Fibres as  fat  releasers  in 
meat  or  ice  cream 
products 
Enhanced commodities  A  food  in which  one  of  the  components  has  been 
naturally  enhanced  through  special  growing 















RUF  could  also be  considered  close  to  a  functional  food  for other  reasons.  Sub‐types of 
functional  foods  also  include  “spreads”139.  However,  this  endorsed  category  currently 
consists  of  cholesterol‐lowering  products,  “containing  phytostanol  esters  which  are 
supposed  to  lower  cholesterol  level”139.  The  spreads  are  currently  commercialized  in  the 
form of margarines, milk, cheese, cream, and eggs139,140. For this reason, despite the existing 













is widely  used.  In  2009,  UNICEF  suggested  that  RUTF  are  “portable,  shelf‐stable,  single 
serving  foods  that  are  used  in  a  prescribed manner  to  treat  children with  severe  acute 
malnutrition”119. Among the most common RUTF brand names is Plumpy’Nut, produced by 
Nutriset  (http://www.nutriset.fr)  in France  initially, and currently  in ten other countries  in 
Africa,  Asia  and  America, 
including  the  US  (Figure  10). 
















Their  manufacturing  sites  include  Norway,  Denmark  but  also  Kenya,  Dubai,  India,  and 
Malaysia.   Other manufacturers  from  other  countries  are  listed  in  Table  7,  published  in 
2012. 
 
Another  example  of  RUTF  is  BP‐100,  produced  by  Compact,  and  more  similar  to  a 
“compressed  biscuit”  than  a  paste.  The World Bank  argues  that  its  “technology  is more 
difficult to re‐produce  in developing countries”40. A similar consideration  is also supported 
by  other  authors141,  and  the  available  literature  does  not  report  the  availability  of  this 
processing  technique  in  any  developing  countries.  However,  in  the  food  technology 
literature, no reference was found to confirm the World Bank statement. 
 
This  product  also  generated  considerations  of  a  different  nature.  In  2008,  WFP  was 
concerned with “the difficulty for the consumers to distinguish between nutritious and non‐
nutritious biscuits, and the possible promotion of a habit of biscuit consumption which may 
in  fact  lead  to  consumption  of  non‐nutritious,  high‐sugar,  biscuits”142.  Because  of  these 
reported reasons, BP‐100 will be not considered in the following sections of this thesis. 
 






meet  the  supplementary nutrient needs of  those who  are not  severely malnourished”119 
and that “growing demand for RUSF products might decrease global demand for RUTF”119. 




In  2012, Owino  et  al.  146  defined  a  ready‐to‐use  complementary  food  (RUCF)  as  a  paste 
“formulated to provide the recommended daily allowance of all micronutrients for 6 to 12 




Nutriset,  provided  significantly  less  daily  energy  than  RUTF  but  a  full  complement  of 
micronutrients in a similar group of children. The study showed that RUSF can prevent child 
stunting  and  support  their  normal  motor  development.  Another  study  reduced  iron 
deficiency in infants,  using the same product147. 
 
In Malawi,  similar products were  tested  in  three other  studies.  In a RCT148, a peanut/soy 
based  fortified spread was associated with higher weight gain  in  infants, when compared 
with  its control, a porridge fortified with fish powder. Another study149 randomized  infants 
to  receive  a  year‐long  dietary  supplementation with  ready‐to‐use  fortified  spread  or  a 
traditional micronutrient‐fortified maize‐soy  flour. The  results did not show a significantly 
larger  effect  than  the  control  on  mean  weight  gain.  However,  incidence  of  severe 
stunting was  tested  in  a  followup  study150  with  a  double  dose.  In  this  case,  the  study 
showed  that  a  twelve‐month‐long  complementary  feeding  with  50  g/d  of  the  same 
supplement was likely to have a positive and sustained impact. 
  
QBmix and Plumpy’soy are other  forms of RUCF, at  least according  to one of  the  leading 
manufacturers’  perspective.  From  its  website3,  Nutriset  define  them  suitable  for 
“prevention of nutritional deficiencies”.  QBmix is currently trialled in few studies, whereas 
Plumpy’soy used  in pregnant women  resulted  in higher birth  length  than did  a prenatal, 
multiple micronutrient, tablet‐based supplementation151. 
 
In  the  literature,  a  number  of  acronyms  and  names were  found  for  RUF  products.  The 
following section fixes the nomenclature used in this thesis. 
1.3.1.5 Proposed nomenclature 




• RUSF    =  ready‐to‐use SUPPLEMENTARY  food –  for MAM  in both  children and 
adults 






















most RUF. Therefore, only  the other  food  ingredients are  to be  indicated. 






For  instance  the  acronym  for  a  theoretical  RUF, whose  formulation  addresses moderate 
malnutrition in children under five years and living with HIV, and whose ingredients include 





















500‐1,000  Kcal/d,  total  lipids  (45‐60  per 
cent),  protein  contents  (10‐12  per  cent 
per cent of their contribution to the total 
energy),  and essential  fatty acids  such as 
omega‐6 (3 to 10 per cent of total energy) 
and omega‐3  (0.3 to 2.5 per cent of total 
energy).  In RUSF  the omega n‐6/n‐3  ratio 
should  be  below  15  and  preferably 
between  5  and  9153.  The  standards  for 
RUTF  are  reported  in  Table  8.  In  2012, 
WHO proposed  the  nutrient  composition 
of  supplementary  foods  for  use  in  the 
management  of  moderate  acute 
malnutrition  in children154, assuming  that 
the  supplementary  food  covers  70%  of 
their energy intake . 
 
In  2007,  a UN  Joint  Statement document  specified  23 micronutrients RUTF  standards of 
both type I and II,  in the form of range, or of minimum amount.  In 2009, Golden28 argued 
that  an  improved  way  to  describe  the  standards  for  RUSF  consists  of  nutrient/energy 
densities, expressed as unit of each nutrient in 1,000 kcal of the product. 
 
Protein  quality  in  RUF  is  important.  This  parameter  is  recommended  by  WHO  to  be 
measured using  the protein digestibility‐corrected amino acid  score  (PDCAAS)155.  In RUTF 
for children under  five, “at  least half of  the proteins contained  in  the  foods should come 











calculations,  this  statement  corresponds  to  a  PDCAAS  of  at  least  100  per  cent156. More 




The  iLiNS project web  site  (http://www.ilins.org/; accessed 05/03/2012)  suggests  that RUF 
formulations “can  include a variety of 
ingredients,  but  typically  contain 
vegetable  fat,  peanut/groundnut 
paste,  milk  powder  and  sugar.”  This 
was  true  for  the  first  clinical  trial,  in 
2003,  undertaken  by  Diop  et  al.  71 
confirming  the  same  efficacy  in  weight  gain  for  both  RUTF  and  F100  formula  milk  in 
children with SAM. Since then, the  ingredients were replaced by others.  iLiNS reports that 
“alternative  recipes  and  formulations  are  currently 
being explored  in efforts  to develop  affordable  and 
culturally acceptable products for a range of settings. 
Other  ingredients  have  included whey,  soy  protein 
isolate,  and  sesame,  cashew,  and  chickpea  paste, 
among others”. 
 
Manary  reported  that RUF “production  sufficient  to 
meet the needs of several thousand children can be 
achieved  with  a  dedicated  manufacturing  facility 










using  technology  appropriate  for  use  in  the  developing  world”158.  The  processing 
technology and production sequence changes according to the ingredient choice. However, 





Most RUF are provided  to  the beneficiaries  in sachets or cups. The content of  the sachet 
can  be  squeezed  directly  into  the  child’s  mouth,  reducing  the  risk  of  environmental 
contamination  –  see  Figure  13.  In 
case of the cup, the content must be 
scooped,  and  the  risk  of 
contamination is higher. The form of 
packaging  is  crucial  for  the 
effectiveness  and  the  safety  of  the 
product.  Koethe  et  al.  129  reports 
that  “RUTFs,  like  other  highly 





maximum  levels  for aflatoxins and microorganisms  such as  coliforms,  clostridium, yeasts, 
moulds, pathogenic staphylococci, salmonella and listeria – see Table 9Table 9. RUTF should 
comply  with  the  Recommended  International  Code  of  Hygienic  Practice  for  Foods  for 
Infants  and  Children  of  the  Codex  Alimentarius  Standard  CAC/RCP  21‐1979  (available  at 
http://goo.gl/jp7Yg). While all added mineral salts and vitamins should be on the Advisory 
List of Mineral Salts and Vitamin Compounds  for Use  in Foods  for  Infants and Children of 
the Codex Alimentarius Standard CAC/GL 10‐1979 (available at http://goo.gl/5RDsE).  
1.3.3 Institutions and organizations with interest in ready‐to‐use foods 
RUF  are  a  fundamental  element  in  feeding  programmes  supported by UN  agencies,  non 
governmental organizations (NGOs) and by an increasing number of national governments.  
 






advocacy,  supply  and  logistic  support  to  other  governmental  and  non  governmental 
institutions and organizations involved in therapeutic feeding for uncomplicated children in 
community settings160. UNICEF is “the leading global procurer of RUTF”119. UNICEF Country 
Offices  identify  the  needs  and  obtain  funding  for  RUTF.  A  purchase  order  is  processed 




of  this  thesis  reported  the exponential  increase of UNICEF demand  for RUTF  since 2007. 
Similarly, WFP, another UN agency,  is  constantly augmenting  its procurement of RUSF.  In 
2012, the WFP Executive Board  released the Nutrition Policy  Item number 53, which puts 
the  three  following priorities  at  the  very  top of  its  agenda:  (i)    treating moderate  acute 
malnutrition  (wasting);    (ii)    preventing  acute  malnutrition  (wasting);    (iii)    preventing 













national  governments.  In  these  partnerships, NGO  receive  and  deliver  the  RUF  through 









Figure  15  ‐  Logos  of  the  academic  institutions, 





The  President’s  Emergency  Plan  for 
AIDS  Relief  provides  nutritional 
support  services  in  HIV  care  in  sub‐
Saharan  African  countries.  In  2011, 
Anema et al.  130  found  that  in a  total 





African, American and European academic  institutions and one manufacturer  interested  in 
the  development  and  improvement  of  RUF  spreads.   International  Lipid‐Based  Nutrient 
Supplements  (iLiNS)  Project is  a  “research  collaboration  that  grew  out  of  a  shared 
commitment  to  accelerate  progress  in  preventing  malnutrition”.  This  academic‐private 
sector  partnership,  based  at University  of  California  /  Davis,  includes  the  universities  of 




The  Irish University of Cork has  recently engaged on a  research  looking at  the  impact on 









of the patent.  In 2009, MSF wrote an open  letter “calling  for the establishment of a more 














These  MoH  have  showed  a  wide  range  of  responses  towards  the  introduction  of  RUF 
products. In some cases they endorsed directly the latter into their policies and nutritional 
protocols, whereas in others, they took more evidence‐based approaches. The two extreme 
cases may be  represented by  the  recent events  in Kenya and  India,  two  countries whose 




the  MoH.  Since  RUTF  was  endorsed  by  the  UN  in  2007,  the  demand  for  RUTF  by 
humanitarian organizations  in East Africa has  far exceeded  the  available  supply.  In 2012, 
USAID reported54 that “too few regional businesses are willing to tackle the challenges that 
RUTF  manufacturing  presents”.  Insta  Products  is  one  of  them.  This  Kenyan  processing 
factory  located  in the outskirts of Nairobi since 2009, supplies an average of 4,500 metric 




national  prevalence,  1,200,000  infected  Kenyans  and  50  per  cent  of  the  population  are 
living  in  food  insecurity  (data  from 2005)166. The Government  soon became aware of  the 
benefits  that,  via  Insta,  a  public‐private  collaboration  could  provide  to  the  health  of  its 
citizens. Since 2010, with the support of USAID, the local MoH has included RUF in the HIV‐
related  services  package,  for  in‐  and  out‐patient  hospital  care. One  of  the  pillars  of  the 
programme  is  a  private‐public  partnership  that  includes  capacity  building within  Kenya's 
Ministries such as Medical Services, Public Health and Sanitation, as well as with grass‐root 
organizations167.  In  the  protocol  endorsed  by  the  government,  RUTF  is  “prescribed”  in 




programme  includes  155  primary  health  sites,  which  facilitate  support  to  261  satellite 
health facilities. By June 2010, the HIV nutrition program reached a total of 171,281 clients, 





this  country,  is  extremely  large. More  than  eight  hundred  thousands  under‐five  Indian 
children suffer from severe acute malnutrition168. For decades Indian hospitals have treated 





Indian  states, apparently without  the  authorization  from  the  local  authorities. Therefore, 
the national government stated that these supplies were to be sent out of the country. The 





This debate was only  started  in  two  Indian  states, but  soon  it became a  concern  for  the 
entire  country.  In  2009,  the  MoH  organized  a  “National  Consensus  Workshop  on 
Management of Children with SAM  through Medical Nutrition Therapy”. On this occasion, 




Less  than a year  later,  the  journal  Indian Paediatrics  (volume 47, number 8) published an 
issue with nine original papers written mostly by  Indian  authors. Based on  the  available 
evidence, the papers supported the endorsement of RUTF, and urged the  improvement of 
the existing guidelines. Their evidence‐based conclusions are expected to contribute, in the 






Some  of  these  articles  critically  looked  at  the African  experience.  Three  papers  included 
systematic and narrative reviews of the efficacy, the safety and the coverage of RUTF‐based 
interventions in Africa9,62,101. The same journal issue looked also at what was done in India. 
Two  studies171,172 evaluated  the  feasibility and  the outcome of home‐ and hospital‐based 
rehabilitation of severely malnourished children without using RUTF or F100, but using local 
Indian dietary prescriptions. Both studies showed that the recovery rate in the children was 
suboptimal.  A  third  study,  describing  a  randomized  controlled  trial,  assessed  the 
effectiveness  of  a  locally  made  therapeutic  spread  in  decreasing  mild  to  moderate 
malnutrition. The authors report that “the RUTF was prepared at a local bakery and packed 












models  already  tested  in  India:    (i) dairy  cooperatives  and private manufacturers  able  to 
produce  large  quantities  to  meet  regional  requirements,  (ii)  small  and  niche  food 
manufacturers producing smaller volumes, but with a larger presence in most parts of India; 





A  paper  titling  “Management  of  Children  with  Severe  Acute  Malnutrition:  A  National 
Priority”173  closed  the  Journal  issue. One  of  its  sections  reports  that  in  India  “there    is  












new  target groups. This seems  to be confirmed by  the number and  the pace of evidence 
published in the last few years. Only a sample is reported here. 
 
In  2009,  Chaparro  and  Dewey174  suggest  that,  in  large  general  food  distributions,  RUF 
spreads may have more potential to reach children under two and pregnant and  lactating 
mothers,  than other  food commodities, however, more evidence  is needed.  In 2012,  in a 
factorial  randomized  trial,  RUF  spread was  showed  to mitigate weight  loss  among  HIV‐

















gain. The  latter may not be  ideal when  leading  to a  rapid  increase  in  fat rather  than  lean 
body mass, and negative,  long term, health consequences.   Moreover,    in   other   settings,  
with   different   underlying   nutrient   deficiencies   and  infectious disease profiles,   similar  
weight  gains would perhaps occur with nutrient levels  different  from  those in use95,176–178. 






The  peanut‐based  of  Ready‐to‐Use  Therapeutic  Food  was  not  a  formulation  optimized, 




Therefore,  a  validated method  to  design  and  trial  novel  optimized  RUF  is  currently  not 
available. This was officially recognised only in 2008, during the conference which approved 
the use of RUSF spread to prevent and/or treat MAM28,153. UN, NGO and academic bodies 
expressed  the  need  for  an  evidence‐based method  to  test  and  validate  novel  improved 













therapeutic  feeding  programmes  includes  milk  powder  and  peanut  butter.  These  two 
ingredients  seemed  to  be  among  the  causes  of  a  low  level  of  acceptability  among 
beneficiaries  in  Cambodia,  as  reported  by  MSF180.  A  qualitative  socio‐anthropological 
investigation, conducted by Boudier, from the French Institute of Research for Development 
(IRD) explored this aspect181. A traditionally accepted ingredient (fish sauce) was introduced 
into  the  formulation,  and  its preference  assessed  in  a  trial with  a  simple design  180.  The 













In Malawi,  similar  conclusions  from  an  acceptability  study had  a negative  impact on  the 
subsequent RCT. Fellows (personal communication; 2008) reports that an initial pilot study, 
with no control for comparison, that tested the preference for an improved RUTF in wasted 
children,  showed  high  acceptability,  among    children  and  caretakers,  after  one  day  of 
testing.  Chickpeas  and  sesame  were  among  the  ingredients.  The  RCT  was  therefore 
initiated.  However,  the  randomized  delivery  of  the  improved  RUTF  had  to  be  soon 








negative  impact on  the health and, potentially,  the survival of vulnerable undernourished 
people. Moreover,  trials with  a  short  duration,  and/or weak  design, may  fail  to  identify 
potential  risks  of  low  acceptability  and  safety.  Therefore,  it was  agreed  that  any  sort  of 
deviation  from  tested  RUF  formulations  should  be  carefully  based  on  sound  evidence, 
derived  from robust randomized   controlled   trials    (RCT)182. However, at present, there  is 




A paediatric RUF  is currently used  in adults.  In 2007, the UN officially approved the use of 
RUTF  for  the  treatment of  acute malnutrition  in  children under  five  years of  age  55. The 
same paediatric  formulation  is currently  supplied  to  large HIV programmes aiming at  the 
nutritional  rehabilitation  of wasted  adults.  However,  as  reported  in  section  1.2.1.5,  this 
formulation  is  costly,  and  its  choice  in  this  life‐stage  group  only  partially  supported  by 
conflicting  evidence116,127.  These  controversies were  recommended  to  be  urgently  better 
understood129. Understanding patients’ adherence to RUTF may shed some light. 
 
Looking  at  how  adult  patients  comply with  a  prescription  based  on  the paediatric RUTF 
formulation  seems  crucial,  but  the  current  data  are  little.  Furthermore,  the  method 
designed to carry this research may suggest  lessons to  improve the RUF spread and/or  its 
delivering intervention. 
1.4.4 How can the cost of RUF be minimized? 
Ways  to  reduce  RUF  costs  need  to  be  further  explored  and  improved.  According  to 






In  RUF,  some  ingredients  are more  expensive  than  others. Milk  powder, when  present, 






per cent cheaper  than milk,  is not available anywhere, may be culturally unacceptable  in 




for  locally  produced  RUTF.  The  regional  agriculture  economy  may  benefit  due  to  local 
purchase of the  ingredients,  increasing national self‐reliance on  local food crops. Based on 
these considerations, frequently found in the international debate about RUF use, it would 
be very advantageous if locally available and cheaper commodities could replace expensive 





formulation of a RUF  that  fulfils pre‐defined nutrients  requirements, using  region‐specific 
foods  that  are  culturally  acceptable,  and  that  can  be  processed  with  locally  available 
technologies.  
1.4.5 How can micronutrients  specifications  in novel RUF be determined, 
when requirements are unknown? 
In some forms of malnutrition of global public concern, evidence may be often too little or 
too weak  to determine  improved nutrient  requirements. Therefore,  the  specifications  for 
RUF  cannot be determined. An example  is provided by wasting  associated with HIV. The 
current RUTF  formulation showed  relatively satisfactory survival  rates  in children affected 
by HIV and/or TB43,185. However the same  is not true  in adults116, and a recent systematic 
review study urges further research “to test high‐dose multiple micronutrient supplements” 
which  “may  be  appropriate  only  for  short‐term  nutritional  rehabilitation  in  underweight 
and malnourished adults with HIV”75.  
 


























This area of  research  is  strategically  important  for global nutrition and health. The  thesis 
explores  the development of methods  to  fill  the knowledge gaps described above. These 























This  case‐study  covers  all  the  raised  issues  related  to  RUF  design  and  testing.  The 
prevalence of HIV wasting among adults is a public health concern, as described in section 





formulation  is urgently needed (issue number 1 described  in section 1.4.1).  The  improved 
RUF  should  be  acceptable  and  safe  (issue  number  2  in  section  1.4.2).  The  section  1.4.3 
describes how the design must be consumer‐driven. Therefore, the product improvements 
must  be  based  on  the  preferences  and  the  suggestions  expressed  by  the wasted  adults 
currently or previously exposed  to  the most common product  (issue number 3  in  section 
1.4.3). The novel  formulation must be economically viable, therefore  its cost should be as 
cheap  as  possible  (issue  number  4  in  section  1.4.4),  while  still  meeting  its  nutrients 
specifications.  Little  is  currently  known  about  the  micronutrient  recommendations  for 
adults with HIV wasting, associated or not with TB. Therefore, in this specific group, the RUF 
micronutrient specifications  represent an additional challenge  (issue number 5,  in section 
1.4.5).  
2.3.2 The sub‐studies 
Each problem or  knowledge  gap described  in  sections  1.4.1  to    1.4.5  guided  the overall 
research aim. In accordance with the framework method, the general research purpose was 
broken‐down  into  four  sub‐studies, which were  applied  to  the  selected  case‐study.  Each 









Specific objective:   To  investigate  compliance  with  RUTF  in  a  HIV/TB 
therapeutic nutrition programme in Kenya 
 
Research questions:  (i)  what  is  the  adherence  to  a  protocol,  when  using  a 











Aim:   Testing  of  a  method  for  optimal  design  of  novel  RUF 
formulations 
  
Specific objective:   To  design  a  formulation  that  fulfils  the  international 





defined  macronutrients  requirements,  and  uses 








Specific objective:  To  compare  the  acceptability  and  the  safety  of  a  novel 




Research question:  What  is  the  consumption,  safety,  and  preference  for  a 












in  a  RUTF  for  wasted  adults  living  with  HIV/TB,  whose 
requirements are currently unknown. 
 























In  the human history,  the  importance of  therapeutic  adherence was early  recognized.  In 
ancient Greece, Hippocrates was aware of  the  fact  that patients pretended  to have taken 
their medication186. At  the end of  the 1950s,  three physiologists drew closer attention  to 
the adherence phenomenon, studying the therapeutic effects of a tuberculostatic agent  in 
out‐patient  settings187.  Later,  in 1975, David Sackett described adherence  in depth, when 
low compliance was found responsible for unpredictable or disappointing responses to one 




compliance  research  is  the  absence of  a  crucial  factor:  the patient’s perspective”189. The 
latter is the element which distinguishes adherence from compliance. According to the large 






“The  extent  to which a person’s behaviour –  taking medication,  following a diet, 
and/or  executing  lifestyle  changes,  corresponds  with  agreed  recommendations 
from a health care provider”. 
 
Claxton  et  al.    agrees  with  this  definition,  suggesting  that  adherence  is 
“an  essential  component  of  a  successful  health  outcome”,  and, most  of  all,  is  “largely 
in  the  domain  of the  patient”192. 
 
In  a  review  of  seventy‐six  studies,  the  same  author  concludes  that  the  definitions  of 
adherence are numerous and varying because of the many ways  in which  it was assessed 
and measured193. However,  distinguishing  degrees  of  adherence,  such  as  partial  or  total 
non‐adherence,  may  be  challenging.  For  instance,  when  dose‐taking  and  dose‐timing 
measures  are  used,  partial  non‐adherence  can  be  defined  as  “taking  less  then  the 
 87 
 




based  on  a  review  of  the  available  literature,  Krueger  et  al.    found  that most  authors 
considered non‐adherence when the consumption of the doses prescribed was lower than 
80  or  90  per  cent,  “while  others  considered  any  missed  dose  as  evidence  of  non‐
adherence”194. Moreover,  from  the  classification  point  of  view,  there  is  agreement  that 
patient’s non‐adherence can be both “intentional or unintentional”190. 
 
In UK,  the  term  concordance has  been  also used  to define  adherence or  compliance.  In 
1998, the members of the Royal Pharmaceutical Society of Great Britain considered that the 
way  of  thinking  about  compliance was  insufficient195.  Therefore  the  current  terminology 
was  changed  from  compliance  to  concordance,  “which means  agreement  and harmony”.  






In  the  literature,  there  is  consensus  that  adherence  to  treatment  is  important,  and  its 
reasons  are many.  Adherence  is  a  “key  link  between  process  and  outcome  in medical 
care”190,197.“The  responsibility  for  fulfilment  of  the  prescribed  regimen  lies  with  the 
patient”192,  and  the most  carefully  chosen  and  optimal medication  cannot  work,  if  the 
patient does not  take  it appropriately”192. This  is  consistent with  the available evidences. 





It  can,  therefore,  be  argued  that  “non‐adherence  is  detrimental”,  because  it  “wastes 





is  little.  This  seems  to  be  because  researchers  are  aware  that  when measurements  of 




expected  to be  cost‐effective. Claxton  et al.    reports  that  “health  care personnel expend 










lipid‐based  RUF  spreads  are  used.  In  2002,  Collins  et  al.  200  voiced  the  importance  of 
understanding  “the  role  of  community  groups  and  mother‐to‐mother  educational 








include  factors related to the environment  in which the patient  lives, the setting  in which 
the treatment is supplied, and the counselling session, if any, that comes together with the 
regimen.  This  section  first  describes  the  determinants  in  general  settings,  and  secondly 
focuses specifically on low‐resources contexts, and in particular on nutrition programmes. 
 
The  environment  of  the  patient  is  an  important  determinant  for  adherence  because 
“patients live in a social environment. Social support involves the help that family members, 



















Counselling  is one of the most  important forms of  interaction between patient and health 
staff.  In  nutrition  and  medical  interventions,  “regular  dietetic  followup  and  detailed 
discussion  of  the  disease  by  the  physician  have  also  been  found  to  be  associated with 
adherence”  193,203.  One  study  suggested  some  possible  reasons.  Correct  application  of 





















Palestinian  refugees, complex procedures  for  the delivery of drugs were deemed  to have 
increased patient drop‐out 206. 
 
In  treatment  adherence,  some  factors were  surprisingly  not  found  to be  influential,  and 
quality of life is among them 193. Hall et al.  193, confirmed by Vermeire et al.  190, found that 
socio‐economic factors and demographic variables such as sex, marital status, and number 






none of  the  latter was  found  to be an ultimate  robust predictor of adherence  level189,207. 
This  unexpected  limit  induced  Lassen  et  al.    to  conclude  that    “none  of  the  suggested 




In  studies  looking  at micronutrient  supplementation,  side  effects may be  responsible  for 
non‐adherence. But some of the available studies show controversial conclusions. Ekstrom 
et al.  209 found that adherence was still low, even when using a form of iron that produces 
few  side  effects. Another  study  seems  to  contradict  these  findings.  In Norway, pregnant 
women  receiving  a  similar  form of  iron  supplements  complied  as well  as women  taking 
placebo 210. The low frequency in reporting side‐effects may explain the difficult to explain 
these  results  in other  studies.  In Burma, only  three per  cent  of women  stated  that  side 












antibiotics, considered  to be  the most effective  form of  treatment  209. The  importance of 
those  adherence determinants may,  therefore,  vary  according  to  the  given  contexts  and 
treatments.  
 
Overall,  there  is  sufficient evidence  to  conclude  that  identifying  the determinants of  low 
adherence  is  an  objective  difficulty,  and  some  authors  tried,  at  least,  to  understand  the 
reasons existing at its root. Claxton et al.  suggests that adherence “data, based on patient 





understanding and  interpreting  the patient’s knowledge, attitude and practice  in order  to 
increase  treatment  adherence.  At  the  consultation,  “patients  hold  sets  of  beliefs  and 
theories about health and illness”190, and, therefore, knowing “what sense individuals make 
of the advice given to them” becomes crucial190. On other hand, Di Matteo et al.   199 also 
hypothesizes  that  “many  patients  misunderstand,  forget,  or  choose  not  to  follow  the 




In  nutrition  interventions  designed  for  poor  settings,  adherence  determinants were  also 
explored,  even  if  not  sufficiently.  For  instance,  in  Kenya,  a  review  214 of  a  large  national 
programme  to  supply wasted adults  living with HIV with a  fortified porridge  flours  found 










Stigma  can  be  attached  to  treatment,  and,  therefore,  influencing  adherence.  The  same 
Kenyan  review  study  214  concluded  that  the  perception,  at  community‐level,  of  a  food 
specifically  targeting  HIV  positive  people,  reduced  its  consumption.  However,  low 
adherence may  be due  also  to other  causes. Because of  food  insecurity  in  the  patient’s 
households, other family members, not necessarily HIV positive, may have consumed his or 
her  limited  supply.   This phenomenon was more  frequent when  the client was a woman. 
Therefore,  in  these  settings  gender  is  an  important  adherence  determinant.  Another 
study127 from Kenya and Uganda reached similar conclusions. In these two countries, gender 
was  found  to  determine  nutritional  recovery  in  HIV  and  TB  severely  wasted  adults, 
supplemented with RUTF spreads.  
 
The  way  of  proposing  the  food  and  its  taste  were  also  found  to  be  determinants  of 
adherence.  In  the  Kenyan  fortified  porridge  programme,  focus  group  participants  felt 




determinants.  The  following  section  quantitatively  explores  the  levels  of  adherence 
reported in the recent medical literature.  
3.1.3 Recent evidence on adherence 




In  2004,  in  a  large meta‐analysis,  Di  Matteo  et  al.    199  included  569  studies  reporting 
adherence, and finding this to be the highest in HIV, arthritis, gastrointestinal disorders, and 
cancer  treatment,  while  the  lowest  adherence  was  reported  in  pulmonary  disease, 
diabetes, and sleep care. In the same study, the average non‐adherence rate was 24.8 per 










that  “in  general,  adherence  rates  are  higher  among  patients  with  acute  conditions 
compared to patients with chronic  diseases”, and apparently,  in these patients, adherence 





that more  than 60 per cent   of  the adults, all with celiac disease, were not  following  the 
dietetic prescriptions. However, “lack of comparability between studies, in terms of design, 
methods,  definitions  and  measurement  of  adherence”  may  weaken  this  study 
conclusions193.  It  can  be  concluded  that  well  documented  levels  of  adherence  are, 
therefore, limited 221. 
Although its current levels could not be ultimately established, adherence to treatment was 














In  one  review  study  213,  three models,  namely    the Health  Belief model,  the  Theory  of 
Planned Behavior, and the Transtheoretical approach, are summarized in the following way: 




Other  researchers  preferred  alternative  approaches.  Roter  et  al.    clustered  the ways  to 




In reading of the vast available  literature, and aware of  its  limits,  I  identified  four general 
model groups to measure adherence to treatment. In the first one, the correlation between 
health outcomes and the dosages, the packaging or the  frequency of the drug  intake, are 
often at the centre of the measurement. This approach  is  for  instance typical  in the often 






The  third model  is  referring  to  Educational  elements  or  “cognitive  didactic  approaches”, 
that  include  “teaching  and  providing  knowledge”  216,  and  are  defined  as  “educational 
interventions  given  with  the  intent  of  improving  the  person's  ability  to 
manage  his  or  her  disease “ 223. These models involve “different ways to educate patients: 





Social models, belonging  to  the  fourth group, are more  focused on  the  support  that  the 
environment of  the patient can provide.  In a  large review study, Di Matteo  213  found that 
“practical,  emotional  or  undifferentiated”  social  supports  had  the  strongest  relationship 




include different approaches. Dulmen et al.    216 describe  them as “effective  for  long‐term 
care”, but also “exceedingly complex and labour‐intensive” to measure. 
 
Despite  the  available models, measuring  adherence  adequately,  remains  challenging  216. 
This  is  for  at  least  two  reasons.  One  is  that  there  is  a  scarcity  of  comparative  studies 
explicitly  contrasting  theoretical models or  their  components  216. The  second one  is  that 
“research  into  a  phenomenon  as  complex  as  adherence  is  inevitably  fragmented”  190, 





The  same  is  true  for  a  standardized  protocol meant  to measure  them with  accuracy  194. 
Most  studies  report  the  method  which  they  applied,  but,  in  general,  their  degree  of 
complexity is high216. This is explained by Di Matteo et al.  in the following way: “there is no 
one  adherence measure  against which  to  calibrate  others, making  concurrent  validation 
impossible” 213. The little documented in the literature is reported in this section.  
 
Measures  of  adherence  can  be  direct  or  indirect.  The  former  consists  only  of  direct 
observation,  is  “practical  only  in  single‐dose  therapy,  intermittent  administration  and 
hospitalized  patients”  225,  and  is  carried  out  whenever  possible  by  an  “independent 
observer”194. Indirect measures may be taken in many more ways, applied individually or in 
combination  194.  These  include  medical  records  and/or  charts,  interviews,  self‐reports, 
collateral  reports,  electronic monitoring,  tests  based  on  Likert  scales,  pharmacy  reports, 
assessments of the motivation to adhere, pill counts or checks on container refilling, diaries, 
physical  and  biochemical  tests  194,213,216.  The  latter  usually  consists  of  “detection  of  a 










et al.    194 explains  this phenomenon based on “the patient’s desire  to appear compliant”, 
and suggesting that “patients do not remember exactly when they took their medication or 
record the  times at which  they  were  supposed  to  take  it”. “Drugs counts also appear to 








Methods  in  studies  looking  at  dietetic  adherence,  may  face  additional  challenges. 
Unfortunately,  despite  the  large  number  of  studies  looking  at  the  efficacy  of  prescribed 
dietetic  patterns  or  supplements,  in most  existing  studies,  the  differences  in  adherence 
levels are not discussed 226. When documentation is available, the methods were described 




Analysis  of  these  measurements  must  often  take  into  account  the  synergic  effects  or 
interactions  between  nutrients  or  foods  that  comprise  the  diet  229–231.  This  can  be  an 











micronutrient  supplementation  programme  using  qualitative  methods.  These  included 
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by‐prescription”  214.  Thanks  to  this  intervention,  in  an  out‐patient  setting, wasted  adults 
received fortified porridge flour. Also in this study, qualitative measures included interviews 
and  focus groups. The data were matched with an  index called  length of  stay, defined as 
“total time that a client remained  in the food by prescription program before s/he exited”. 
The  time,  therefore,  comprised  the days on  active  and non‐active  treatment, periods of 
missed food supplementation, and non‐adherence. The same year, another large report on 
the  same  type of programme was  reviewed by Greenaway  233 using  the  same qualitative 
methods.  
 







In Malawi, Ndekha  et al.    116 also  compared  the  same RUTF  formula but with a  fortified 
porridge flour  in wasted adults  living with HIV. Adherence was measured only when study 








In  the Democratic  Republic of Congo, Bisimwa  et  al.    234  assessed  the  effectiveness of  a 
fortified  soybean‐maize‐sorghum  RUCF  paste.  This was  compared with  fortified  corn  soy 
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blend porridge. The prevalence of underweight and  stunting,  in  infants, was  the primary 
outcome of this study. Adherence to the complementary feeding instructions was measured 




Seven  other  studies  62,101,124,125,128,129,152  looking  at  different  aspects  of  nutrition 




The documented ways  to measure adherence  to nutritional treatment  in  limited‐resource 
settings are limited in number.  This conclusion is consistent with a recent USAID document 
looking  into ways  to  improve  food aid  109, and  reading: “many,  if not most, studies  fail  to 
monitor compliance, which is a key factor in recovery with the use of nutritionally enhanced 
products”.  However,  the  current  situation  is  improved  by  the  contribution  from  the 











The  following  sub‐sections  first  introduce 
the  reader  to  the  generalities  of  this 
country, including its nutrition, health and 
HIV/TB  profiles,  and  then  describe  the 
specificities of the study setting. 
3.2.1 Kenya:  generalities  and 
nutrition‐related facts 
With  its  typical  tropical  climate, Kenya  is 
located  in  Eastern  Africa,  sharing  its 
borders with Somalia and Ethiopia to  the 
North, Uganda  to  the west  and  Tanzania 
to  the  South.  Nairobi  is  the  capital  and 
Mombasa  is  the  second  largest  city  and 
the main  harbour  of  the  region,  located 
on  the  Indian  Ocean  (East  side  of  the 
country).  Kisumu  is  the  third  town  and 
the main port on the Lake Victoria. 
 
According to  the  latest UN data,  in 2009 Kenya had a population of almost  forty millions, 
with a density of 68.6 person per square kilometre 235, which  is close to that reported  for 
neighbouring  countries.  The  same  year,  the  Kenyan  gross  domestic  product  was 
approximately 30 million US dollars, showing an increase in the last years of approximately 




The recent drought and the  food crisis  in the whole region had  large negative  impacts on 











stable  (35,  16  and  7  per  cent,  respectively).  Insufficient  breastfeeding  practice  is  still  an 
issue, with  only  32  per  cent    of  children  less  than  six months  of  age  being  exclusively 
breastfed  41. Maize  is  the basic  staple of  the Kenyan diet. Ugali,  the main dish,  is a  thick 



















has  the  fifth highest burden  in Africa. According  to  the WHO Global TB Report 2009  241, 










In 2007,  the government demonstrated  increased political commitment by upgrading  the 
division dealing with TB health  issues within the MOH, and with  increased  funding  for TB 
control.  A  larger  proportion  of  TB  patients  benefited  from  improved  “Directly Observed 
Treatment  Short course”  services  (DOTS).  The  programme  implements  TB  and HIV/  AIDS 







Homa  Bay,  Nyanza  Province  (Kenya).  At  the  time  of  this  study,  the  MSF  intervention 
supported the district hospital and  four primary health care  facilities.   The district referral 
hospital offers health services to a rural area with approximately 300,000 inhabitants127. In 
collaboration with the Ministry of Health, MSF provided outpatient and  inpatient HIV and 


















In mid‐2006, MSF,  in  collaboration with  the MoH,  began  providing  RUTF  to  all  severely 
malnourished  patients  attending  the  HIV/TB  programme  in  Homa  Bay127.  The  same 
intervention started simultaneously  in the Nairobi slum of Mathare 127. The RUTF provided 










and  were  clinically  assessed  every  two  weeks  or monthly  before  renewal  of  the  RUTF 
prescription 127. 
 
During  the  counselling  sessions  frequently  asked  questions  from  the  patients  and  the 
caretakers  about  the  frequency  and  the  amount  of  RUTF  to  consume  were  answered. 
However,  no  training  and  counselling material were  supplied  to  support  the health  staff 
members  in this activity. During the first or the following visits, the capacity of swallowing 













Patients  who  were  unresponsive  (“uncured”  according  to  the  protocol  definition127)  to 
nutritional  therapy  after  six months  of  treatment  (not  reaching  BMI  ≥  18  kg/m2)  were 
reviewed  by  a  physician  for  further  investigations  and  management  127.  After  clinical 




A written protocol  reported  in detail  the  contents  of  the  nutrition programme,  and was 
available  for  the  programme  staff.  However,  at  the  time  of  the  study,  no  training  was 
provided to the health staff to ease its application.  
 
From  January  2008  to  March  2009,  MSF  admitted  782  malnourished  adults  into  the 








analysis of east African adult patients enrolled  in MSF  interventions,  from 2006  to 2008. 






study  used  multiple  logistic  regression,  and  four  failure  outcome  categories:  patients 







In  the  three MSF  interventions,  15.4  per  cent  (n=8,685)  of  the HIV‐positive  adults were 
enrolled  in  the  nutrition  programme. On  day  one  of  the  treatment,  their  BMI was  15.8 
kg/m2  (IQR  14.9‐16.4),  and  only  12  per  cent  of  the  cohort  had  previously  received ART 
drugs.  At  the  end  of  the  study,  only  47.7  per  cent  (total  n=1,106)  of  the  patients were 
considered  “cured”,  and  their  follow‐up  time  lasted  approximately  four months  (IQR 2.2‐
6.1). Forty‐eight per cent of the patients were “non‐cured within six months”, of whom 11.9 
and 22.6 per cent died or defaulted  from care. More  than  four per cent were discharged 
because of “other reasons”. Increased risk of nutrition programme failure was found to be 
higher  in men  (OR = 1.5, 95 per cent CI 1.2‐2.0),  in patients with BMI below 16 kg/m2 at 
study enrolment  (OR = 2.2, 95 per cent CI 1.7‐2.8), and  in patients who did not start ART 
when eligible (OR = 4.5, 95 per cent CI 2.7‐7.7), as well as for those who were ineligible for 
ART  at  enrolment  (OR  =  1.6,  95  per  cent  CI  1.0‐2.5).  The weight  gain  among  the  cured 
patients was 1.6 g/kg/d.  
 



































In  this  study,  I  applied  three qualitative methods based on  focus  groups,  interviews  and 
direct observations.  I  considered  their  results valid, when  found  to be  consistent, one  to 
another. Focus group discussions involved patients and caretakers, and one separate session 
with members of MoH/MSF medical  staff.  Semi‐structured  interviews were  administered 
one‐to‐one to patients. Direct, unobtrusive, observations of the Plumpy’nut distribution 





















checking  of  information  that  was  not  clear  from  the  recordings.  The  focus  groups  and 











MSc  level,  and  I  was  not  a  MSF  employee.    I  attended  all  focus  groups  sessions  and 
benefited  from  simultaneous  translation  by  an  interpreter.  I  personally  facilitated,  in 
English, the focus group discussion with the health staff, and subsequently transcribed the 
recorded  tape  myself.  Other  discussions  were  facilitated  by  the  study  interpreters. 





I  manually  coded  the  focus  group  discussion  transcripts,  highlighting  key  words,  key 
concepts and any minor or contradictory themes, using both hard‐ and soft‐copies, marking 
methods  and mind‐mapping  approaches.      I  regularly  reviewed  the  records of  the direct 
observations, and  I  summarised  the  found pieces of evidence.  I entered  the quantitative 





I  subsequently prepared detailed  tables  for each  identified  theme and  its associated sub‐
themes.  The theme tables contained separate columns referring to the evidence obtained 
on  each  theme  using  one  of  the  three  research methods  (see  Table  12).  This  allowed 
triangulation of evidence, comparison and discussion of the common themes that emerged.  
Following this process the themes and sub‐themes from the separate tables were compiled 
and  overall  conclusions  drawn.  Conclusions  and  associated  recommendations  were 
discussed with  the  health  and management  staff  of  the  programme  during  a  feedback 
process.  
3.4.2.4 Subjects recruitment and sampling 
The  study  subjects,  enrolled  at  the MoH/MSF  HIV/TB  programme  in  Homa  Bay  health 
district, Nyanza Province, Kenya, came from three groups: patients enrolled in the program 







however,  recruitment  continued  along  the whole  planned  period  (3 weeks).  During  the 
study time, the patients, coming for their usual routine visit, were invited to participate by 




































































and  they were all HIV positive;  two of  them were multi drug  resistant and  their appetite 


























       





 It is similar to a drug rather than a food, in terms of both usage and role in the recovery  X‡§  X  ‐ 
 It “brings strength”  X‡§  X  ‐ 
 It “allows to go back to work”  X‡§  X  ‐ 
 Increases weight gain  X‡§  X   
 Decreases the feeling of hunger   X‡§  X  ‐ 
 Has a smell and packaging which are well accepted  X‡§  X  X 
 Offers the possibility to mix it with other food and therefore reduce:  X‡§  X  X 




Negative aspects reported about Plumpy’nut® ‐ Participants think that:       
 It can cause nausea and vomiting  X‡§  X  X 
 First 3 to 4 days of consumption are crucial for adherence, then later it becomes easier  ‐  X  X 
 The taste is:       
o too sweet  X‡§  X§¶  ‐ 
o too oily  X‡§  X§¶  ‐ 
o too salty   X‡§  X§¶  ‐ 




Sharing Plumpy’nut® with both other adults and/or children is a common practice X‡ X ‐










 food insecurity in the household  ‐  X§  ‐ 




Mixing Plumpy’nut with foods is a common practice  X  X  X 
Reasons for mixing:       
 to reduce monotony of the diet  X‡§  X§  X 
 to reduce nausea, vomit, salty taste  X‡§  X§  X 
 because the Plumpy’nut has separated into oil and solid phases  X‡§  ‐  ‐ 
 because Plumpy’nut with water reminds participants of a traditional food  ‐  X§  ‐ 
 because it was suggested by the health staff   ‐  X§  ‐ 
 
Knowledge and attitudes of medical staff       
Medical  staff  expressed  doubts  about  the  positive  role  played  by  Plumpy’nut  in  nutritional 
rehabilitation; ART was perceived as much more important  ‐  X  ‐ 
       
















Distribution system for Plumpy’nut       



































Overall,  only  14  out  of  22  interviewed  patients  reported  adhering  with  the  prescribed 
amount of Plumpy’nut®. 
3.5.2.1 Perceptions about Plumpy’nut 
Table  12  lists  the  aspects  which  may  both  enhance  or  decrease  the  adherence  with 
Plumpy’nut, and were mentioned during the majority of  focus groups and  interviews.  It 
was frequently reported that Plumpy’nut can be “associated with a drug” (same role and 
effect of a drug), “brings (physical) strength” and “allows to go back to work”.  Increases in 
weight gain were  reported, and  feelings of hunger said  to decrease. The positive  feelings 
about  use  of  the  product  can  be  summarised  by  the  quote:  “ART  is  a  drug  to  fight  the 
infections, but does not give strength like Plumpy’nut® to go back to work”. 
 




mentioned oral  thrushes  as  the main  cause  for  low  acceptability.  In  contrast,  the health 
staff focus group voiced that the initial clinical conditions including swallowing capacity are 
crucial  for  the patients’ adherence. The  interviewees provided  suggestions about how  to 
improve the product (see Table 12). 
 





other  adults,  and  this  was  confirmed  by  most  focus  groups.  The  medical  staff  was 











considered  part  of  the  “medical  drug  prescription”. Only  one  interviewee  reported  that 
Plumpy’nut could be actually harmful for an HIV negative person. 
 
One member  of  the medical  staff  suggested  that  Plumpy’nut  is  so  important  for  the 





















The  prescribed  supply  of  Plumpy’nut  per  outpatient  was  monthly  and  weighed 
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approximately  12  kilograms.  A  malnourished  outpatient  without  a  carer  did  not  have 
strength enough to carry such weight. Therefore, the outpatients were  invited to take half 




It  can  be  speculated  that  these  patients  spread  out  the  two weeks  provision  along  the 
entire month. This is consistent with the reports of many patients. No data could be found 
on  how  many  patients  came  back  to  collect  the  missing  mid‐month  supply  or  the 
relationship with defaulting and survival.  
3.5.3.2 Stigma associated with therapeutic foods 








Among  the  in‐patients  who  were  directly  observed,  all  the  ones  with  a  severe  clinical 
condition could not adhere to the prescribed amount. Two of these died during the course 
of  the  study. Alternative  therapeutic diets, such as  therapeutic  liquid milks  (formulas F75 
and F100), whose intake may have been easier for severely ill patients, were not available.   
 
It was  reported  and  observed  that  in‐patients  in  the ward with  the most  severe  clinical 





showed  swallowing  difficulties  due  to  extended  oral  thrush.  The MoH/MSF  protocol  for 
therapeutic nutrition did not require the medical staff to report the presence or the degree 
of  swallowing  difficulty.  Therefore,  quantitative  data  were  not  available,  and  written 
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prescription  reports  of  oral  thrush  treatement  could  not  be  availed  for  the  research. 
However,  direct  observation  confirmed  that most malnourished  patients  enrolled  to  the 






















Factors  intrinsic  to  the  product  design  are  many,  and  their  nature  is  varied.  Their 
interpretation must  take  into  account  the  origin  of  this  RUTF.  Although widely  used  for 











Despite  the  problems  of  taste  and  consistency  acceptability,  the  results  of  this  research 
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suggested  that most  patients  valued  the  nutritional  therapy  provided  by  Plumpy’nut.  
Their  attitude  towards  the  product  was  more  positive  than  most  medical  employees, 
perhaps  because  of  lack  of  staff  training  on  the  anticipated  benefits.  However,  the 
interviewed  patients would  reduce  the  sweetness  (somebody  suggested  the  addition  of 
lemon  juice), and would  like  to  change  the  consistence  into  something  “more  liquid”, or 
“into the  form of a biscuit” or powder.   Rarer comments mentioned  included suggestions 
for  improving  the packaging,  such as  “the  sachet packaging  should be  replaced with  ice‐
cream cup with lid”. 
3.6.2  Factors related to programme design 
Certain problems  in  accessing  and  consuming  the  therapeutic  food were  accentuated by 
the design of the overall programme and inappropriate staff training. 
Patients  were  not  informed  about  how  to  correctly  consume  the  RUTF.  For  example, 
counselling  messages  inappropriately  advised  adding  the  RUTF  to  tea,  and  feeding 
strategies  that were  not  feasible  for  the  patient.    Suggesting  to  eat  RUTF  at meal  times 






have  recommended  small bites of RUTF  throughout  the day until  the  twenty‐four hours 
prescription of sachets had been consumed.   Box 1 presents the most common questions 






community  based  organisations  to  support  home‐based  care.  Their  importance  is 
recognized  in  many  HIV  and  nutrition  interventions  and  protocols  244–248.  The  health 






the  topics  to  be  covered  should 
respond  to  the  following  questions 
expressed  by  patients  during  the 
study:  What  is  Plumpy’nut 
(food/drug;  composition)?  Who  is 
supposed  to  use  it?  What  are  its 
components?  How  often  should  I 
eat  it along the day? What should  I 
do when  I do not manage  to eat  it 
because of nausea, vomiting or lack 
of  appetite?  Could  I  mix  it  with 
other foods? What should I avoid to 
drink  or  eat  together  with 
Plumpy’nut?  What  are  the 
consequences if I share my ration of 
Plumpy’nut with other persons? Is 
it  good  for  somebody  who  is  not 
HIV positive to eat Plumpy’nut? Is 
it  good  for  somebody  who  is  not 
thin  to  eat  Plumpy’nut?  When 
should  I  stop  eating  Plumpy’nut? 
Will  I  become  thin  again  when  I 
stop eating it? 
In  case  of  extremely  frail  patients,  the  carer  played  a 
fundamental role in trying to overcome key barriers for 
adherence  like  just  opening  the  sachets  or  mixing  it 
with other foods.  
Both  groups  of  adherence  determinants  identified  in 




clinical  information  such  as  patients’  survival,  CD4 
count, weight  gain  or  BMI  changes which might  have 
helped in understanding the impact of such programme 
in  presence  of  household/community  sharing,  food 
mixing,  lack  of  counselling,  and  clinical  difficulties  in 
swallowing  among  others.  The  access  to  the  clinical 
information  was  not  granted  by  MSF  and  the  MoH, 
because of confidentiality‐related reasons.  






protocol  (2007),  such  tool  did  not  seem  to  be  priority.  That  was  in  view  of  the  only 





aim  to  understand  the  link  between  nutritional  therapy  and  ART  adherence. Moreover, 
RUTF are meant  to be used  in out‐patient programmes, but  this  study was  restrained by 





The  two study  interpreters were not only employed as health promoters  in  the MoH HIV 
programme,  but  also  HIV/TB  patients  in  the  same  intervention. One  of  them  had  been 














when  present.  Patients  who  are  not  able  to  swallow  at  all  should  be  hospitalized  and 
treated according  to  the  in‐patient nutritional  therapeutic protocol developed by WHO  70 
which utilises milk based liquid therapeutic nutritional products, such as F75 and F100. 
 
The  study  showed  that  the  Plumpy’nut,  designed  for  malnourished  children,  needs 
improvement to meet the palatability preferences expressed by adult patients. Reduction of 































features are described and contextualized,  in  the  sections  called “Evolution of  the use of 
Linear Programming”, and “Linear programming applied to nutrition”. Following the  latter, 
other sections focus, in order, on the description of the method in mathematical terms, on 
the  specific  objectives  of  this  sub‐study,  on  the  phases  which  composed  the  applied 




Linear  Programming  (LP),  an  algorithm  useful  for  planning  and  decision  making,  has 
contributed to shaping the modern world.  
 
The  founders  of  this  tool  are  generally  regarded  as  George  Dantzig,  who  devised  the 









an  optimal  way.  In  most  cases,  cost  minimization  is  the  final  goal  of  LP  applications.  
Examples  include  airline  crew  scheduling,  shipping  or  telecommunication  networks,  oil 
refining and blending, and stock and bond portfolio selections 250. Linear Programming has 






It  is, however, only today that LP  is applied  in small‐scale companies, where  its use allows 
minimizing costs, and maximising profits, within the available resources. This delay is due to 
the  relatively  recent  advent  of  powerful  personal  computers  251,252.  As  the  inventor 










applications. For  instance, LP cuts costs  in production of animal  feeds  254,  improving  their 
formulations 255, and helping in the determination of their nutrient requirements 256. Linear 
programming also helped  in determining to what extent cow food  intake  is constrained by 
the maximum  feeding time available each day, by the daily rumen processing capacity, by 



















The  following  sections  describe  examples  of  LP  applications  used  to  answer  the  two 
questions above.  
 
WHO urges countries  to promote  improved  feeding practices  to ensure optimal health  in 
adults, and  ideal growth and development in children 261. Linear programming contributed 
in  refining  the  same  WHO  nutrition  recommendations.  For  instance,  in  a  Malawian 
population, LP evaluated and  improved diets recommended for young children during the 





French  low  socio‐economic  groups would make  to  reduce his or her  food budget, while 
retaining  a  diet  as  close  as  possible  to  the  one  in  the  average  population.  The  study 




The therapeutic  formula milk F100  is used as  the standard therapy  for SAM, according to 
WHO  70.  However,  it was  not  clear  if  optimized  combinations  of  local  foods  from  poor 
countries  could  achieve  the  same  nutrient  density  levels  of  F100.  With  this  objective, 
Ferguson et al.  263 explored the feasibility of formulating diets based on foods from Ghana, 





Linear  programming  can  contribute  to  develop  food‐based  dietary  guidelines, which  are 
required to combat micronutrient deficiencies. With this purpose  in mind, Ferguson et al.  





In  other  two  studies,  LP  helped  in  optimizing  the  diet  of  two  populations.  In  Thailand, 
Anderson and Earle 260 used LP to achieve an ideal diet formulation to be at the least cost, 
to meet specific nutritional requirements, to avoid over‐supply of certain nutrients. The LP 
model  included  the composition of 150 common Thai  foods.  In Malawi, Briend et al.    265 
used  LP  to determine  a  lowest‐cost, nutritionally adequate diet  for  children using  locally 
available food.  
 
A  method  called  Nutrient  Profiling  ranks  foods  based  on  their  nutrient  contents,  and 
identifies commodities with a quality which is considered nutritionally good for their price. 
In a LP study, this approach was validated by Maillot et al.   266  in a  large French survey.  In 
the  first part of  the study,  the authors correlated  intake data of  foods with  their nutrient 





Food  prices  can  be  analysed  by  LP  to  assess  the  economic  values  of  fortified  food 
supplements.  Food  prices  and  nutrient  contents  are  linearly  related  to  food  weight. 
Therefore, LP can estimate the effect of introducing a food supplement on the minimal cost, 






study  268  aimed  to  assess  the  application  of  population‐specific,  food‐based  feeding 
recommendations, developed with LP, to combat micronutrient deficiencies. The LP model 






Despite  its  potential, most  of  the  acquired  knowledge  in  LP  applied  to  nutrition  often 
 126 
 
remains  limited  to  the  research  realm.  Briend  et  al.    suggests  that  “its  application  into 
human nutrition practice  is  long overdue”  251. That  is  true  if considering  the solutions  for 
complex calculations, offered by relatively affordable computers of the current times. This 
aspect will be  further described  in  the  following  section  called  “Software  to  apply  linear 
programming”.  
 




























more of  the DV  (W1, W2,…Wn  )  to ensure  that  the nutrient content of  the product meets 
design requirements and does not exceed upper thresholds. 
 












Models  including  non‐linear  constraints  may  have  several  solutions  (local  optimums) 
depending on the initial values, and cannot be solved using LP. In optimizing dietary models, 
imposing the acceptable range of the ratio between the energy contribution  from protein 
and  total energy  is an example of a non‐linear  constraint.  If not  too  complex, non‐linear 




























A LP solution  is  feasible when all  its constraints are achievable  in combination. When the 
highest possible concentration of a nutrient is less than a minimum constraint, or when the 
lowest  concentration  of  a  nutrient  is  higher  than  a maximum  constraint,  or  an  equality 
constraint cannot be respected, the model is considered unfeasible 263,264. 
 
Models which  are  non‐optimal may  be  reformulated,  based on  informed  decisions  from 
Sensitivity  Analysis,  which,  using  LP  jargon,  measures  the  strength  of  the  different 
constraints. More precisely,  the Sensitivity Analysis quantifies how much  ingredient  costs 






























The  process  of  finding  international  consensus  on  these  aspects  has  taken  time.    In 
February 1947, the Committee on Calorie Conversion Factors and Food Composition Tables 
was convened by FAO, and only in 1989 did the FAO service INFOODS published the first set 
of  food  identifiers, also called “tag‐names”. Since  then,  tag‐names  in FCD have constantly 
been updated 271 and organized in at least four systems: 
 
 The  food  classification  systems  are  specific  for  nations  (or  regions),  whose 

















come  together with  the  tables, and describe  the methods used  to  compile  the datasets, 
their calculation processes, the units applied271. The notes are important in comparing food 
nutrients, coming from different databases. The variety of the methods and the calculation 
processes  in use  is  large, and  this makes  the collation of composition data  from national 
and regional datasets into global collections challenging. It is not surprising that most of the 
international  FCD  tables  are  expensive  to  compile,  and,  for  this  reason,  the  same 
collections are often only commercially available, rather than for free distribution. 
 
The  web  site  of  the  FAO  INFOODS  Secretariat 
(http://www.fao.org/infoods/tables_int_en.stm),  however,  reports  at  least  fifteen 
international non commercial FCD tables, but most of them are dealing with specific food 
groups. These  include  foods  important for biodiversity aspects  (FCD released by  INFOODS 
Food  Composition  Database  for  Biodiversity),  sea  food  (Chemical  and  Nutritional 
Composition of Finfishes, Whales, Crustaceans, Molluscs and Their Products), staple crops 
(ILSI Crop Composition Database), and  tropical  foods  (Tables of Representative Values of 
Foods Commonly Used in Tropical Countries) among others.  
 
At  least  two  studies  263,265    looking  at  LP‐optimized  diets  used  a  FCD  called World  Food 
Dietary  Assessment  System  (WFDAS)  273.  This  is  the  base  for  the  FAO  food  composition 
database called Minilist 273,274, and includes a list of 48 nutrients in 1,800 foods coming from 
six  countries  (Egypt,  Kenya,  Mexico,  Senegal,  India,  and  Indonesia)  in  four  continents. 
























In  trialling diet  recommendations or  specific  food  specifications,  LP  replaces at  least  two 
more  traditional methods,  termed,  by  some  authors251,  “trial  and  error  approach”  and 
“expert  guessing”.  The  first  approach,  an  iterative method used  to design diets,  requires 
multiple backwards steps, and repeated diet designs to arrive at a solution that may or may 
not be optimal. Therefore,  it  is very  resource  intensive  269. The other  traditional method, 
based on more generic experts’ advice, may  instead suffer  from a  lower degree of  rigour 
than LP 269.  
 
In  the  management  of  undernutrition,  LP  is  important,  because  has  the  potential  to 
improve  food‐based  formulations. For  instance,  the most common RUTF product  is based 
on results from a limited number of studies, in a few settings, showing rapid weight gain 277. 
Consequently,  in  other  settings,  with  different  underlying  nutrient  deficiencies  and 
infectious disease profiles,  similar weight gains would perhaps occur, with nutrient  levels 




Linear programming  can decrease  the  cost of RUF  spreads. As  reported  in  section 1.3.3, 




products  40.  In  RUF design,  optimizing  the  combination  of  affordable,  acceptable,  locally 




designing  cheaper  formulations  of  a  RUF,  which  fulfils  predefined  macronutrient 






Aim:   Testing  a  method  for  optimal  design  of  novel  RUF 
formulations 
  
Specific objective:   To  design  a  cheaper  RUF  formulation  that  fulfils 
international  macronutrient  requirements  and  food‐
related standards 
 
Research question:  How  can  linear programming based methods be used  to 
design the cheapest  formulation of a RUF that fulfils pre‐








In  this  study,  the  LP  elements  are  the  same  described  in  the  section  “The  linear 






The overall  formulation, which, overall,  included design, manufacture, and  testing of  the 











to  confirm  that  the desired  texture was  achieved,  and  to  compare  the  LP‐model macro‐
nutrient estimates with  the  laboratory‐based  results.  In phase D,  safety and acceptability 
tests were  conducted with  the  unfortified  product,  and  are  described more  in  depth  in 






















for 100 g foods
(objective function, decision 
variables, mathematical 
linear constraints)

























In  this  phase,  I  selected  the  FCD  and  identified  the  commodities  to  use  in  the  RUTF 
formulation.  
 












For  the  identification  of  the  commodities,  I  relied  on  the  Kenyan  cereal/pulse  blends 
processor Insta Products EPZ Ltd (Athi River, Nairobi), which, since the early 80s , has been 
the  largest  food aid producer  in  the region, supplying humanitarian organizations such as 
MSF,  WFP,  and  the  Kenyan  MoH  (Stuart  Allison,  private  communication;  2008).  Since, 
nutrition interventions across the entire East Africa currently distribute food products from 
Insta,  at  the  time  of  this  study,  this  manufacturer  seemed  a  strategic  choice  for  the 
potential production, at scale, of future RUF spreads.  
 
In  close  consultation with  Insta,  I  identified one  commodity  for each of  four preselected 













Representativeness  of  the  food  prices  is  important  to  achieve  a  realistically  cheaper 
product.  In  view  of  this,  Insta  staff  ensured  that  the  food  prices  for  the  selected 
commodities were representative of an overall period lasting three to five years, accounting 

































Therefore,  the per centage of sugar was constrained  from 15  to 18 per cent  (see 





In  small  amounts,  sorghum  improves  the  taste  of  extruded  pulse/cereal  blends 
(personal communication: Stuart Allison, Insta Products EPZ Ltd; March 30th, 2008). 



















Once  the  RUF  is  shown  to  be  acceptable  and  safe  (see  Figure  17),  a  premix  of 
vitamins and minerals is added to the formulation (Phase D). The weight of the food 






centage  allows  the  inclusion  of  essential  complementary  components  such  as 
vitamin  stabilizers  and  a micronutrient  carrier, which  consists of  a  refined  starch 
powder (DSM, private communication; 2008).  
 










Soybeans, g n.a.  31.9
Maize, g n.a.  15.3
Sorghum, g n.a.  7.0





















1 The  cost of  the  currently available product  (Plumpy’nut®)  is approximately 0.5 USD/100 g when 
delivered in East Africa, at the time of this study. The reference includes costs such as manufacturing, 
transport from Europe, packaging, and import taxes. 




















This  is  “based on  comparison of  the  concentration of  the first  limiting essential  amino  acid 


















coming  from protein  is higher  than 0.10 and  lower  than 0.12.  This was expressed  in  the 
following non‐linear form: 
  
(P1W1 + P2W2 … + PnWn) / (E1W1 + E2W2 … + EnWn)  > 0.10   and  < 0.12     
  













avoiding  to  linearize non‐linear  constraints wherever possible, because of  the  complexity 
entailed  in the process. Therefore,  I avoided  including more complex non‐linear/linearized 





In  the  figure,  the  colours  (if  visible)  are  associated with  elements which  are  part  of  the  linear  programming‐based 
model:  blue for the ingredients formulation, red for the “target” of the LP model (minimization of the final formulation 
price),  yellow  for  the  constraints  applied  in  the model, orange  for  the  standards  to  apply, purple  for  the  linearized 
constraints and which, originally, were not‐linear. The Microsoft add‐in Solver function  is visible  in the window on the 
right side. 
corrected  Amino  Acid  Score  (PDCAAS;  see  Box  5  for  its  description)  281,  and  true  faecal 




















In  this  phase,  I  compared  the  lab‐based  results  of  the  prototype  against  the  LP‐based 
estimates.  I  considered  the model  to  be  acceptable  only  if,  in  the  two  sets  of  data  the 
difference in the relative energy density was below 10 per cent, and the difference in both 




To  be  acceptable,  the  prototype  should  also  have  been  aligned with  the  considerations 






purpose,  first  I  performed  a  Sensitivity  Analysis, with  the  SF  add‐in.  The  output  of  this 
function consists of a table reporting how much individual ingredient costs and formulation 
constraints  can  vary, without  requiring  a  change  in  the  values  of  the  other  LP  decision 
variables  or  constraints.  Secondly,  I  increased  or  decreased  the  constraints,  within  the 




When  producing  the  prototype  at  Insta  Ltd.,  I  also  considered  food  technology‐related 







Extrusion‐based  technologies may help  in achieving  these  results. According  to one  large 
review  study,  the  correct  application  of  these  processing  techniques  achieves  levels  of 
starch  gelatinization  sufficient  for  digestion  159  while  destroying  most  antinutritional 
factors159. However, another study suggests that the overall digestibility does “not seem to 
substantially  improve”285  in presence of extrusion. This  is so, because extrusion  led,  in this 
study, to a higher carbohydrate  fermentation  in the colon, presumably as a result of  fiber 
solubilisation,  with  a  possible  suppressive  effect  on  appetite.  Moreover,  this  industrial 


















this  study. However, essential  (n‐3) and  (n‐6)  fatty acids were missing  in  the WFDAS. For 




these  and  the other  commodities  are  available  in  the  footnote  in Table 13. Data  for  soy 
beans and palm olein oil were selected from another source, USDA SR20 (released in 2009), 























Expressed as  relative difference,  the  total energy  in  the LP model was 3.0 per cent  lower 
than  the  lab‐based  figures.  The  protein  and  the  lipid  contents  estimated  with  LP  were 














Nutritional:         
Total energy, kcal >518.9 1.24  0.03 
<550.0 31.0  <0.001
Protein energy/total energy  > 0.10  1.18  0.004 
  < 0.12    10.38  <0.001 
Fat energy/total energy  > 0.45  <0.001  77.85 
  < 0.60  0.01  0.33 
(n‐3) Fatty acids energy/total energy  > 0.003  <0.001  2.87 
> 0.025 8.54  <0.001
(n‐6) Fatty acids energy/total energy  > 0.03  <0.001  36.3 
< 0.10  0.003  <0.001
Palatability:        
Sugar level, g >15 <0.001  0.50 
<18 2.4 <0.001
Sorghum, g  >7  0.87  0.02 
  <10  <0.001  3.0 
Texture:   
Fat level, g >28 <0.001  6.6 
  <36  1.4  <0.001 
Maximum food ingredient weight:  
Final amount, g =97 0.001  0.05 



















  A  B  B ‐ A = C  (C/A) x 100 
Energy 
 kcal/100, g 518.9  534.7  66.0  3.0 
Protein 
g/100, g 13.0  15.3  2.3  17.7 
Protein energy/total energy 0.10  0.11  0.01  ‐ 
Lipid 
g/100, g 34.6  33.6  ‐1.0  ‐2.9 
Fat energy/total energy 0.60  0.56  ‐0.04  ‐ 
1 Sources of food composition are 273,283.  
2  Methods  applied  (parameters,  other  information):  Pearson  (energy);  Gafta  May  91 
(protein, Nx6.25%;  lipid). By Polucon Services Limited, Msaada Avenue, Mombasa, Kenya; 







Although  today  this method  can  be  easily  applied, historically,  LP has  received  relatively 
little attention. This  is so, perhaps, because computers were not widely available when LP 
was  first  conceptualized and disseminated252. The example  illustrated  in  this  chapter was 
implemented  using  software widely  available  (Microsoft  Excel Office  2007  and  its  Solver 
add‐in function). 
In  the  optimized  solution,  three  calculated  energy  and  nutrient  densities  were  exactly 
equivalent to the upper or  lower  limits  from the pre‐set constraints. This type of result  is 
often  observed  when  applying  Linear  Programming.  As  a  consequence,  criteria  which 
behave  in such a way become  influential  in the  final optimized  formulation. Therefore,  in 
these  cases,  it may  be  relevant  to  compare  the  calculated  values  with  the  real  values 
coming from the prototype. In my formulation, the energy from (n‐6) fatty acids could not 









was not  surprising,  since  it  is known  that protein  content,  in particular  from  cereals and 
pulses, can vary by a factor or two, depending on variety and fertilizer usage 286. Except for 
protein, these results  indirectly confirmed the relative accuracy of the FCD. However, food 



















using  this more  laborious method.  In more  complicated  cases,  a method based on Goal 
Programming may become more interesting than the approach described in this thesis.  
 
In  phase  C  (Figure  17)  of  the  present  study,  adjustments  to  the  formulation  were  not 









kilogram  of  Plumpy’nut®  costs  approximately  5.00 USD  (personal  communication: Malik 
Allouna, MSF/France, Kenya mission; 2008). This suggests that  the  indicative price  for  the 
food  ingredients  component  was  3.4  USD/kg  at  least  for  Plumpy’nut®.  Therefore,  the 
ingredient  costs  for  the  LP  derived  RUTF  prototype  formulation  (approximately  0.70 
USD/Kg)  is  likely  to be substantially cheaper, even after  the addition of  the micronutrient 
premix4. Importantly, the lower transport and importation costs are also likely to result in a 
price  advantage  for  locally  produced  RUTF.  The  regional  agriculture  economy may  also 
benefit  due  to  local  purchase  of  the  ingredients.  However,  more  robust  methods  for 
economic assessment of RUF formulations are needed to support decision makers.  
 
Future  standard  protocols  for  RUF  design  should  address  also  other  economic  aspects, 
including validated methods to obtain food price data in low‐income countries for use in LP 





Since  the  1970’s,  researchers  have  realized  that  most  foods  exhibit  variations  in 
composition,  and  that  a  single  table  value  cannot  fully  represent  any particular  food  286. 
Nutrients figures must therefore be considered as estimates 286.  
 
Section  4.4.4  describes  the  improvements  proposed  for  FCD  data  collection  and 
management. For example,  INFOODS    271,274 and Codex Alimentarius web pages  287  report 














the  final  RUTF  protein  quality. However,  the  Kenyan manufacturer  reported  that US  soy 






different.  Unfortunately,  the  laboratory  used  in  this  study,  and  probably most  industrial 
laboratories in Africa, are not equipped to measure (n‐3) and (n‐6) fatty acids. Rancidity of 
these  nutrients  is  a major  risk  for  the  stability  of  food  product  with  high  fat  content. 
Therefore, close monitoring of its shelf life is important.  
 
Other  important  limitations of  the  chosen  approach were  related  to difficulties  in  taking 
into account the presence of anti‐nutritional factors in cereals and legumes. Michaelsen et 
al.    153  consider  anti‐nutritional  factors  “to  have  a  negative  impact  on  the  solubility  or 
digestibility of required nutrients and thereby reduce the amounts of bioavailable nutrients 
and  available  energy  in  the  foods”.  These  factors  include  (i)  phytate  and  polyphenol 
compounds,  which  inhibit  the  absorption  of  proteins  and  minerals,  like  iron,  zinc  and 
calcium;  (ii)  alfa‐amylase  or  protease  inhibitors,  which  reduce  respectively  starch  and 
protein  digestion,  (iii)    phytohemagglutinins,  which  bind  carbohydrate‐containing 
molecules,  (iv)  saponins,  which  have  negative  effects  on  the  permeability  of  the  small 
intestinal mucosa, and (v) high content of soluble dietary fibers or alfa‐galactosides, which 
may  lead  to  flatulence. Therefore,  these  factors may contribute  to  reduce  the nutritional 
rehabilitation of the beneficiaries of RUF’s, or to prevent their growth or weight gain. For 














The second study, by  Irena et al.289  tested  the  formulation optimized  in  this chapter. This 


















The  RUTF  cost  (based  only  on  food  ingredients)  was  approximately  four  to  five  folds 
cheaper  than  the  current  standard  product  (food  ingredients  and  premix).  Using  the 
methods  described  here,  public  health  nutritionists  and  food  technologists  could  apply 








RUF  formulations  with  similar  macronutrient  composition  (e.g.  protein  quantity  and 
quality), but different  in food  ingredients (e.g. dairy products replaced by combinations of 










5 Trialling  the  acceptability  and  the  safety  of  a  novel  RUF 







Ready‐to‐use  foods  must  be  both  acceptable  and  safe  in  order  to  be  efficacious.  This 
chapter describes concepts of acceptability and safety and their determinants in health care 
and, most  of  all,  in  food  science.  It  includes  a  brief  review  of  the  ways  of measuring 













In  food  science,  disciplines  such  as  dietetics, medicine,  agriculture,  social  anthropology, 
sociology  and  psychology  fuelled  research  exploring  food  acceptability  294. However, Mc 
Ewan suggests that “there  is no clear consensus as  to what  food acceptability actually  is” 





accept  a particular  food or drink,  in particular  circumstances,  at  a moment  in  time”  is  a 
more adequate way  to describe  the  same concept299. However,  in  these and many other 
existing  definitions,  three  components,  namely    physiology,  attitudes  and  sensation,  are 






There  is consensus that “the process by which man accepts or rejects  foods  is of a multi‐








the  food’s  chemical  and  nutritional  composition,  including  the  role  of  chemosensory 
compounds 301, but also the environment  in which the flavours are perceived 301. Also, the 
physical structure and properties of foods300,  including their visual attributes such as  light, 
fluid  and  thick  appearance,  creaminess,  and  flavour  notes  300  are  known  to  affect  food 
acceptability.  In  some  studies,  the  interaction  of  chemical  senses  with  other  oro‐nasal 
sensation301  and  sweetness‐related  factors302  are  well  described,  whereas  the  hedonic‐
response  to sweetness  is known  to be potentiated by  the presence of  fat components302. 




















consumer.  These  include  her/is  gender300,302,304,  age300,304,  genetic300,302, 
physiological295,300,302, hunger/appetite conditions295, or specific metabolic  issues302. Among 
the  latter,  the  literature  reports  that  the  food  consumer  is  influenced  by  her/is  overall 




“the  recall  of  pleasure”301,  and  “the  prediction  of  future  feelings”  301 were  found  to  be 
strong determinants. Others described  in depth were potential behavioural  issues such as 
eating  disorders302,  abnormal  “brain  mechanisms”  302,  but  also  beliefs,  attitudes,  food 
habits,  radical  opinions  about  food  choices,  perceptions  of    product  safety  302,  or  “food 
appropriateness” to specific situations or the time of consumption 305.  
 
Food  acceptability  determinants  may  have  also  a  social  dimension.  For  instance,  the 
“effort”  to  obtain  or  the  price  of  the  chosen  food302  or  social‐cultural  aspects  related 
directly  to  the  food  choices302,  including  their  “convenience”,  their  “prestige”,  the 




Food  acceptance  cannot  be understood  without accounting  for  its  context, as  suggested 
by Rozin et al. 301. This last group of determinants are related to the environment in which 





Urban  and/or  rural  environments302, or more  generally  the  location of  the  consumption, 
may  influence  the  acceptability  of  foods.  For  instance,  the  consumer  reaction  in  a 
institutional setting,  like a food‐sensory analysis  laboratory,  is known to be often different 
from the one observed in a public place like a restaurant, or a private situation like a home 
or a kitchen 295,304,306. Moreover the level of ability to make food choices, like, for instance, 







the  described  determinants  affect  each  other  is  not  entirely  understood.  However,  few 
models  have  been  proposed.  For  instance,  Costell  et  al.    300  suggest  that  a  consumer’s 
response to a given food is mainly defined simultaneously by four intertwined elements. A 
sensory  component  is  the  first  one  which  is  described  and  correlated  to  the  sensory 
properties of  the product. Another  is an affective  component,  responsible  for positive or 
negative  responses  towards  a  product, whereas  a  cognitive  component  comes  from  the 
knowledge  and  opinions  about  the  same  food  item.  A  behavioural  component  involves 
intentions or actions, defining how willing a consumer  is to do something  in a pre‐defined 
situation.  In  other words,  a  food  consumer  never  responds  to  an  individual  component 










to understand but  their study  is, nevertheless,  important.   This  is because    it can provide 
help in understanding eating disorders306, and in measuring the acceptability of novel foods, 




Depending  on  the  subject  under  study,  “different  approaches,  study  designs  and 






The most common are described  in the  following parts of this section, and  included both 
qualitative  and  quantitative  approaches,  such  as  general  questionnaires  and  interviews, 
food  frequency  questionnaires,  food  intake  measurements,  Likert‐scale  questionnaires, 





suffer  from  observer  biases,  due  to  the  limited  capacity  of  human  memory,  and  its 
involuntary distortion of events 294. Repeated 24‐hour recalls are, therefore, often preferred 
294  and  complemented  by  in‐depth  interviews300  in  order  to  reduce  this  data  collection‐
based problem. 
 
Food  frequency questionnaires are  tools easy  to administer, and,  therefore, often used  in 
food acceptability studies. Although inaccurate for the comparison of individual diets, these 
questionnaires  remain valid when    looking  for  the degree of acceptability existing among 
defined study groups294. 
 
Food  intake measurements are common  in many acceptability studies294,302,303.  Intakes are 
expressed as the simple weight of intake, or, more accurately, as weight of intake per person 
body weight per  time unit. However,  these measurements  can be  resources demanding, 
time‐intensive,  and may  alter  the  subjects’  eating habits, distorting  the  interpretation of 
reality 294.  
 
Likert‐scales  can  be  used  to measure  the  degree  of  acceptability  or  rejection  of  health 
treatment307,  foods302,  or  food  supplements308,  but  also  their  names,  label  design, 
appropriateness305. These methods are quick to administer, require minimal  labour305 and 
they come  in different validated versions292 with  scales  from 5  to 15 points. Their  results 
should be expressed as the median score308.   
 























of  interpretations.  Children  are  often  guided  by  taste  alone, whereas,  in  contrast,  food 
choices of adults  tend  to be  influenced by nutritional beliefs and social attitudes  302, and 









single,  simple,  restricted,  refined,  experimental  situation,  it  is  impossible  to  comprehend 
either the variety or possible patterns of the variables controlling them”306. Therefore, only 
an  adequate  combination  of  the  research  methods  and  instruments  described  can  be 
comprehensive enough to assess the acceptability of one, or more foods307.   
 
In my  study, measuring  the acceptability of  ready‐to‐use  foods presented  challenges  and 
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For  instance,  the  “development  of  food  thermal  processing”  (or  food  bottling),  which 
occurred  at  the  end  of  the  eighteenth  century  thanks  to  the  contribution  of  Nicolas 
Appert310,  contributed  to  the  victory  of many Napoleon’s wars.  That was  because,  food 











According  to  Chassy  et  al.  309  “the  situation  is  far  different”  in  low  economy  countries. 
There,  consumers  and  concerned  institutions  are more  focused  on  “obtaining  adequate 
food  supplies  and  ensuring  food  security,  than  they  are  with  food  safety,  although  – 




will  cause  no  harm  if  it  is  used  as  intended,  under  the  anticipated  conditions  of 
















defences309. An example of  these substances  is  represented by  the antinutritional 
factors  found  in  legumes  309.  In  the millenniums of human history,  the process of 
crop domestication reduced the initial concentration of such toxicants; 
 
d. Inadequate  forms  of  semi‐industrial  /  industrial  processing,  and  home‐based 




In  summary,  a  food  and  its  ingredients  are  considered  safe,  when  their 
processing/preparation methods  are  correctly  applied  and,  simultaneously,  chemical  and 
microbiological  analysis  confirm  that  their  (a),  (b),  and  (c)  determinants  are  within 






its safety assessment  is always an essential part of  its development313. For  instance, since 



























in human OR animal beings
No need 
for further controls
 on safety 
of the novel RUF
 
The  text  in  bold  indicates  the  application  of  one  of  the  guiding 
principles  supporting  the  testing  of  a  novel  food  safety.  Source: 
adjusted from the references 101,309,312,313,315,316. 
determined  bench‐mark  product,  called  the  “comparator”313.  The  principles  are  called 
“history of safe use”, “substantial equivalence”, and “safety‐in‐use”, and are described in the 




Since  the  1990s,  the  expression  “history of  safe use”  is  found  in documents  guiding  the 
choice  of  comparator  foods  prepared  by  regulatory  authorities  (see  Figure  19).  This 




For  instance,  a  piece  of 
evidence  for  considering a 
comparator  safe  is  the 
documented  absence  of 
‘history  of  un‐safety’  313. 
This  is  defined,  ideally,  as 












considered  “safe  in  use”, 





Sometimes, no comparator with an acceptable  ‘history of safe use’ may be  found.  In  this 
case,  the  novel  food  is  not  necessarily  unsafe,  but  requires  complex  assessment 
programmes313. These are not described here, because  I  identified a  suitable  comparator 
food, as described in the methods section of this chapter. 
 
Whenever  its “history of safe use”  is documented, the comparator  food assists  the safety 
evaluation of the novel food, testing the existence of  a “substantial equivalence” between 




safety  risk  between  the  comparator  and  the  novel  food  (see  Figure  19).  The  founding 
assumption  is  that  food  components, which  are  identical  in  the  two  products,  pose  the 
same  level  of  risk309.  Therefore,  both  in  the  comparator  and  the  novel  food,  their 
components must be first characterised, and subsequently critically compared.  
 
At  least  two  types  of  components  are  generally  considered.  The  typical  information 
components  include the  food chemical and microbiological hazards,  food preparation and 




Based on  this principle, only  two cases are possible.  If  the components of both  foods are 
identical,  “substantial  equivalence”  between  the  novel  food  and  its  comparator  is 
confirmed.  Therefore,  at  least  according  to  the  European  guidelines  315,  novel  foods 
demonstrated to be substantially equivalent to their comparators are to be considered safe, 
and  no  further  safety  assessment  is  required. However  some  authors309  argue  that  this 




substantial equivalence between  the novel  food and  its comparator.  In view of  this  , any 
highlighted hazard needs to be further understood 315.  In the  literature315, the comparison 













groups  should  depend on  the  trial  design, which  is  ideally  factorial  316.  Few  other  study 
design  features  should  be  considered.  These  include:  limiting  the  chance  of  both  the 
















case,  EFSA  suggests  to  estimate  the  nutritional  risk  posed  by  hypothetical  higher  intake 
ranges of  the novel  food  in  the population of  interest315. Effects  from prolonged  storage, 






our  study,  the  macronutrient  profile  in  the  novel  food  meets  the  standard 





When  testing  safety‐in‐use  of  novel  foods,  allergenic  reactions may  occur  in  association 
with one or more ingredients. However, in this case, EFSA recognizes that it is not possible 
to  make  an  assessment  without  “testing  in  humans”315.  Furthermore,  based  on  the 
international  code  of  Good  Clinical  practices,  the  need  to  assess  a  possible  risk  of 
allergenicity  in humans must be also  justified by  the  level of potential benefits  315.  In our 
study, peanuts are  ingredients  in  the control product, although absent  in  the novel  food. 













hazards  require  closely monitoring of  the  study  individuals’ health  condition,  in order  to 
ensure that they stop consuming the paste as soon as any adverse event may start to arise. 
















controlled  clinical  crossover  trial  with  HIV/TB  patients  in 
Kenya 
 
Research question:  What  are  the  lessons  learnt  in  applying  a  method  to 







The  trial RUTF  (produced by Valid Nutrition, Derry Duff,  Ireland, at  Insta Limited, Nairobi, 
Kenya) contained soybeans, maize and sorghum, no micronutrients premix, and  is referred 
to here as SMS‐RUTFh  (“h” standing  for adult HIV/TB). The control product  (Plumpy’nut®, 
produced by Nutriset, Malaunay, France318) contained peanut butter, milk powder, a premix 
of vitamins and minerals, and is referred to here as P‐RUTF. Both products contained sugar 
(24‐28  and  15/100  g  respectively  for  P‐RUTF  and  SMS‐RUTFh)  and  their macronutrients 
(energy, protein,  lipids) closely met  the UN  requirements  for RUTF as  reported  in chapter 
1.3.2. Both their consistencies were paste‐like, but their tastes and colours were different.  
5.5.2 Study population 


















The  study  design  was  a  two‐arm  crossover  randomized  control  trial.  At  enrolment  the 
patients were given a number from 1 to 2, randomly generated using an Excel spreadsheet 
(Rand function), that corresponded to one of the trial groups. Each group received one of 
the  two products during each phase, which was assigned  to  the participants  following an 
AB/BA sequence.   
 
Under direct observation, during  two weeks  (10 working days), water ad  libitum and 250 




















The  consumption  criterion  consisted  of  three  sub‐criteria.  The  sub‐criteria  ‘average 
consumption’ was satisfied if average SMS‐RUTFh intake was more than 75 per cent (187.5 
g) of  the offered  amount within one  hour  (criterion  1.1;  Table  18), whereas  SMS‐RUTFh 
‘daily consumption’ was met if its intake was higher than 75 per cent of the offered food for 
more  than  75  per  cent  of  the  days  on  the  trial  (criterion  1.2).  Finally  the  ‘comparative 
energy  intake’  criterion  (1.3) was  satisfied  if  the  average  energy  intake  per  kg  of  body 
weight was significantly higher than 75 per cent of the energy intake from the P‐RUTF. 
5.5.4.2 Criterion 2: safety 
Soy, maize,  sorghum  RUTFh was  considered  acceptable  from  the  safety  point  of  view  if 
participants  did  not  report  any  of  five  co‐morbidity  events more  frequently  than  in  the 
control  product  (criteria  2.1‐2.5;  Table  19).  This  parameter was  expressed  as  the mean 
number of days  in which morbidity events occurred during product consumption (10 days 





A  product was  considered  preferred  if  its  score was  higher  than  the  alternative  in  the 
following aspects: general preference, colour, taste, sweetness, and texture (criteria 3.1‐3.5; 
Table 20).   At the end of the trial, each participant was asked to select the most preferred 


















have been  immediately  referred  to  the  local  clinic,  and withdrawn  from  the  study  if  the 
cause was considered to be related to RUTF intake.  
5.5.5 Sample size 
A paediatric acceptability  crossover  trial on RUTF  321  involved a  sample  size of  thirty‐one 
children, during two days of RUTF  feeding, to detect a significant difference with alfa and 
beta  errors  of  0.05  and  0.95.  Its  power  calculation,  based  on  of  RUTF  daily  intake, 
considered one standard deviation an acceptable difference to be detected.  
 
However  since  previous  research  on  RUTF  acceptability was  not  available  in  adults,  the 





Student’s  T  test  and  regression  models  were  used  to  test  for  differences  between 
continuous data. The Wilcoxon rank‐sum (Mann Whitney) test and sign test were used for 
non‐normally distributed, un‐paired, continuous data, whereas the Wilcoxon matched‐pairs 
signed‐rank  test was used  for non‐normally distributed, paired continuous data,  including 




for  potential  confounders,  including  clinical  events,  socio‐economic  data  and 
 168 
 
anthropometry  at  enrolment.  Logistic  regression  models  explored  if  preference  for  a 
product could be influenced by group membership. 
 
Analysis  of  ordinal  score  for  preference  criteria  was  based  on  logistic  (not  ordinal) 
regression, after regrouping the data into two categories (scores 1 and score 2, 3, 4 or 5 out 




so  that  the participant’s  series of  repeated measurements were  considered  as  individual 

























kinds  of  food  intake  at  household  level,  between  the  two  groups.  No  difference  was 
detected between  the  two weeks DDS, nor within  the  same week  for  the  same patients 
Table 17. No carry over regarding amount and daily energy intake was reported (P>0.05).   
 















































  Tuesday Thursday Tuesday Thursday
   
Group 1 (n=19)  7.4 (6.5; 8.2) 7.7 (6.9; 8.5) 7.4 (6.5; 8.3)  7.6 (7.0; 8.2)
Group 2 (n=21)  7.8 (7.1;   8.5) 6.7 (5.9; 7.6) 7.7 (6.8; 8.6)  6.9 (6.7; 7.7)
   









Both  average  and daily  consumption measurements were  above  the  threshold  (P<0.001; 
Table 18) for SMS‐RUTFh, confirming that: all the patients consumed more than 75 per cent 




A  linear  regression  model  (robust  standard‐error,  40‐cluster  analysis;  R2=  0.11;  P=0.01; 
N=779) showed that the difference between the energy intakes of the two products (SMS‐
RUTFh and P‐RUTF) was not statistically significant (P=0.06) when adjusted for confounders 
identified  by  a  stepwise  analysis  (initial  BMI,  negatively  correlated  with  energy  intake, 
P=0.002;  presence  of  throat  sores,  negatively  correlated,  P=0.13;  9  subjects  out  of  41 
reported presence of throat sores). 
 
Other  potential  confounders, which  showed  no  or  very  small  influence  in  the  explored 







However  when  applying  robust  standard  error  analysis,  the  data  showed  that  these 
morbidities were significantly more  frequent than when subjects were consuming P‐RUTF 













participants. However,  for most patients,  the preferred product was  the one allocated  to 
them  in  the  first phase of  the  trial. For participants  starting phase 1 with product A,  the 
odds  to  prefer  product A were  5.4  times  (95%  CI,  1.4‐20.4)  higher  than  for  participants 
starting product A in phase 2 (P=0.02). 
 




to  the  first  provided  product”,  but  felt  that  “the  products were  increasing weight”  and 





















(230.9; 255.0)  187.5§    <0.001  <0.001 







(81.4; 94.0)  75.0    <0.001  <0.001 
































  A B  
       
C2.1: Nausea  0.16 (0.05; 0.47)  0.09 (0.05; 0.14)  0.04 
C2.2: Vomit  0.04 (0.01; 0.19) 0.02 (0.01; 0.04) 0.03 
C2.3: Stomach pain  0.14 (0.05; 0.38) 0.16 (0.10; 0.25) NS 
C2.4: Flatulence  0.13 (0.05; 0.36)  0.16 (0.09; 0.26)  NS 
C2.5: Diarrhoea   0.36 (0.03; 0.70)  0.31 (0.13; 0.49)  NS 









Criteria  SMS‐RUTFh*  P‐RUTF*  P value 
(n=39) (n=41)  
       
C3.1: General preference       
Median (IQR) 1 (1;2) 2 (2; 3) <0.001 
Mean (95%CI) 1.4 (1.2; 1.5)  2.4 (2.1; 2.8)   
       
C3.2: Colour       
Median (IQR) 2 (1; 3) 2 (1; 3) NS 
Mean (95%CI) 2.0 (1.6; 2.4)  2.1 (1.7; 2.4)   
       
C3.3: Taste       
Median (IQR) 1 (1; 2) 3 (2; 4) <0.001 
Mean (95%CI) 1.5 (1.3; 1.8)  2.7 (2.3; 3.1)   
       
C3.4: Sweetness        
Median (IQR) 1 (1; 2) 3 (2; 4) <0.001 
Mean (95%CI) 1.7 (1.3; 2.0)  2.3 (2.5; 3.3)   
       
C3.5: Texture       
Median (IQR) 2 (1; 4) 2 (1; 2) 0.02 
Mean (95%CI) 2.3 (1.8; 2.7)  1.7 (1.4; 1.9)   







The present  study demonstrated  that most pre‐stated criteria  for acceptability of a novel 




The  findings  of  this  study  suggest  that,  in  this participant  group,  SMS‐RUTFh  intake was 





were statistically  similar when adjusted  for possible confounders; but  the study might be 




a  similar  conclusion.  In SAM patients,  cases of  swallowing difficulty, need  to be detected 
early  by  medical  staff,  and  ideally  addressed  with  appropriate  in‐patient  care  using 
therapeutic milk formulas (F75 and F100)70. As soon as the swallowing capacity is restored, 
generally  in  a  few  days,  RUTF‐based  nutrition  can  be  started  and  home‐based  care 
established. 
 
The  regression  analysis  found  no  evidence  of  increased morbidity  associated with  SMS‐
RUTFh  consumption  for  most  parameters.    Although  the  frequencies  of  nausea  and 
vomiting  were  higher  in  SMS‐RUTFh  than  in  the  control  product,  they  never  affected 
participants for a prolonged period, and days of  illness appeared to be randomly scattered 
along  the  time  course  of  the  trial.  The  regression  models  showed  that  the  two  co‐










The  order  the  RUTFs  were  offered  to  the  participants  was  important.  SMS‐RUTFh 




Some  constraints  were  highlighted.  The  participants  of  the  trial  were  enrolled  in  the 
MoH/MSF HIV programme and had all been exposed  to P‐RUTF.  Information of  this kind, 
acquired  prior  to  direct  experience,  could  have  shaped  the  food  consumption  and 
preferences as suggested by Costell et al. 300.  
5.7.2 Lesson learnt about the method 
This  study  highlighted  important  aspects  in  the  application  of  methods  to  assess  RUF 
acceptability. Among these, the results confirmed that a combination of both quantitative 




The sample size  (n=41) compares  favourably with an  Indian study, whose sample size was 
powered for a difference of at least one standard deviation. Determining the equivalence or 
non‐inferiority  of  SMS‐RUTFh  to  the  current  standard  product,  rather  than  its  statistical 
superiority to pre‐stated thresholds, represents an alternative study design used to robustly 
validate a novel  therapy  325, but  requires a  large  sample  size  326. Other  randomized  trials 





have been  too  short  to  simulate  the  nutrition  rehabilitation  therapy  in wasted  adults  (3 
months; MSF/Kenya,  personal  communication,  2008).  The main  use  of  RUTF  is  in  out‐







of  the product and  the  findings of  the  trial. A  taste  comparison between RUTF with and 




also  other  legumes  and  cereals,  are  potential  carriers  of  this  toxin.  Therefore,  they  can 
increase  the  risk associated with morbidities. Safe  limits of aflatoxin  level  intakes are  still 




There  is  no  “gold  standard”  to  test  food  acceptability.  In  spite  of  such  a  constraint,  this 
exploratory study demonstrated the utility of this method and the acceptability of a novel, 
























This  research described an  innovative method  to design and pre‐test  improved and  cost‐
effective  RUF  spreads,  prior  to  subsequent  clinical  trialling.  A  case  study  was  used  to 




As documented  in the  first part of this thesis, undernutrition,  in all  its sub‐forms,  is still a 
worldwide  morbidity  and  mortality  risk  factor  both  for  children1  and  for  adults45.  Its 
consequences, notably  the physiological  and psychological  impairment of  its  victims,  are 
often among the main causes of reduced survival. Eight decades of medical and nutrition 
research  (section  1.2.1)  has  led  to  improved  dietary  solutions  in  low‐resources  settings, 
based  on  lipid‐based,  ready‐to‐use  food  products  described  in  section  1.3.  Section  1.4 
detailed  how  the  lack  of  a  framework  to  design  and  validate  improved  and,  potentially, 
cheaper  formulations  is currently  limiting the global scale‐up of their production and use, 
despite funding being available 40.  
 
The method described  in  this  thesis proposes an evidence‐based  framework  for  the pre‐
clinical product design and validation. The following sections discuss the key findings of the 
proposed new approach, highlight  the potential  implications  for  interested policy‐makers, 
donors, public health practitioners, and  food technologists,  list areas  for  further research, 
and explores the limitations encountered. 
7.1 Key findings 
Based on  the  results  reported and discussed  in detail  in  the previous chapters,  I describe 
here  the main  key  findings  observed  in  the  application  of  the  proposed method  to  the 





method,  in  a HIV  programme  in  Kenya,  found  a  low  level  of  reported  adherence  to  the 
prescribed dose of P‐RUTF. Other important findings suggested that an improved approach 








linear programming,  formulated  a RUTF which was  three  to  five  times  cheaper  than  the 





Subsequently,  I  tested a method  to confirm  the acceptability and  the  safety of  the novel 









process  to develop, pre‐test and clinically  trial novel RUF products. The clinical  trialling  is 
not part of the aim of this thesis. However, for reasons of completeness, it was included in 
the  framework  described  in  Figure  29.  Furthermore,  a  complete  clinical  protocol  was 
designed  in  collaboration with MSF/Netherlands  to  trial  the  RUF  developed  in my  case 
study. 
 
In my  framework,  the design  and  the pre‐testing were organized  in  a  sequence of  three 
phases or process stages. The  results of each phase  formed  the basis  for  the subsequent 
phase. In Figure 29, the outputs of phases A, B and C were respectively (i) the set‐up of all 























for 100 g foods
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Without premix in the formulation















In  stage  A  of  the  framework,  the  group  to  be  rehabilitated  by  the  RUF  spread  in  a 




may  be  required,  from  the  perspective  of  the  consumers.  The  same  study  also  offered 
important insights into the barriers limiting RUF adherence from a programme‐based point 
of view. However,  the  latter are  intervention‐specific, and  therefore do not appear  in  the 
flow chart in Figure 29.  
 
In  phase  A  the  potential  food  ingredients  are  identified,  along  with  data  on  the 
















 To  ensure  that  the  LP‐based  prototype  meets  the  pre‐set  macronutrient 
requirements (method discussed in sub‐study 2); 
 






RUF;  when  their  requirements  are  not  available,  these  must  be  separately 
determined (sub‐study 4) 
 
In  the  LP‐based  prototype,  the  macronutrients  must  be  as  close  as  possible  to  the 
requirements  pre‐determined  for  the  target  group.  Therefore,  the  prototype 
macronutrients were analysed in a laboratory specializing in food analysis. 
 
In our  case  study,  the prototype macronutrients were  found  to be within  the acceptable 
pre‐set range. However, if this had not been the case, the sensitivity analysis tool, described 
in the same sub‐study, could have helped to identify how to improve the LP model settings, 
if  necessary  by  relaxing  some  of  the  constraints  and  re‐running  the  LP  model.  In  the 
algorithm on Figure 29,  the dotted arrow describes  this path. The macronutrients  in  the 
second optimized formulation would have been re‐tested as an additional check. 
 





acceptability  and  its  safety  had  to  be  confirmed.  They  were  compared  in  a  crossover‐
controlled trial in which two groups alternately received the prototype (intervention; SMS‐
RUTFh) and the current most frequently used product (control; P‐RUTF). The strengths and 




the pre‐set  requirements  for  the  target  group. When  these  are  known,  a premix  can be 
designed. 
 
However,  the micronutrient  requirements may not be available.  In  this  case,  sub‐study 4 
suggested a method  to determine  the specifications of  the  final  formulation  for  the RUF. 




target group  for  the  improved RUF  spread.  In our case study,  twenty‐three micronutrient 
specifications were  proposed.  The  limitations of  the described method  are  case‐specific, 
and the sub‐study 4 discusses them in depth. 
 
Once mixed with  the optimized  formulation prototype, micronutrient  fortificant powders 
may  change  the  final  taste  of  the  RUF.  For  this  reason,  before  proceeding with  clinical 
trialling, a sensory analysis  should be undertaken.  If  taste‐related  issues arise, alternative 










by existing models and  frameworks that are currently  in  industry. One of the  these  is  the 











and  health  staff members  expressed  the  need  for  RUTF  “to  increase  body  strength  and 
weight”,  for a decreased sweetness and  for a  texture making swallowing easy. The WHAT 
section  also  included  other  elements.  Among  the  agencies  endorsing,  supplying  and 
delivering RUTF to HIV/TB wasted adults, there is a demand for an increase in survival and 
recovery rates. The product should be also safe and cheaper than the current formulation, 
possibly  formulated with  locally available  ingredients, which,  therefore, may better meet 
the patients’ taste and preferences. 
 
For  each  element,  reported  in  the  WHAT  section,  I  identified  specific  quantitative 
objectives, which are included in the TARGETS section of Figure 30. These included meeting 
pre‐set  palatability  (sugar  15‐18%;  sorghum  >7  g/100  g)  and  UN  2007  macronutrient 
requirements. Nonetheless,  in the comparison with the current standard, the product had 
to comply with a lower cost (USD/kg), a texture based on a fat content of 28‐36 per cent, an 
equivalent  or  higher  consumption  or  preference  rate,  and  an  equivalent  or  inferior  co‐
morbidity event incidence. In the study group, based on the available literature, I assumed 
that  improved micronutrient  specifications  would  lead  to  a  reduction  of  side‐effects  in 
adults taking TB drugs, and an increase in survival and recovery rates. Therefore, the related 




TARGET  (see  in Figure 30). For  this purpose, during  the  formulation phase,  I proposed  to 
decrease the sugar level, introduce sorghum, and optimize the combination of cheaper, but 
nutritious ingredients in order to meet pre‐set requirements of macronutrients and texture. 
To  confirm  the  increase,  decrease  or  equivalence  of  the  pre‐set  TARGETS  based  on  the 
current standard  (P‐RUTF),  I compared  the  latter with  the novel  formulation, which were 
given  to,  respectively,  a  control  and  an  intervention  study  groups.  In  the  absence  of 
micronutrient  requirements  for  the  target group,  I developed a method, based on  robust 
scientific evidence, in order to achieve improved RUTF specifications.  
 
In  the  “QFD  roof”  (Figure 30),  I  identified which activities,  from  the HOW area, could be 
clustered for convenience. The HOW activities were grouped into the sub‐studies 2, 3 and 4. 
That was done because the  linear programming sub‐study could simultaneously tackle the 




Table  27  ‐  Definitions  of  internal  and  external  validity, 
applicability and transferability. 
Term  Definition 
Internal validity  The  likelihood  that  study  results  are  valid  for  the 
original study population.  
External validity  The likelihood that  study findings could be 




Transferability The  likelihood  that  the  study  findings  could  be 














proposed  QFD  met  all  the  pre‐set  improvement  goals,  and  all  the  activities  were 
consistently object‐driven.  
 
For  the  purposes  of  this  thesis  research,  the  QFD  approach,  summarised  in  Figure  2, 
represented  an  efficient  tool  for  planning  purposes.  The QFD matrix  suggested  an  ideal 
sequence of steps to take in order to design and pre‐test novel RUF formulations, allowing 






In addition  to  the case study presented  in  this  thesis,  the proposed design and validation 
framework may  contribute  to 
improve  the  design  of  other 
types  of  RUF  products.  It  is 
hoped that these may be used 
to rehabilitate and/or prevent 
forms  of  malnutrition,  in 
settings,  and  in  life‐stage 
groups which  differ  from  the 
ones  described  here. 
However,  prior  to  this,  the 
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generalizability  of  any  innovative method must  be  proved,  before  decision makers  and 
donors can endorse it.  
 
In  public  health,  the  definition  of  generalizability,    and  the  criteria  to measure  it,  are  a 
current  concern  464–467,  because  of  their  complexity.  The  literature  reports  at  least  four 
terms  associated  with  the  concept  of  generalizability  (see  in  Table  27).  Those  include 
internal and external validity, applicability and transferability.  
The  internal  and  external  validity  is  the  likelihood  that  study  results  may  be  valid 







in  other  world  regions  and  study  populations.  In  most  cases,  the  purpose  came  from 
implementing agencies, and their urgent demand for  improved  formulation solutions. The 
outputs  consisted  of  the  design  and  the  pre‐testing  of  novel  RUF  spread  formulations, 
designed for other forms of malnutrition, and targeting other age groups and geographical 
settings. Although  not driven  by  the  same  research  goal,  the  application  of  the method 
proposed  in  this  thesis  is  this  way  is  helping  to  define  the  level  of  “applicability”  or 
“transferability” of its results to other contexts.  
 
For  this  reason  the  following  section  summarizes  the  experiences  gained  from 
implementing the developed framework in other settings.  
7.2.2 Experiences  in  implementing  the  developed  framework  in  other 
settings 
In Sri Lanka  in 2009,  in  in collaboration with the  local Medical Research Council, and with 
funds from Irish Aid, a formulation based on soy, rice, milk powder and lentils was designed, 
and  its acceptability and  safety pre‐trialled among children  from a  slum  in Colombo. The 
research protocol  followed  the methods described  in  sub‐study numbers 3  and 4 of  this 
thesis. However, the control products were both Plumpy’nut and BP‐100. The collected data 






current moment, the  formulation  is to be  tested  for  its effectiveness  in Bangladesh by an 
international  NGO.  More  information  about  the  design  and  the  pre‐testing  study  are 
available in a published paper, available in annexes. 
 
In 2010,  in Vietnam,  in  collaboration with  the national Nutrition  Institute,  a  formulation 
based on soy, rice, mung beans and milk powder was designed based on the findings from 
sub‐study number 2. The  formulation  is currently being  tested  for  its acceptability, safety 
and effectiveness by other research institutions.  
 




powder  and  sorghum.  In 2012,  the  findings  comparing  the  latter with  a  fortified 
porridge were  reported  in  a  peer‐reviewed  journal  234  (the  paper  is  available  in 











 One  SMS‐RUTF  was  trialled  in  wasted  Zambian  children.  It  contained  the  food 








In  spite  of  the  successful  application  of  the  proposed  method  in  at  least  six  study 
populations and settings, the generalizability of the framework cannot be taken for granted. 




However,  it  can  be  argued  that  the  applicability  of  the  proposed method  seems  to  be 
promising,  at  least  in  the  regions  and  for  the  groups where  the proposed  framework  to 
improve the current RUF spreads was applied. 
7.3 Implications of this study 





cheaper  RUF  formulations.  Moreover,  their  recommendations  for  further  research 
coincided with the identified knowledge gaps tackled in this thesis. Since the applicability of 





to distribute RUTF, based on  the UNICEF  Supply Division  requirements, were nineteen  94 
and “expected to increase in the coming years, especially in countries where RUTF is used” 
94.  The  World  Bank  expects  these  firms  to  be  fuelled  by  economic  sources  including 
“government  finances,  private  sector  corporations,  and  international  financial  aid”  40. 









nutrition  rehabilitation  programme,  clinical  information  about  the  patients  could  not  be 
collected.  This may  have  helped  in  understanding  the  impact  of  RUF‐based  approach  in 




an  improved  RUF  product.  Although  the  proposed  approach  achieved  its  goal with  one 
constraint adjustment, the economic aspects of the choice of the ingredients, the impact of 
using  alternative  food  composition  databases  and  the  advantages  of  more  complex 
mathematical models may  have  improved  the  proposed  approach.  In  particular,  future 








Furthermore,  in  the proposed method  framework,  the RUF  spread does not  contain  the 
micronutrient  premix,  because  the  premix  is  designed  and  procured  on  the  basis  of  a 
formulation already proved acceptable. This means  that  the proposed  framework  fails  to 






of  the  results  has  been  challenging.  In  view of  this,  the  validity of  the method must  be 
confirmed.   
 
The overall method described  in  this  thesis  is consistent with  the use of  the QFD model, 
which also showed some limitations. For instance,  QFD does not address the fact that food 
“raw materials  show a natural predisposition  for variation” which does not  tally with  the 
 270 
 
somewhat  inflexible character of QFD charts  regarding changes  462,468. This same problem 
was confirmed, in section 4.9, by the limitations of the food composition databases used to 
optimize  the  LP model.  Furthermore, QFD  does  not  capture  the  interactions  among  the 
attributes listed by the consumers, limiting the potentiality of the method.  
7.5 Recommendations for further research 











point  of  view  of  the  current  standards.  Therefore,  a  tailored  approach may  be 
needed. Among the most urgent specifications required are protocols to determine 
the shelf life of these products, and of their micronutrients, taking into account the 
extreme  conditions  (i.e.  temperature,  transport,  etc.)  of  the  humanitarian  food 
supply chain. 
 
Research question – how can  field‐based, quick and  reliable quality  tests  (microbiological 
and chemical) be developed to ensure the efficacy and the safety of RUF products?  
 






However, food quality  laboratories  in developing countries have a  limited capacity 
to  perform  both  these  kinds  of  analysis.  This was  confirmed  by  a  recent  study 
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looking  at  the  development  of  one  RUF  spread  in  Africa  146.  Quick,  cheap,  and 
portable  tests  should  therefore  be  urgently  designed  and  produced  to  allow 
operators  in  the  field  to check on  the RUF  safety before  its delivery. They  should 
come with acceptable ranges for each key nutrient of the RUF product.  






In  undernutrition  research,  little  is  known  about  the  real  level  of micronutrient 
absorption. This might be because the research methods for this kind of study are 
costly  and  complex  to  implement  469.  This  last  issue may  present  an  additional 
challenge  in  low‐resource  settings.  In  the  available  literature,  some  authors  28,174 
suggest lists of chemical forms for most micronutrients to be included in foods used 
in  feeding programmes. However,  their  absorption  ratio  remains  undocumented. 
This matters for each micronutrient. Studies  identifying the optimal chemical form 
for both  type  I and  II micronutrients  for RUF  formulation  are urgently needed  in 
order to optimize their absorption. 
 
Research  question  –  can  the  digestibility  of  RUF  products  be monitored  and,  if  needed, 
increased? 
 
Little  is known about  the current  level of digestibility  in undernourished patients, 
when  fed with RUF products. UNICEF  Supply Division and MSF  consider  food aid 





However,  nausea  and  vomiting  were  more  frequent  in  association  with  RUTF 






digestibility  in  undernourished  people.  Only  one  study  was  found  looking  at 
digestibility improvement using different techniques to process food aid items. This 
study 285 compared the starch digestibility of a blended corn‐soy flour mix, prepared 
with  and  without  extrusion  cooking.  The  study  was  conducted  in  eight  healthy 
volunteers, using 13C enrichment of breath samples  for 8 hours, measuring breath 
H2 concentration during 12 hours to assess bacterial fermentation in the colon, and 
asking  the  volunteers  to  report  hunger  on  a  visual  scale  during  eight  hours  at 
intervals of  four hours. The conclusions suggested  that extrusion did not seem  to 
substantially  improve  blended  foods  digestibility  and may  promote  carbohydrate 
fermentation in the colon and increase satiety. 
 
However, other  techniques,  such as  infra‐red or micronization,  that exist  in  some 
low‐income countries and may be used in combination with extrusion, may provide 






Section 1.3 reported how RUF production  is getting closer to the areas where  it  is 
used. This approach has implications for the final RUF costs. Beside the ingredients 
and transport, the processing and the packaging are the most expensive steps, and 
they  influence  the product  shelf  life. With nitrogen‐flush packaging,  for  instance, 
the  spread  can  be  safely  consumed  after  two  years  from  the  production  470. 
However,  the   machinery  needed  “is  the most  expensive  component  of  a  RUTF 
production line” and, RUF spreads packed with non‐airtight sachets will need to be 
consumed within  a  few   months,    limiting    their   utility  470.  This  is  an  additional 










policies  and  practices.  This  is  because  “the  ratio  of  net  health‐care  costs  to  net 
health  benefits  provides  an  index  by  which  priorities  may  be  set”  471.  Cost‐
effectiveness was only found described  in a few studies, which were limited to one 
type of RUTF 472–474 and focused on the programme rather than the product. It can 
be speculated  that with a proliferation of  formulations,  the economic perspective 








Conflicting  evidence  surrounds  the  use  of  probiotics,  prebiotics  and  synbiotics. 
Recently, Cunnigham et al.  475 report increasing evidence that “probiotics bacteria may  
stabilize   CD4   cell   numbers    in   HIV‐1    infected    children   and   are    likely    to   have 
protective  effects  against  inflammation  and  chronic  immune  activation  of  the 
gastrointestinal  immune system”.  In most studies, probiotics and  their derivates were 
mostly provided  in  liquid‐based food carriers. When offered to the consumer  in a RUF 
spread, the results were  less positive. Kerac et al.   152,476 report that  in an African, HIV‐


















Categories  of  foods  are  described  by  international  organizations  to  ease 
transnational  trade  operations.  Today,  RUF  products  are  global  products with  an 
increasing regional consumption among vulnerable people in low‐resource settings. 
However, RUF items do not yet benefit from a formal legal recognition framework, 
and no  legal definition of RUF  is  currently available. Section 1.3.1.1 of  this  thesis 








availability on  the market,  thereby  limiting  the  rehabilitation of people  in need.  The 
impact of this approach was not documented sufficiently and possible alternatives need 
to be further explored. However, new  legal forms aiming to protect  innovations, while 





















This  thesis designed  and  pre‐tested  an  innovative method  to  improve  cost‐effective  RUF 










 Sub‐study  1  concluded  that  the  level  of  reported  compliance  with  the 
prescribed  dose  of  the  current  standard  RUTF  was  low.  Based  on  the 
collected evidence, an  improved approach  to  treating malnourished HIV‐
positive adults  in  limited  resource  contexts  is needed and must  consider 




 The  conclusions  of  the  sub‐study  2 were  that  a mathematical  approach 
called  linear  programming  can  contribute  to  the  design  of  RUF 
(therapeutic, supplementary, or complementary), targeting different forms 
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 ‘Linear  Programming:  A  Nutritional  Perspective  –  watch  on 
http://goo.gl/w79Gg 
 
 Medicus Mundi  ‐  “An  Ideal Match?! Connecting NGOs and Academia  in Research  for 
Global Health”. September 2011. Amsterdam.  
 A cheaper ready‐to‐use therapeutic food (RUTF) specific for wasted adults living 







































QUESTIONNAIRE – Patient         I.D. CODE: ______ 
 


























































































































































Check list of contents for the study subject consent 
 
Survey Information Sheet for Requesting Participants Consent - IMPORTANT for 
the ADMINISTRATOR or the information sheet (to read BEFORE starting): 
 
Explain the following topics ONLY if: 
 the patient is ABLE to understand them. I.e.: same language of the speaker (DhoLuo, or 
English, etc.), healthy mental status, not under drugs, etc. 
 TIME is available to explore all the different aspects, including answering to possible 
questions 
 
TOPICS to cover for informed consent: 
(please tick on the little box beside) 
The University of London and Valid International are working together with MoH, MSF, 
KEMRI and other implementing partners to promote the nutritional status of the adult 
population in the Homabay area who are malnourished and who are also living with HIV. 
The aim of the survey is to test a new nutritional therapy specific for people are 
malnourished and who might be having the virus of HIV and therefore in need of ART. 
 
 
The new nutritional product will be tested in this first phase of the study on patients who 
are HIV+, under ART but who are not malnourished or in complex clinical conditions 
 
 
If you decide not to participate to the study you will still receive the routine health care 
  
Two different therapeutic nutritional products are now available and being tested. The old 
one is currently used by MSF when adults or children are malnourished disregarding their 
HIV status. A new one has been designed specifically for people living with HIV and may 
help to decrease the possibility of infections and produce quicker weight gain. 
 
 
You will be not told which nutritional therapeutic product you are given to make the results 
of the study more objective. But, if you wish, you can request to know which one you have 
received at the end of the study. 
 
 
The new product is very similar to the old one, but is cheaper and has different amounts of 




The risk of the new product being at all harmful has been minimized as much as possible 
by carrying out various analysis on the product 
 
 
If the new product is found to be more efficient than the old one in helping people living 
recover and gain weight many people in the whole world will benefit enormously from it. 
 
 
If the new product will perform just as well it will be still good because the new one is 
cheaper than the old one so more product can be produced and more people can benefit. 
 
 
If you decide to take part in the survey you may choose to stop participating at any time 
you wish and nothing bad will happen. You will continue to receive any food aid and/or 
health care you are already getting in the normal way.  
 
 
If during your treatment you delay in coming to the clinic, somebody from our team will try 
to call your phone number (if any) and to try to understand the reason for your defaulting.   
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If you do not want this to happen now or later, you will be still entitled to participate to get 
full medical assistance 
 
During the study you may be invited to be interviewed about problems you faced along the 
consumption of the food. Your opinion will be very important to allow us to improve the 
product and the delivery service for other people. The opinions you will share with us will 
be not associated to your identification.  
 
 








Which criteria for admission? If not respected you will be not admitted – sorry! 
 
 BMI 18.5 – 20 
   
 Residents or living close to Homa Bay town  
 
 
What should I do to participate to the study? 
 
Every day you MUST come with you the MSF or MoH patient card (blue or yellow)  
You will come/arrive to the study site (Homa Bay downtown): 
 between 11:30am and 13:00pm and you will remain there only for two or three hours 
maximum 
 
 every day (from Monday to Fridaty):  
o from the 30th of June to the 11th of July (2 weeks) and   
o from the 21st of July to the 1st of August (other 2 weeks)  
VERY IMPORTANT: 
If you will miss more than 2 days: 
 you will be asked not to come back to the study 
 
 
 you will be not admitted anymore  
 
What will I get during the study?  
you will get free lunch based on Plumpynut or the new product  
you will get clean drinkable water 
  
you will get a reimbursement of 100 KSh for the transport  every day  







Homa bay: __/__/2008 
CONSENT FORM 
 
Title of project: 
A randomized controlled non-inferiority trial of a  low-cost, nutrient-dense food, for malnourished 
HIV positive Kenyan adults being treated with standard ART  -  
 
Acceptability Trial phase 
 
      (Please put your initials in the box) 
 
1. I confirm that I have read and understood the information details of the study provided in information 
sheet dated for the above study and have had the opportunity to ask questions. An gi adier ni asomo 




2.  I confirm that I have had sufficient time to consider whether or not I want to be included in the study An gi 
adiera ni ne omiya thuolo moromo mondo ayangi awuon ka adwaro donjo e risachni kata ooyo. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving 
any reason, without my medical care or legal rights being affected. Angeyo ni donjo e risachni en yiro 
mara kendo anyalo wuokie samoro a mora mahero ma onge gima aluoro ka luwore gi ngimana mapile 
 
 
4. I understand that sections of any of my medical notes may be looked at by responsible individuals from 
the research project team or from regulatory authorities where it is relevant to my taking part in research.  
I give permission for these individuals to have access to my records. Angeyo ni bugena mag osubtal 
inyalo ngiyo gi jotich mochungne risachni 
5. I am happy to receive the tracing team in case I do not come to the fixed appointment. An gi adier ni 
asomo kendo awinjo andikegi duto maluore gi risachni kendo. Mora mahero ma onge gima aluoro ka 





I agree to take part in the above study. Ayie mondo abed achiel kuom joma odonjo e risachni 
 
 
1 form for Patient;  
1 to be kept as part of the study documentation,   
 
(Continued on next page)                                 
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1 form for Patient;  















Name of Person taking consent 
(if different from researcher) 
(Nying ngama ndiko jatuo) 
 Date (Tarik)  Signature 





(to be contacted if there are any 
problems)  
(Nying ngama ochungne risach 
ma onego wuogo ka nitie wach 
moro) 
 Date (Tarik)  Signature 
(Seyi mar ngama ochung ne 
risachni) 
     
 
Comments or concerns during the study  
 
If you have any comments or concerns you may discuss these with the investigator 
(Filippo Dibari, Tel. 0728 163455).   If you wish to go further and complain about any aspect 
of the way you have been approached or treated during the course of the study, you should 
write or get in touch with anyone of the MoH/MSF clinicians who are fully aware of the 
study (tel. 05922401), the MSF field coordinator (Tel. 05922401). 
 
Ka ini wach moro amora to inyalo wuoyo gi ngama ochungne risach ni miluongo ni Filippo. 
To ka wach moro ochuanyi inyalo wuoyo gi to Migawo mag thieth e Homa Bay District kata 




Survey Id. No. __/__/      Date of interview __/__/2008 
First name………………………………………..       Age (years) __/__/ 
Village/Town of residence…………………………………………. 
Sex         (1=Male)  (2=Female) 



















































































Please describe the foods (meals and snacks) that you ate yesterday from the moment you 
woke up until when you went to bed, whether at home or outside the home. Start with the 
first food eaten in the morning. Diher nyisa chiemo mane miichamo nyoro chakre saa mane 
ichiewo nyaka saa mane idhi nindo, e odi kata oko mar odi.Chakna gi chiemo mi chamo gokinyi. 
Question 







Any foods made from millet, sorghum, maize, 
rice, wheat (ugali, bread, biscuits, cakes 
porridge or pastes or other locally available 
grains.  
Chiemo mora mora molos gi bel, kal, bando,ochele, 










pumpkin, carrots or sweet potatoes that are 
orange inside, sweet pepper and other vitamin 
A rich vegetables. 






3 WHITE TUBERS 
AND ROOTS 
Irish potatoes, white yams,white sweet 
potatoes cassava, or foods made from roots. 







4 DARK GREEN 
LEAFY 
VEGETABLES 
dark green/leafy vegetables e.g. amaranthus, 
black night shade, spider plant, cowpeas 
leaves, pumpkin leaves, kales, spinach, 
cassava leaves + other wild ones. 
Mchicha/ododo, dek, boo, susa, sukuma,spinach, it 








other vegetables (e.g. tomato, onion, 
eggplant) , including wild vegetables 





6 VITAMIN A 
RICH FRUITS 
ripe mangoes, paw paws, water melon +other 
locally available vitamin A-rich fruits 
























7 OTHER FRUITS Oranges, passion, pineapples, Ovacado, bananas, 
including wild fruits. 





8 ORGAN MEAT 
(IRON-RICH) 
liver, kidney, heart, gizzard, intestines or other 
organ meats or blood-based foods. 






9 FLESH MEATS beef, pork, lamb, goat, rabbit, wild game, chicken, 
duck, or other birds. 













Fresh or dried fish or shellfish. Manumo koso mothol; 
Omena, ngege, mbuta gi mamoko 11 (YES=1) 
 
(NO=2)
12 LEGUMES, NUTS 
AND SEEDS 
 
beans, peas, lentils, nuts, seeds or foods made from 
these. 





13 MILK AND MILK 
PRODUCTS 
chakgi 




14 OILS AND FATS 
Mor tedo 






sugar, honey, sweetened soda or sugary foods such 
as chocolates, sweets or candies 








Spices, black pepper, salt), coffee, tea alcoholic 
beverages e.g. beer, wine 






             












Group:  (1)  (2) 





1.1. Ask them if they liked the ____________  and circle their responses from the list 
below   
 
 
     
(very happy) (happy) (okay) (Not happy) (very unhappy)
1 2 3 4 5 
 
                                                                                  
 









1.3. Ask them what it is that they like about the _____________ and record their 
responses in the order they are given. 
 
a.           
b.           
c.           
d.           
 
 
1.4.  Ask them what they do not like about the ______________ and record their 
responses in the order they are given 
 
e.           
f.           
g.           









2. Make sure that by the end of the answers, they have given their opinion on each of the 





 very happy happy okay not happy very unhappy
      
Colour     
 1 2 3 4 5 
      
Taste     
 1 2 3 4 5 
      
Sweetness     
 1 2 3 4 5 
      
Texture      
(thickness/smoothness) 1 2 3 4 5 
 
 























[  Acceptability TRIAL – Homa Bay – Valid International / MSF-F ] 
 
PART 1 - At admission 
 
To fill by Valid International staff member:  
 
1. Remember to the client that he/she could not qualify due to the criteria 
2. No. of the MoH/MSF card:  __/__/__/__/__/__/__/__/ 
3. First name: __/__/__/__/__/__/__/__/__/__/__/__/__/__/__/ 
4. CRITERIA 1 - Age (years): __/__/  
5. CRITERIA 2 - To be filled by MSF Medical staff member – possible clinical exclusion 
criteria 
Presence of oedema Yes/No 
Adults with severe cerebral palsy or obvious dysmorphic features suggestive of an 
underlying syndrome (e.g. Trisomy 21) – excluding lipodistrophy 
Yes/No 
Amputated limbs (if occurring during the trial) Yes/No 
With general mental health problems (e.g. Down syndrome, etc.) Yes/No 
Any uncontrolled or untreatable systemic opportunistic infection at the time of study 
entry or irreversible oral problems that prevent adequate swallowing (NB: typical 
AIDS oral thrush would not be an exclusion criteria) 
Yes/No 
 
Name (capital letters) of MSF Medical Staff Member: 
_______________________________________________________ 
 
Signature: _________________________________ Date: __/__/2008 
To fill by Valid International staff member:  
CRITERIA 3 - Weight (kg):  __/ , __/__/ Height (meters):  __/ , __/__/   BMI (kg/m2):  __/ , 
__/__/ 
(ONLY acceptable range: 18.5 – 19.9) 
CRITERIA 4 - Village/Town of residence: __/__/__/__/__/__/__/__/__/__/__/__/__/ NB: H.Bay or very close!!!! 
CRITERIA 5 - Under Antiretroviral drugs right now? __/ (no=1; yes=2)   NB: he/she MUST be under ART!!!!!! 
CRITERIA 6 - Did the patient give his/her informed consent given:  __/ (no=1; yes=2) NB: consent SHOULD be 
given!Sex: __/ (Female=1; Male=2)  If a woman, is the patient lactating? __/ (No=1; Yes=2) 
Marital Status: __/ (Married=1; Not Married=2; Widower=3) 
Phone number(s) for contact (if any): __/__/__/__/__/__/__/__/__/__/__/__/__/__/ 
Under Plumpynut in the past?  __/ (No=1; Yes=2) 
FUCHIA number: __/__/__/__/__/__/__/__/__/__/__/__/__/ 











































































































































































































Weight (in kg) __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ __/__/ , __/ 
MUAC (in cm) __/__/ , __/     __/__/ , __/     
Did the patient come with a 
carer?                 (No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
 Presence of oral sores? – 
check!                (No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Presence of throat sores? – 
check!                (No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Does the patient manage to 
swallow? – make a test! 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Ho do you feel today? 
 Not hungry?=1 
 Little hungry=2 
 Hungry=3 
 Very hungry=4 __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Does the patient present any 
visible sign of illness? 
(No=1; Yes=2) 









PART 3 – 24 HOURS RECALL – sheet 1/2 
Question: Koro adwa penji ka inyalo paro matin kuom gik motimore chakre nyoro kogwen nyaka sani, be inyalo yiena atim 
kamano?   Now I am going to ask you to remember few things regarding what happened since yesterday at dawn until now, is that ok 



































































































































































































Question 1: Chakre nyoro kogwen, 
be isewinjo koyo kata liet? Since 
yesterday morning at dawn did you feel any 
fever? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 2:Chakre nyoro kogwen, 
be isediewo? to ka ne odiewo, idhi 
e choo didi? Since yesterday morning at 
dawn did you have any case of liquid dhiarrea? 










































Question 3: Chakre nyoro kogwen 
be isewinjo ka chuny lewi? Since 
yesterday morning at dawn did you feel any 
nausea? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 4: Be ise ng’ok chakre 
nyoro kogwen? Have you vomited since 
yesterday morning at dawn? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 5: Chakre nyoro 
kogwen,be isewinjo ka iyi obir? 
Since yesterday morning at dawn did you feel 
a sort of fullness of the stomach? 









































































































































































































Question 6:  Chakre nyoro 
kogwen, be isewinjo ka iyi rami? 
Since yesterday morning at dawn did you feel 
pain at your belly?                  (No=1; 
Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 7:  Chakre nyoro 
kogwen, be isebedo gi chandrwok 
mar golo muya? Since yesterday 
morning at dawn did you have problems like 
flatulence? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 8: Chakre nyoro kogwen, 
be dendi kamora amora no oili ma 
ok ni kare? Since yesterday morning at 
dawn did some parts of your skin unusually 
itching ? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 9: Chakre nyoro kogwen, 
be isebedo ki fuolo? Since yesterday 
morning at dawn did you have cough attacks? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question 10: Chakre nyoro 
kogwen, be isewinjo gimoro 
mopogore kata nyien kata gimora 
amora ma diher nyisa? Since 
yesterday morning at dawn did you notice 
anything strange or new? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 




































































































































































































kogwen, be isemwonyo yien moro 
amora mag vitamins? Since yesterday 
morning at dawn did you take any vitamins 
pills? 
(No=1; Yes=2) 
Question 12: Chakre nyoro 
kogwen, be isemadho nyuka mi 
imiyo u gi MSF?(ma ok plumpy) 
Since yesterday morning at dawn did you take 
any fortified porridge provided by MSF? (NB: 
not the plumpynut!)                   (No=1; 




PART 4 - PRODUCT 
 

































































































































































































1. Did you calibrate the scale 
before using it? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
2. Did you take the tare of the 
container ? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
3. Kind of product 
(Plumpynut=1; RUTFH=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
4. Time to start (hours : minutes) __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/ __/__/ : __/__/
5. Quantity given 
(in grams) - 250 grams A __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
6. Quantity left (in grams) 
 B __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
7. Quantity wasted and/or 
spilled (in grams) C __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
8. Quantity eaten 
(in grams) 
NB: D = A – B - C  
D 
__/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
Question:    Be  diher  mondo  omedi 
chiemo no icham ka? 
Do  you  wish  to  have  an  extra 
amount to eat here? 
(No=1; Yes=2) __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
9. Time to finish (hours : minutes) __/__/ : 
__/__/
__/__/ : 




PART 5 - WATER 
 

































































































































































































1. Brand of water (name) <_____> <_____> <_____> <_____> <_____> <_____> <_____> <_____> <_____> <_____> 
2. Quantity given (in ml) 
        250 ml or more A __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
3. Quantity left (in ml) 
 B __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
4. Quantity wasted and/or 
spilled (in ml) C __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ __/__/__/ 
5. Quantity drunk (in ml) 
 
NB: D =  A – B - C  
D 






































































































































































































The patient : 
 Refuses to continue = 1 
 Is reluctant to continue = 2 
 Accepts to continue but not very 
enthusiastic = 3 
 Is eager to continue taking = 4 __/ __/ __/ __/ __/ __/ __/ __/ __/ __/ 
Question: Koro akwayo mondo 
ibed abeda thuolo mondo inyisa 
kaka iwinjo chiemo ma wamiyi ni? 
You can honestly express your 
opinion. How do you find the 
product?  
 Ober (Good) = 1 
 Omit ahinya (Too sweet) = 2 
 Moo ng’eny (Too oily) = 3 
 Chumbi ng’eny (Too salty) = 4 
 Mit ahinya kendo moo ng’eny 
ahinya (Too sweet & oily) = 5 
 Omit ahinya kendo chumbi 
ng’eny ahinya (Too sweet & salty) 
= 6 
 Chumbi ng’eny kendo moo 
ng’eny ahinya (Too salty & oily) = 
7 
 Omit ahinya, chumbi ng’eny 
kendo moo ng’eny ahinya (Too 
sweet & oily & salty) = 8 __/  __/  __/  __/  __/  
 
SIGNATURES OF THE RESPONSIBLE 
(for the client) 
 
 







Public Health Nutrition: page 1 of 8 doi:10.1017/S1368980010003435
A qualitative investigation of adherence to nutritional therapy in
malnourished adult AIDS patients in Kenya
Filippo Dibari1,2,*, Paluku Bahwere1, Isabelle Le Gall3, Saul Guerrero1,
David Mwaniki4,5 and Andrew Seal2
1Valid International, 35 Leopold Street, Oxford OX4 1TW, UK: 2UCL Centre for International Health and
Development, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK: 3MSF-France, Nairobi,
Kenya/Paris, France: 4Centre for Public Health, Kenya Medical Research Institute, KEMRI/CPHR, Nairobi,
Kenya: 5Academy for Educational Development/Regional Office for Eastern and Central Africa, Nairobi, Kenya
Submitted 2 June 2010: Accepted 25 October 2010
Abstract
Objective: To understand factors affecting the compliance of malnourished,
HIV-positive adults with a nutritional protocol using ready-to-use therapeutic
food (RUTF; Plumpy’nutR ).
Design: Qualitative study using key informant interviews, focus group discussions
and direct observations.
Setting: Ministry of Health HIV/programme supported by Me´decins Sans Frontie`rs
(MSF) in Nyanza Province, Kenya.
Subjects: Adult patients (n 46) currently or previously affected by HIV-associated
wasting and receiving anti-retroviral therapy, their caregivers (n 2) and MoH/MSF
medical employees (n 8).
Results: Thirty-four out of forty-six patients were receiving RUTF (8360 kJ/d) at the
time of the study and nineteen of them were wasted (BMI, 17 kg/m2). Six of
the thirteen wasted out-patients came to the clinic without a caregiver and were
unable to carry their monthly provision (12 kg) of RUTF home because of physical
frailty. Despite the patients’ enthusiasm about their weight gain and rapid
resumption of labour activities, the taste of the product, diet monotony and
clinical conditions associated with HIV made it impossible for half of them to
consume the daily prescription. Sharing the RUTF with other household members
and mixing with other foods were common. Staff training did not include ther-
apeutic dietetic counselling.
Conclusions: The level of reported compliance with the prescribed dose of RUTF
was low. An improved approach to treating malnourished HIV-positive adults in
limited resource contexts is needed and must consider strategies to support
patients without a caregiver, development of therapeutic foods more suited to
adult taste, specific dietetic training for health staff and the provision of liquid






Undernutrition associated with HIV is a public health
concern in Africa. Demographic and health surveys in eleven
sub-Saharan countries estimated that 10?3% of HIV-infected
women (aged 15–49 years) had a BMI,18?5kg/m2(1); data
for men were not available. In urban Lusaka, Zambia, 9% of
adults (3624 out of 40 778) started anti-retroviral therapy
(ART) with a BMI,16?0kg/m2(2).
Despite the increasing availability of ART, and
patients enrolled in food programmes while on treatment
reporting greater adherence to their medication(3,4),
HIV wasting is still common. Although the beneficial
effects of ART on severe malnutrition in adults are well
documented, Carr(5) reported severe toxicity associated
with ART in well-nourished individuals, and it has been
suggested that side effects may be worse in malnourished
individuals(6).
However, the relationship between nutritional status,
therapy and survival of adults undergoing ART is con-
troversial. According to Paton et al.(7), a BMI, 17 kg/m2
at the time of starting ART is associated with decreased
survival in adults. A large observational study of patients
receiving ART in Kenya and Cambodia (n 5069) showed
that a weight gain of only 5 % in 3 months increased
survival in adults with a BMI, 17 kg/m2(8).
Bahwere et al.(9) reported that a novel ready-to-use
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available paediatric RUTF, was acceptable to malnourished
Malawian patients who were not receiving ART, and that it
improved their physical activity performance, nutritional
status and survival.
On the other hand, Ndekha et al.(10) found no differ-
ence in short-term survival when providing an energy-
dense RUTF, or a lower-density porridge-based food,
despite an increased weight gain with RUTF (n 450).
A retrospective analysis(11) of surveillance data on
adults under ART (n 329) and with a BMI, 17 kg/m2,
who were either receiving or not receiving an RUTF
(Afya; Compact AS, Bergen, Norway), also reported that it
was difficult to conclude a clear benefit of supplementary
food in the early months of ART in terms of survival.
In 2007, the UN officially approved the use of RUTF for
the treatment of acute malnutrition in children(12). This
approach has also been adopted in nutrition and health
programmes in developing countries targeting adults
with HIV/AIDS. However, only a paediatric formulation is
commercially available and there is limited evidence for its
efficacy, and little data on acceptability and adherence to
this formulation in HIV/tuberculosis (TB)-positive adults.
To understand why nutritional support may not be
providing consistent benefits, it is necessary to investi-
gate, among other things, the compliance of patients to
nutritional treatment and understand the factors that
affect this. In the present paper, we use ‘compliance’
to describe the extent to which a person’s behaviour –
taking medication, following a diet and/or executing
lifestyle changes – corresponds to agreed recommenda-
tions from a health-care provider(13–15).
The research questions of the present study aim (i) to
understand and describe compliance with a protocol based
on a specific RUTF (Plumpy’nutR ; Nutriset, Malaunay,
France) among malnourished adults living with HIV; and
(ii) to determine any key barriers to compliance.
To our knowledge, the present study is the first
to qualitatively investigate compliance with nutritional
protocols based on RUTF that aim at rehabilitating mal-
nourished HIV adults. We report the results according to
the COREQ (consolidated criteria for reporting qualitative
research) guidelines(16).
Experimental methods
The present research took place in Homa Bay, Nyanza
Province, which is on the Kenyan side of Lake Victoria. In
Kenya, in 2007, the prevalence of HIV was the highest
in Nyanza Province (15?3 %), more than double the
national prevalence estimate(17). In January 2006, the
non-governmental organisation Me´decins Sans Frontie`res
(MSF), France, introduced a nutritional rehabilitation
programme for malnourished adults enrolled in the
Ministry of Health (MoH) ART programme, Kenya, which
utilised the most commonly available RUTF (brand
name: Plumpy’nutR ; 8360 kJ/d (2000 kcal/d) equal to four
sachets of 92 g each). Adults ($15 years of age) were
considered malnourished (admission criteria) when BMI
was ,17 kg/m2 and/or middle upper-arm circumference
(MUAC) was ,185 mm and/or the presence of oedema
was observed. Discharge criteria from the nutrition pro-
gramme included BMI$18 kg/m2 and MUAC$ 185 mm,
and absence of oedema in at least two consecutive visits.
Along with the supply of RUTF, the medical staff provided
generic nutritional counselling. These same staff members
had never received any specific training in therapeutic
nutritional treatment counselling for HIV adult patients.
Subjects recruitment and sampling
The study subjects, enrolled at the MoH/MSF HIV/TB
programme in Homa Bay health district, Nyanza Province,
Kenya, came from three groups: patients enrolled in the
programme (some already nutritionally rehabilitated);
their caregivers; and medical staff (counsellors, nurses and
clinical officers). Patients ,15 years of age were not
admitted into the study group. The patients were recruited
either at MoH/MSF HIV clinics A and B at Homa Bay
hospital or from TB wards 7 and 8 of the same hospital.
The study followed a non-probabilistic, purposive,
heterogeneous, non-proportional quota sampling system.
Data saturation was achieved after approximately two-
thirds of the study; however, recruitment continued along
the entire planned period (3 weeks). During the study
period, patients coming for their usual routine visit were
invited to participate by the nurse in charge of the nutrition
programme. All the health staff working at the clinic during
the study agreed to participate. All focus group discussions
and interviews occurred in a quiet area within the HIV
clinic compound in the presence of researchers only,
whereas direct observations were made in the TB multi-
drug resistance ward at Homa Bay hospital.
Data collection and data analysis
The research applied three qualitative methods and the
results were triangulated. Focus group discussions involved
patients and caregivers and one separate session with
members of the MoH/MSF medical staff; semi-structured
interviews were administered to patients on a one-to-
one basis; direct unobtrusive observations were made of
Plumpy’nutR distribution and consumption in the HIV/TB
wards. The questionnaires and focus group discussions used
a variety of techniques, including free listing, ranking exer-
cises and open-ended questions (see footnotes in Table 3).
Questionnaires and focus group guides
Two guides were developed and piloted for use in the focus
groups: one for patients and caregivers and one for the
health staff members. The guides and questionnaires cov-
ered four topics: (i) information provided to patients about
the recommended use and consumption of Plumpy’nutR ;
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Plumpy’nutR in their therapy; (iii) dietary practices and
Plumpy’nutR consumption; and (iv) patient’s and caregiver’s
experience of the Plumpy’nutR distribution system.
A checklist for the direct observations was developed
and covered the ways of consuming Plumpy’nutR , their
advantages and disadvantages, together with the role of
the caregiver.
All focus group discussions were recorded on tape,
allowing the checking of information that was not clear
from the written notes. The focus group discussions
and interviews did not last for more than 1.5 and 1 h,
respectively. The direct observation sessions lasted
between 30 min and 1 h. A small number of photographs
were taken with the informed consent of patients.
The research team and the relationship with subjects
The focus group discussions and interviews were con-
ducted in the Luo language. Two native speakers, a female
and a male, were recruited as interpreters and provided
with 2d training on the study and methods to be used.
Time for familiarisation with the study guides was provided.
The principal researcher was a Caucasian male who
was trained in public health nutrition at MSc level, and
was not an MSF employee. He attended all focus group
sessions and benefited from simultaneous translation by
an interpreter. The principal researcher personally facili-
tated, in English, the focus group discussion with the
health staff, and subsequently transcribed the recorded
tape himself. Other discussions were facilitated by the
study interpreters. The discussion transcript was not
returned to the members for comments or corrections. All
participants were provided with information about the
study and assured that clinical services or RUTF provision
would not be affected by refusal to participate.
Identification of common themes
The focus group discussion transcripts were manually
coded by the principal researcher, highlighting keywords,
key concepts and any minor or contradictory themes.
Records of direct observations were reviewed and evi-
dence summarised. Quantitative data from the interviews
and the clinical and socio-economic profile of the focus
group participants were entered in EpiInfo version 3?4?3
(Centers for Disease Control and Prevention, Atlanta, GA,
USA) and analysed in the STATA statistical software pack-
age version 8?0 (Stata Corp., College Station, TX, USA).
Detailed tables were prepared for each identified theme
and its associated sub-themes. The theme tables contained
separate columns referring to the evidence obtained on
each theme using one of the three research methods. This
allowed triangulation of evidence and comparison and
discussion of the common themes that emerged. Following
this process, the themes and sub-themes from the separate
tables were compiled and overall conclusions drawn.
Conclusions and associated recommendations were
discussed with the health and management staff of the
programme during a feedback process.
Results
From January 2008 to March 2009, MSF admitted 782
malnourished adults into the therapeutic nutrition pro-
gramme; the monthly mean weight gain was 1?8 (SD 0?5)
and 1?8 (SD 0?6) g/kg per d, respectively, for severely and
moderately malnourished adults.
Study group characteristics
Table 1 provides descriptive data on the forty-six parti-
cipating patients. Thirty-four were still under treatment
with Plumpy’nutR . More than half of them were women
and the average age was 33 years. All patients were
married and the majority had their spouse still alive;
twelve out of the forty-six patients were widowers. All
subjects who were approached agreed to participate in
the study and provided written informed consent.
Table 2 summarises the methods used and the number
of patients, caregivers and health staff participants.
Twenty-two current and ex-patients received one-to-one
interviews and eighteen participated in focus group
discussions. Six in-patients were directly observed. Two
caregivers were recruited to participate in focus group
discussions. Eight MoH/MSF employees participated in
the focus groups with the medical staff (counsellors,
nurses and medical doctors). None of the subjects were






















Married (missing records51) 45 100
Spouse alive 33 73
Widowers 12 27
Mean number of children (missing
records51)*
3?0
Serological status (missing records56)
HIV positive 24 60
HIV/TB positive 16 40
Nutritional rehabilitation (missing
records51)
Enrolled into the nutrition programme at
the time of the study
No longer meeting admission criteria
of malnutrition-
15 33




Discharged by the time of the study 11 25
TB, tuberculosis; MUAC, middle upper-arm circumference.
*Age not specified.
-BMI$17 kg/m2 and/or MUAC$185mm.
-
-
This group included thirteen out-patients and six in-patients. The in-patients
were from the TB multi-drug resistance ward.
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Among the out-patients (n 13) who were still mal-
nourished, six travelled to the clinic without a caregiver
on the day of the study (two missing data). One walked,
whereas the rest took public transport; the average time
to reach the clinic was almost 2 h. The six in-patients
recruited for the direct observations were found in the
TB wards of Homa Bay hospital and they were all HIV
positive; two of them were multi-drug resistant and their
appetite might have been affected by their TB status
and/or HIV status, plus by side effects of specific drugs.
Understanding compliance
The following sections summarise the key themes emer-
ging from the analysis of the results. Only fourteen out of
twenty-two interviewed patients reported complying with
the prescribed amount of Plumpy’nutR .
Perceptions about Plumpy’nutR
Table 3 lists the aspects that may both enhance or
decrease compliance with Plumpy’nutR , and were
mentioned during the majority of focus groups and
interviews. It was frequently reported that Plumpy’nutR
can be ‘associated with a drug’ (same role and effect of a
drug), ‘brings (physical) strength’ and ‘allows to go back
to work’. Increases in weight gain were reported and
feelings of hunger said to decrease. Positive feelings
about the use of the product can be summarised by the
quote: ‘ART is a drug to fight the infections, but does not
give strength like Plumpy’nutR to go back to work’.
Turning to the negative perceptions of participants,
some patients complained that the taste of Plumpy’nutR
was responsible for nausea and vomiting. Participants
also argued that the ‘first 3 or 4d are the most critical ones’
and that ‘after then, it becomes easier’ to comply with the
prescription. Among the patients interviewed, only one
out of forty mentioned oral thrush as the main cause for
low acceptability. In contrast, the health staff focus group
voiced that the initial clinical conditions including swal-
lowing capacity are crucial for patients’ compliance. The
interviewees provided suggestions about how to improve
the product (see Table 3).
The medical staff expressed doubts about the role of
Plumpy’nutR in promoting weight gain, since ‘ART is far
more important in severely malnourished patients’.
Sharing practices
Compliance was found to be closely linked with food-
sharing practices. More than half (fourteen out of twenty-
two) of the interviewed patients reported sharing
Plumpy’nutR with children and other adults and this was
confirmed by most focus groups. The medical staff was
particularly concerned about the sharing practice at the
community level, because of their observation that ‘yin the
hospital wards, it is common’. In two of the focus groups,
patients reported incidents of Plumpy’nutR trading or sell-
ing. This, however, seems to be limited to schoolchildren,
because among adults the product was associated with
HIV treatment and was thus potentially stigmatising. The
majority of patients who declared that they tried to prevent
sharing (‘hiding the product in the closet from children’;
‘yor from adults’) did so because Plumpy’nutR was con-
sidered part of the ‘medical drug prescription’. Only one
interviewee reported that Plumpy’nutR could be actually
harmful for an HIV-negative person. One member of the
medical staff suggested that Plumpy’nutR is so important for
household food security that sharing represents a strategy
to delay the moment of programme discharge.
Mixing Plumpy’nutR with other foods
Only one patient reported consuming Plumpy’nutR exclu-
sively, whereas mixing Plumpy’nutR with other food was
a common practice mainly with local staple starchy food
(ugali), fresh vegetables, fish, rice, cereals, legumes, meat,
cooked vegetables (sukuma wiki) and chapatti (in order of
reported frequencies). Monotony of diet, nausea, vomiting
or salty taste were the main reasons for mixing. Stirring
Plumpy’nutR into hot water produces something that is
similar to a popular, peanut-based, traditional food (ogila).
Some others mentioned that ‘once you start mixing the
Plumpy’nutR , it is hard to go back and eat it alone’. Members
of the medical staff suggested (contrary to programme
recommendations) that patients with severe clinical condi-
tions (e.g. oral thrush) should mix the Plumpy’nutR with tea.
Key barriers to compliance
Inability to transport ration
Physical weakness, absence of a caregiver during
collection of supplies, cost of transport and stigma were
key barriers to compliance. The prescribed supply of
Plumpy’nutR per out-patient was monthly and weighed
approximately 12 kg. A malnourished out-patient without
a caregiver did not have enough strength to carry such
weight. Therefore, the out-patients were invited to take
half of the monthly ration and come back to collect the
second half of the supply in 2 weeks’ time. Health staff
members reported that most patients could not afford to
travel twice a month to the clinic. It can be speculated that
these patients spread out the 2 weeks’ provision along
the entire month. This is consistent with the reports of




















Individual interviews with current and ex-patients 22
Five focus group discussions from three to five
participants, including:
Current and ex-patients 18
Caregivers 2
Direct observations on individual in-patients and their
caregiver’s role
6
One focus group discussion with health staff 8
*None of the study subjects participated in more than one method.

























> Only approximately half of the patients complied with the prescribed amount X- – X
Positive aspects reported about Plumpy’nutR – participants think that:
> It is similar to a drug rather than a food, in terms of both usage and role in recovery
> It ‘brings strength’
> It ‘allows to go back to work’
> Increases weight gain
> Decreases the feeling of hunger
> Has a smell and packaging that are well accepted




























Negative aspects reported about Plumpy’nutR – participants think that:
> It can cause nausea and vomiting
> The first 3–4d of consumption are crucial for compliance, becoming easier later




> Consistency should be more liquid or like a biscuit or a powder (milk powder)























Sharing Plumpy’nutR with both other adults and/or children is a common practice X- X –
Reasons for sharing:
> Food insecurity in the household
> Children like it












Mixing Plumpy’nutR with foods is a common practice X X X
Reasons for mixing:
> To reduce monotony of the diet
> To reduce nausea, vomit, salty taste
> Because the Plumpy’nutR has separated into oil and solid phases
> Because Plumpy’nutR with water reminds participants of a traditional food




















Knowledge and attitudes of medical staff
Medical staff expressed doubts about the positive role played by Plumpy’nutR in nutritional
rehabilitation; ART was perceived as being much more important
– X –
Patient counselling
> Counselling messages focus on:
J human nutrition (e.g. ‘proteins are available in meat, eggs and cheese’)
J improvement of general conditions when consuming Plumpy’nutR (weight gain, appetite,
strength)
> Most patients did not know the relationship that exists between HIV infection, their thinness
and their ART therapy
> Staff declared that they did not know what counselling to provide to patients with severe
clinical conditions (e.g. oral thrush)
> Most patients do not receive routine information about why, when and how to consume




















Distribution system for Plumpy’nutR
> Half of the patients still under nutritional rehabilitation come to the HIV clinic without a
caregiver
> The patients cannot carry more than a 2 weeks’ supply of Plumpy’nutR (,6 kg) instead of the
whole month’s supply
> The appointment schedule for ART or clinical check-ups is monthly in most cases; therefore,
patients or caregivers do not come back to collect the missing 2 weeks’ supply of
Plumpy’nutR
> Very weak patients are in absolute need of the caregiver even to open the sachets, to mix it
with other food (when needed) and consume it
> Bulky supply (6–12kg) and branded container (box) are very noticeable and associated with







*The focus groups involved either patients together with caregivers (five groups, with three to five participants) or health staff members (one group with eight
participants).
-Tool used: closed and/or open questions.
-
-
Tool used: free listing.
yTool used: ranking exercise to select the main themes reported here.
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patients came back to collect the missing mid-month
supply or the relationship with defaulting and survival.
Stigma associated with therapeutic foods
In a region where HIV-related secondary malnutrition is
common and treated with Plumpy’nutR , this product has
become strongly associated with HIV. For this reason
many patients were reluctant to walk home with boxes
reading the brand name (Plumpy’nutR ). One patient said
‘I can disguise the ART tablets saying that they cure
something else, but I cannot disguise Plumpy’nutR
because a month’s supply is too bulky and visible’.
Clinical status and role of the caregiver
Among the in-patients who were directly observed, all
patients with a severe clinical condition could not comply
with the prescribed amount. Two of them died during the
course of the study. Alternative therapeutic diets, such as
therapeutic liquid milk (formulas F75 and F100), the
intake of which may have been easier for severely ill
patients, was not available.
It was reported and observed that in-patients in the
ward with the most severe clinical conditions can consume
Plumpy’nutR only if mixed with other suitable food (e.g.
water or porridge). This requires assistance from the care-
giver. Patients with severe clinical conditions were so weak
that they did not have sufficient strength even to open the
sachet and mix the product with food.
Discussion
The present study has indicated that compliance with
therapeutic feeding within this HIV programme is likely
to be low. We have identified a number of issues that may
reduce the consumption of RUTF to below the prescribed
level. Although the nature of the study setting might have
affected the patients’ response, some of the findings are
likely to be generalisable to other HIV and adult nutrition
programmes that use this specific therapeutic food and a
similar nutritional protocol.
The present study identified two groups of factors that
limit specifically an RUTF-based protocol compliance:
(i) factors directly related to the product design and
(ii) factors related to programme design.
Factors related to product design
Although widely used for other patient groups, it is
important to note that Plumpy’nutR was designed for
treating severe acute malnutrition in children. There is
evidence(18) to suggest that reported symptoms such
as nausea and vomiting when consuming RUTF could
be related to the drug treatment too. The taste of
Plumpy’nutR was not considered suitable by many adult
patients and therefore they often reduced intake or mixed
it with other food. This practice may compromise the
efficacy of RUTF by reducing overall energy and nutrient
intake and delaying nutritional rehabilitation.
Despite the problems of taste and consistency accept-
ability, the results of this research suggested that most
patients valued the nutritional therapy provided by
Plumpy’nutR . Their attitude towards the product was more
positive than that of most medical employees, perhaps
because of lack of staff training on the anticipated benefits.
However, the interviewed patients would reduce the
sweetness (somebody suggested the addition of lemon
juice), and would like to change the consistency into
something ‘more liquid’ or ‘into the form of a biscuit’ or
powder. Rarer comments mentioned included suggestions
for improving the packaging, such as ‘the sachet packaging
should be replaced with ice-cream cup with lid’.
Factors related to programme design
Certain problems in accessing and consuming the ther-
apeutic food were accentuated by the design of the
overall programme and inappropriate staff training.
Patients were not informed about how to correctly con-
sume the RUTF. For example, counselling messages
inappropriately advised adding the RUTF to tea and
advised feeding strategies that were not feasible for
the patient. Advice to consume RUTF at meal times
(3 times/d) and/or together with ART drugs was not
conducive to ensuring adequate intake. Some of the
patients admitted that they disregarded such advice
because of the ‘strong’ – difficult to eat – nature of the
product, their bad clinical conditions combined with ART
side effects (lack of appetite, nausea, vomiting, etc.).
More appropriate advice would have been that based
on therapeutic feeding guidelines(19) and should have
recommended having small bites of RUTF throughout the
day until the daily prescription of sachets was consumed.

















During dietetic counselling* sessions, the topics to
be covered should respond to the following ques-
tions expressed by patients during the study: What
is Plumpy’nutR (food/drug; composition)? Who is
supposed to use it? What are its components? How
often should I eat it along the day? What should I do
when I do not manage to eat it because of nausea,
vomiting or lack of appetite? Could I mix it with
other foods? What should I avoid to drink or eat
together with Plumpy’nutR ? What are the conse-
quences if I share my ration of Plumpy’nutR with
other persons? Is it good for somebody who is not
HIV positive to eat Plumpy’nutR ? Is it good for
somebody who is not thin to eat Plumpy’nutR ?
When should I stop eating Plumpy’nutR ? Will I
become thin again when I stop eating it?
*For an example of dietetic counselling material for HIV ther-
apeutic feeding in adults, contact filippo@validinternational.org.
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patients during the present study. The same questions
lead to key counselling messages.
Frail patients who came to a clinic appointment with-
out a caregiver sometimes ended up losing half of the
prescribed RUTF supply, as they were unable to transport
the food to their home. The situation could be improved
by re-design of the distribution system, perhaps involving
community-based organisations to support home-based
care. Their importance is recognised in many HIV and
nutrition interventions and protocols(20–24). The health
programme also needed to acknowledge and address
the stigma factor attached to Plumpy’nutR . This could
involve the use of anonymous packaging.
In case of extremely frail patients, the caregiver played
a fundamental role in trying to overcome key barriers
for compliance, such as simply opening the sachets or
mixing it with other foods.
Main limitations of the present study
The present research did not correlate the collected data
with clinical information such as patients’ survival, CD4
count, weight gain or BMI changes that might have
helped in understanding the impact of such a programme
in the presence of household/community sharing, food
mixing, lack of counselling and clinical difficulties in
swallowing among others.
The present research did not aim to understand the link
between nutritional therapy and ART compliance. RUTF
is meant to be used in out-patient programmes, but the
present study was restrained by lack of observations at
the community level.
The two study interpreters were not only employed as
health promoters in the MoH HIV programme but were
also clients of the MoH/MSF HIV/TB programme. One of
them had been previously successfully rehabilitated in the
nutritional programme. Therefore, they might have pre-
viously met some of the patients enrolled in the study
and/or developed specific perceptions about the topic,
introducing possible bias.
Conclusions
Overall, the research suggests that training and information
material is needed to ensure that medical staff can support
the patient to overcome the first most crucial phase of
the treatment. The very first contact with the patient should
include a test to assess the swallowing capacity. Reduced
capacity to swallow is common and it may imply a
lower compliance with nutritional therapy and an increase
in mortality risk. Consistent with the community-based
management of malnutrition approach, medical staff
should ask the patient to consume some amount of RUTF
in his presence to verify his swallowing capacity. Accord-
ing to the results of this test, dietetic solutions must be
discussed and agreed upon together with the patient and
the caregiver when present. Patients who are unable to
swallow at all should be hospitalised and treated according
to the in-patient nutritional therapeutic protocol developed
by WHO(25), which utilises milk-based liquid therapeutic
nutritional products such as F75 and F100.
The study showed that Plumpy’nutR , designed for
malnourished children, needs improvement to meet the
palatability preferences expressed by adult patients.
A reduction in the perception of sweetness and fat com-
ponents was solicited by the patients. However, any
HIV/TB therapeutic nutrition programme should not
introduce newly designed RUTF until positive clinical
results have been demonstrated.
Further studies more closely correlating compliance
and recovery rates are likely to improve the perception
of medical staff towards the effectiveness of this kind of
programme, possibly improving their performance as well.
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Abstract
According to the United Nations (UN), 25 million children ,5 y of age are currently affected by severe acute malnutrition
and need to be treated using special nutritional products such as ready-to-use therapeutic foods (RUTF). Improved
formulations are in demand, but a standardized approach for RUTF design has not yet been described. Amethod relying on
linear programming (LP) analysis was developed and piloted in the design of a RUTF prototype for the treatment of wasting
in East African children and adults. The LP objective function and decision variables consisted of the lowest formulation
price and the weights of the chosen commodities (soy, sorghum, maize, oil, and sugar), respectively. The LP constraints
were based on current UN recommendations for the macronutrient content of therapeutic food and included palatability,
texture, and maximum food ingredient weight criteria. Nonlinear constraints for nutrient ratios were converted to linear
equations to allow their use in LP. The formulation was considered accurate if laboratory results confirmed an energy
density difference ,10% and a protein or lipid difference ,5 g × 100 g21 compared to the LP formulation estimates. With
this test prototype, the differenceswere 7%, and 2.3 and21.0 g × 100 g21, respectively, and the formulation accuracywas
considered good. LP can contribute to the design of ready-to-use foods (therapeutic, supplementary, or complementary),
targeting different forms of malnutrition, while using commodities that are cheaper, regionally available, and meet local
cultural preferences. However, as with all prototype feeding products for medical use, composition analysis, safety,
acceptability, and clinical effectiveness trials must be conducted to validate the formulation. J. Nutr. 142: 955–961, 2012.
Introduction
Since 2007, the United Nations (UN)5 (1) has recommended the
use of ready-to-use therapeutic food (RUTF) at the community
level for the treatment of pediatric severe acute malnutrition
(SAM) in low-income countries (1). The reason is that RUTF does
not require any preparation or addition of water before ingestion,
can be stored for long periods without refrigeration, allows in-
dividual packaging, and can therefore be used effectively in situ-
ations with nonoptimal hygiene conditions (2). Moreover, RUTF
meets the specifications for type I and II micronutrient densities
(1,3) that have been found to contribute to effective management
of SAM in children (3). A classification of this range of products is
available elsewhere (4). Plumpy’nut is the most common com-
mercial brand that has been clinically trialed so far (5,6), but an
increasing number of therapeutic products are being tested.
RUTF is not always available where needed. India alone
counts 8 million SAM children (7) in need of nutritional reha-
bilitation (8), yet it has not been possible to legally import RUTF
from Europe since 2009. In this and other countries, the re-
latively high cost of Western brands and local policies have
prevented the widespread importation of RUTF, boosting the
demand for regionally appropriate solutions (9).
The market for products to use in feeding programs is large.
The World Bank estimates that each year, ;$6.2 billion are
needed to treat 3.5 million children,5 y of age affected by SAM
ormoderate acute malnutrition (10). If not treated on time, these
might represent more than one-third of all pediatric deaths
worldwide (10). A large coalition of international institutions is
currently engaged in raising the needed funds (11).
However, some aspects of therapeutic feeding still require
more evidence-based understanding. The current RUTF formu-
lation is based on results from a limited number of studies, in a
few settings, showing rapid weight gain (12). Consequently, in
other settings, with different underlying nutrient deficiencies and
infectious disease profiles, similar weight gains would perhaps
occur, with nutrient levels different from those in use (13–16).
1 Supported by Valid Nutrition via a grant from the Irish International Cooperation.
2 Author disclosures: F. Dibari, E. H. I. Diop, and S. Collins (Director) work for Valid
Nutrition. Valid Nutrition is involved in trialing, manufacturing, and marketing the
ready-to-use foods described in this paper. A. Seal, no conflicts of interest.
* To whom correspondence should be addressed. E-mail: filippo@validinterna-
tional.org.
5 Abbreviations used: DV, decision variable; FCD, food composition database;
LP, linear programming; OF, objective function; PDCAAS, protein digestibility--
corrected amino-acid score; RUF, ready-to-use food; RUTF, ready-to-use
therapeutic food; SAM, severe acute malnutrition; TFD, true fecal digestibility;
UN, United Nations; WFDAS, World Food Dietary Assessment System.
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The current commercial formulation of RUTF is not acceptable
to all the patients in need of therapeutic nutrition in developing
countries. A study reported that adult HIV-positive wasted patients
in Africa struggled to comply with the current RUTF-based
treatment (17). The same study recommended improving the for-
mulation to meet the tastes of the beneficiaries and increase its
acceptability.
Evidence-based nutrition research ideally relies on costly
randomized clinical trials. Therefore, a robust method is re-
quired to design the trial RUTF before randomized clinical trial
implementation. At present, there is no internationally endorsed
protocol to design products of this kind.
A design method based on linear programming (LP) can help
in the development of novel RUTF and other products with
similar properties, termed here ready-to-use foods (RUF). LP
analysis is an operational research approach that is used to
model complex multifactorial problems, including diet-related
ones (18). Since 1959 LP has been applied to human nutrition
(19) and since 1983, also to diet planning for developing
countries (20). More recently, with the aid of specific software,
LP was used for complementary feeding programs (21) or in
the design of diets for specific populations (22,23). LP is also
used to design personal diets, define institutional nutritional
practices, support decision-making in nutrition education or
agricultural programs, define food fortification activities, and
undertake analysis of economic constraints on human diets (22–
24). LP can be used for assessing the economic value of fortified
food supplements (25) and in predicting limiting nutrients in
specific diets (21).
LP is a suitable decision tool for designing novel food-based
formulations. The method helps by identifying the cheapest
possible combination of food ingredients that meet a set of
nutritional requirements (20,23,26), avoiding a “trial and error”
approach (21,27).
The objective of this study was to test a LP-based method for
designing the cheapest formulation of a RUF that fulfils
predefined macronutrients requirements by using region-specific
foods that are culturally acceptable and can be processed with
locally available technologies. To our knowledge, this is the first
study describing how LP can be used to design RUF. The study
should be of interest to international nutritionists and food
technologists involved in designing novel RUF.
Materials and Methods
Developing a LP model for RUTF
LP is a tool to optimize (minimize or maximize) a linear objective
function (OF) while respecting multiple linear equality and inequality
constraints (21). When used for selecting the lowest cost diet/formula-
tion, the OF can be expressed in the following form (22):
Y¼ k0 þ k1W1 þ k2W2 þ :::þ knWn;
where Y is the cost, k1, k2… kn are constants, equivalent, for instance, to
the cost per unit weight for food ingredients F1 to Fn, and W1, W2,…Wn
are the decision variables (DV), i.e., the weights of foods F1, F2…Fn in
grams. The usual aim will be to minimize the cost of the formulation (Y)
by changing the weight of the different ingredients while meeting a range
of different constraints. These mathematical constraints (equality,
greater than, or less than) are imposed on one or more of the DV (W1,
W2,…Wn) to ensure that the nutrient content of the product meets design
requirements and does not exceed upper thresholds. A LP solution is
feasible when all its constraints are achievable. When the highest
possible concentration of a nutrient is less than a minimum constraint,
when the lowest concentration of a nutrient is higher than a maximum
constraint, or an equality constraint cannot be respected, the model is
considered unfeasible (16,18). Constraints in food formulation problems
may be linear or nonlinear, but LP can be applied only when all the
constraints are linear (22). A constraint is considered linear when it can
be expressed in the following way:
k1W1 þ k2W2 þ.þ knWn $a0 or
k1W1 þ k2W2 þ.þ knWn #b0 or ;
k1W1 þ k2W2 þ.þ knWn ¼ c0
where a0, b0, and c0 are constants. Models including nonlinear
constraints may have several solutions (local optimums) depending on
the initial values and cannot be solved using LP.
In this study, we transformed nonlinear nutrient ratio constraints,
such as the proportion of energy coming from protein, the proportion of
energy coming from fat, and the proportion of energy coming from (n-3)
and (n-6) fatty acids, into equivalent linear constraints. For example, the
UN specifications for RUTF require that the proportion of total energy
(E) coming from protein is .0.10 and ,0.12 (1). This was expressed in
the following nonlinear form:
ðP1W1 þ P2W2.þ PnWnÞ=ðE1W1 þ E2W2.
þEnWnÞ $0:10 and # 0:12
where P1, P2,…Pn and E1, E2,…En represent, respectively, the energy
content from protein and the total energy content (kJ) in W1, W2,…Wn
(g) of each food ingredient F1, F2…Fn. Therefore, the protein:energy
constraint (C) was expressed as a linearized function of the weight of
different foods:
W1ðP120:10E1Þ þW2ðP220:10E2Þ.WnðPn20:10EnÞ $ 0
and
W1ðP120:12E1Þ þW2ðP220:12E2Þ.WnðPn20:12EnÞ # 0
Some authors (21) suggest avoiding nonlinear constraints wherever
possible because of their complexity. Therefore, we avoided including
more complex nonlinear constraints in the formulation such as protein
quality expressed as protein digestibility-corrected amino-acid score
(PDCAAS) (28) and true fecal digestibility (TFD) (28,29). However,
these 2 parameters were calculated and manually assessed in the final
model.
In this study, the OF consisted of identifying the lowest price given by
the sum of each food ingredient cost (C1, C2,…Cn) multiplied by the DV
(food weights: W1, W2,…Wn) while respecting the predefined con-
straints. Other definitions and graphic illustrations of LP theory are
available elsewhere (16,18,20–22,26).
An example of a RUTF formulation optimized by LP
To explore the use of LP, we used it in the process of formulating a
prototype RUTF that could be used in both adult and pediatric
therapeutic feeding programs in East Africa and could be manufactured
from locally available commodities. Such a product would yield
considerable reductions in the logistic complexity and costs in large
humanitarian operations.
The overall design, manufacture, and testing of the RUTF consisted
of 4 phases (Fig. 1). The preliminary stage A involved identifying the
target group and the desired composition of the prototype product.
Potential food ingredients, nutrient composition, and price data were
then identified and compiled. The DV, constraints, and OF for the LP
model were defined and used in step B to set up and solve the LP model
using Microsoft Excel (version 2007) and the Solver add-in. Phase C
consisted of assessing the sensitivity of the optimized model and then
manufacturing a small-scale test batch of the RUTF prototype to check
the texture and compare the calculated composition with laboratory-
based results. In phase D, safety and acceptability tests were conducted
with the unfortified product. At the same time, the fortificant premix was
designed, added, and its shelf life monitored. Soon after, clinical trials
were used to validate the prototype formulation. Results from phase D
will be reported elsewhere.
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Phase A: FCD and food prices
Choice of the FCD. The validity of the LP-optimized prototype
formulation depends on the accuracy of the food composition database
(FCD). The FCD sources were selected by using the following criteria:
1) the widest representation of commodity composition data from
around the world; 2) the largest number of nutrient data values per
food; 3) food descriptors matching the selected ingredients; and 4)
internationally respected datasets, ideally with methods cited in peer-
reviewed journals.
Choice of the food ingredients. Initially, one of the largest East African
food aid manufacturers (Insta Products EPZ) identified one specific com-
modity for each of 4 preselected food categories: cereals, sugar, and oil.
Most East African capitals host extrusion industrial units for precooking
and milling of cereals and/or pulses blends. In mixes of preground pulses
and cereals, the correct application of extrusion processing achieves levels of
starch gelatinization sufficient for digestion (30) while destroying most
antinutritional factors (30).
Phase B: Setting up and running the LP model
The design of the RUTF had to respect several prestated conditions, which
were derived from specifications for this class of product and from
experience gained in the design of similar products. Four groups of con-
straints were considered: energy and nutrient concentration, palatability,
texture, and total food ingredient weight. The linear and linearized nu-
trient concentration constraints that were applied are listed in Table 1.
FIGURE 1 Proposed design and validation method for novel RUF. RUF, ready-to-use food.
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Energy and nutrient concentration constraints. LP constraints were
introduced to ensure that the RUTF formulation met the UN 2007
standards (1) for energy density and the ratios of protein, fat, and
essential fatty acids to energy (Table 1).
Palatability-related constraints. Palatability constraints are common in
dietary LP (21) and aim to avoid the creation of unacceptable tastes. In a
study (17) looking at compliance with the current commercially available
pediatric RUTF, HIV/TB-wasted Kenyan adults voiced the need for a
reduction of the current sugar content (28%) (31). Lower sugar density
was also shown to be acceptable to,5-y-old Zambian children in another
preliminary study (personal communication, Abel Hailu, Valid Nutrition).
Therefore, the sugar content was constrained to 15–18% (Table 1).
Sorghum improves the taste of extruded pulses/cereals blends, even if
present in a small amount (personal communication, Stuart Allison,
Insta Products EPZ). We introduced a minimum constraint of 7–10% for
sorghum (Table 1) based on work with preliminary formulations.
Texture-related constraints. Texture-related constraints aim for a
specific consistency in the food mix. RUFmust have a paste-like property
in order to be squeezed into the mouth by the adult and children patients,
or by their caregivers. Therefore, a fluid consistency was not suitable. A
texture similar to a biscuit can produce choking in children (32) and
therefore was also considered unacceptable. A solid phase particle size
,200 microns (31) and a fat range of 28–36% generally lead to a
suitable paste texture during preliminary tests. The latter criterion was
included as a constraint in the LP model (Table 1).
Total food ingredient weight constraint. Once the RUF is shown
to be acceptable and safe (Fig. 1), a premix of vitamins and minerals
is added to the formulation (phase D). The weight of the food
ingredients therefore needs to be constrained to allow sufficient space
for inclusion of the vitamin and mineral fortificant in the finalized
product. Calculations indicated that up to 3% of the final product
weight might be required for the premix. We therefore used an
equality constraint to fix the weight of the RUTF food ingredients at
97 g (Table 1).
LP model and the software. The process of running the LP model
consisted of: 1) creation of the data layout on a Microsoft Excel
spreadsheet; 2) activation of add-in Solver Function, which is supplied
with standard installations of Excel; 3) assignment of the OF, DV, and
constraints; 4) running the LP procedure to solve the OF; and 5) a
sensitivity analysis. Steps 1–3 were applied following the procedure
suggested elsewhere (21).
Phase C: comparison with laboratory results and sensitivity
analysis
Comparison of FCD-based figures with the results from laboratory-
based analysis. The Kenyan manufacturer (Insta Products EPZ)
produced the prototype RUTF formulation in small batches and a local
laboratory (Polucon Services Limited) performed the analysis (in
triplicate) of the total energy, protein, and fat contents (Table 2). LP
estimates, based on the FCD figures, were defined as acceptable when the
difference in relative energy density was ,10% and the difference in
both protein and lipid densities were ,5 g  100 g21. Both differences
were prestated and based on cutoffs used in food technology practice.
Sensitivity analysis. Sensitivity analyses reported by the Solver Function
(see Table 3) were used to quantify how much ingredient costs and
formulation constraints can vary without requiring a change in the values
of the LP DV. This can be useful if ingredient costs are likely to vary and
decisions need to be made about when to consider reformulation.
Results
The FAO-Minilist (33) was the first choice as the FCD source,
because it fulfilled most of the selected criteria. FAO-Minilist,
downloaded from the Nutrisurvey Web site (34), is a selection
from the larger World Food Dietary Assessment System
(WFDAS) database (35). The WFDAS is based on data from 6
countries from East, West, and North Africa, Central America,
and South and Southeast Asia. All these areas are affected by
malnutrition and are therefore of interest for the goal of this
study. Other published studies have used the WFDAS dataset for
LP dietetic purposes (16,21). FAO-Minilist and WFDAS in-
cluded phytate among the antinutrients, although relevant
nutrients, such as (n-3) and (n-6) fatty acids, were missing.
Therefore, we added values for these nutrients from the USDA
SR20 and Nutrisurvey databases (34,36).
Maize, soy, sorghum, palm olein oil, and sugar were the
chosen commodities. Nutrients for maize (descriptor for this and






OF, cost minimization, $ NA1 0.07
DV: weights of the selected foods2
Soybeans, g NA 31.9
Maize, g NA 15.3
Sorghum, g NA 7.0
Oil, g NA 27.3
Sugar, g NA 15.5
Constraints
Energy and nutrients
Energy, kJ/100 g 2174.0–2299.03 2169.0
Protein energy/total energy4, % 10.0–12.0 10.0
Fat energy/total energy4, % 45.0–60.0 60.0
(n-3) Fatty acid energy/total energy4, % 0.3–2.5 0.9
(n-6) Fatty acid energy/total energy4, % 3.0–10.0 10.0
Palatability
Sugar (sweetness), g/100 g 15.0–18.05 15.5
Sorghum (taste improvement), g/100 g 7.0–10.0 7.0
Texture-related
Fat content, g/100 g 28.0–36.0 34.6
Maximum food ingredient weight
Final total weight, g 97.0 97.0
Monitored variables (not included as constraints)
Quality of protein expressed as PDCAAS,6 % 75.0–89.07 85.7
TFD,8 % NA 83.0
Limiting amino acid NA Lysine
1 The cost of the currently available product (Plumpy’nut) is ~$0.50/100 g when
delivered in East Africa, at the time of this study. The reference includes costs such as
manufacturing, transport from Europe, packaging, and import taxes. All the figures
refer to 100 g of product. DV, decision variable; LP, linear programming; OF, objective
function; PDCAAS: protein digestibility-corrected amino acid score; RUTF, ready-to-
use therapeutic food; TFD, true fecal digestibility.
2 Soy descriptor: soy flour full fat, raw [USDA SR20 (36)]. Maize descriptor: maizemeal,
wholegrain, white [FAO-Minilist (33); item code CF00096]. Sorghum descriptor:
sorghum, decorticated, flour [FAO-Minilist (33); item code CF00154]. Palm oil
descriptor: oil, vegetable, palm [USDA SR20 (36)]. Sugar descriptor: sugar, white,
cane, or beetroot [FAO-Minilist (33); item code SF00168].
3 The UN specification is 2174 kJ  100 g21 (1). The constraint was relaxed to 2169 kJ 
100 g21 to achieve a feasible LP solution.
4 The constraint formulae were converted to a linear form as described in ’’Methods.’’
5 The available literature (31) on pediatric RUTF reports a sugar content of 28 g  10021.
The constraint range was reduced to 15–18 g to make it more suitable for wasted
adults living with HIV/TB [based on (17)].
6 From (28).
7 Calculation of PDCAAS based on (1,31,44) and using food composition data from
(34,35).
8 TFD coefficient calculated using the following foods (and descriptors): maize (corn,
extruded cereal), soy (soy flour), sorghum (sorghum, cooked) (28,29).
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the other commodities are listed in the footnote in Table 1),
sorghum, and sugar were obtained from FAO-Minilist (year of
release not specified). Data for soybeans and palm olein oil were
selected from USDA SR20 (released in 2009), because their
descriptors were closer to the available commodities. However,
lysine and tryptophan in soybeans data from USDA SR20 were,
respectively, 27 and 58% higher than in the WFDAS data. The
prices of maize, soy, sorghum, oil, and sugar were 0.30, 0.60,
0.30, 1.20, and $0.70  kg21 respectively.
The final price of the formulation was $0.70  kg21. The
initial minimum energy density constraint (2174 kJ  100 g21)
was manually relaxed by 0.2% (2169 kJ  100 g21) to achieve a
possible solution (Table 1). All the resulting ratios between
energy from protein (0.10), from fat (0.60), and from (n-3) and
(n-6) fatty acids (0.009 and 0.10, respectively) and the total
energy content matched the UN standards (Table 1). The quality
of the protein (PDCAAS: 85.7%; TFD: 83.0%; lysine was the
limiting amino acid) was close to the upper level of the reference
range (75–89%). PDCAAS and TFD specifications and descrip-
tors are included in Table 1.
The total energy in the LP model was 3.0% lower than in the
laboratory-based figures. The protein and lipid contents esti-
mated with LP were 2.3 and 1.0 g  100 g21, respectively, lower
and higher than the contents measured in the sample (Table 2).
Discussion
The method described above was used to successfully design a
prototype RUTF formulation for the rehabilitation of HIV/TB-
wasted adults and children ,5 y with SAM in East Africa. The
safety and acceptability of the prototype RUTF was subse-
quently confirmed in a trial (F. Dibari, P. Bahwere, H. Huerga, A.
H. Irena, V. Owino, S. Collins, A. Seal, unpublished data).
Today, LP can be easily applied, whereas, historically, it re-
ceived relatively little attention, perhaps because computers were
not widely available when LP was first conceptualized and dis-
seminated (22). The example illustrated in this paper was im-
plemented using widely available software (Microsoft Excel Office
2007 and the Solver add-in). Other proprietary software, specif-
ically designed for nutritional use and including LP functions, are
also available, namely Microdiet (37) and Nutrisurvey (34).
In our study, laboratory analysis confirmed that the energy,
protein, and lipid values of the prototype formulation were
within the preestablished cutoffs, before and after that the
energy constraint was relaxed (0.2%) (Table 2). The relative
difference in the energy density (3%) was below the threshold of
10% and the protein and lipid absolute differences (2.3 and
1.0 g  100 g21, respectively) were lower than the limit of
5 g  100 g21. However, the relative difference in protein was
large (17.7%). This was not surprising, because it is known that
protein content, in particular from cereals and pulses, can vary
by a factor or two, depending on variety and fertilizer usage
(38). These results indirectly confirmed the relative accuracy
of the FCD; however, food composition analysis (phase C in Fig.
1), at least for protein, remains a recommended step.
In this RUTF prototype, the subjective texture criteria (not
too gritty, not too fluid) and the criteria for a sufficiently high
PDCAAS were met. If the PDCAAS had not been close to the
desired value, the limiting essential amino acid in the formula-
tion, lysine in our case, could have been included as a constraint
(Table 1). Introducing a minimum constraint for the final
content of lysine would have forced the model to include a
greater proportion of lysine-rich foods in the formulation.
Taste constraints were also introduced in line with other LP
studies in human nutrition (21). Trials confirmed that the RUTF
prototype adequately met the sweetness preferences of both
adults and children. However, it was found that it was not
possible to meet the initial energy constraint. A global optimum
model was successfully found by gradually relaxing the total
energy constraint.







Total energy, kJ .2169 0.03 1.24
,2299 ,0.001 31.0
Protein energy/total energy .0.10 0.004 1.18
,0.12 ,0.001 10.38
Fat energy/total energy .0.45 77.85 ,0.001
,0.60 0.33 0.01
(n-3) Fatty acid energy/total energy .0.003 2.87 ,0.001
.0.025 ,0.001 8.54
(n-6) Fatty acid energy/total energy .0.03 36.3 ,0.001
,0.10 ,0.001 0.003
Palatability
Sugar, g .15 0.50 ,0.001
,18 ,0.001 2.4
Sorghum, g .7 0.02 0.87
,10 3.0 ,0.001
Texture
Fat, g .28 6.6 ,0.001
,36 ,0.001 1.4
Maximum food ingredient weight
Final amount, g 97 0.05 0.001
1 All the values refer to 100 g of product. Calculations were performed using Microsoft
Excel (2007) with the Solver add-in function and the Sensitivity Analysis Report option.
TABLE 2 Comparison of the LP-optimized model and the laboratory composition analysis of the
same formulation
Calculated nutrient densities1 Laboratory results2 Absolute difference Relative difference
A B B 2 A = C (C/A) x 100
Energy kJ/100 g 2169.0 2235.0 66.0 3.0
Protein g/100 g 13.0 15.3 2.3 17.7
Protein energy/total energy 0.10 0.11 0.01 —
Lipid g/100 g 34.6 33.6 21.0 22.9
Fat energy/total energy 0.60 0.56 20.04 —
1 Sources of food composition (34,35). LP, linear programming.
2 Methods applied (parameters, other information): Pearson (energy); Gafta May 91 (protein, Nx6.25%; lipid). By Polucon Services Limited,
Msaada Avenue, Mombasa, Kenya; test report no. 2008/1282.
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Goal programming, an alternative to LP, can also be applied
to dietary problems and is described elsewhere (39). It allows the
solution to have a range of OF rather than a single one (27).
However, goal programming is more complex to apply. Because
a solution could be found to the LP model by manually relaxing
the energy constraint by only 0.2%, we avoided using this more
laborious method.
In the present study, adjustments to the formulation (phase C
in Fig. 1) were not needed. However, in another context, a sen-
sitivity analysis could been used to guide the analyst on howmuch
individual DV coefficients or constraints could be varied without
requiring a change in the values of the DV or other constraints.
Our findings support the use of LP as a valuable tool to ensure
that products meet nutritional design requirements while mini-
mizing the cost of manufacture. According to UNICEF (40), 68%
of Plumpy’nut’s final overall price, excluding manufacturing and
transport costs, consists of food ingredients. In Kenya in March
2008, 1 kg of Plumpy’nut cost ~$5.00 (personal communication,
Malik Allouna, MSF/France, Kenya mission). This suggests that
the indicative price for the Plumpy’nut food ingredients compo-
nent was $3.40/kg. Therefore, the ingredient costs for the LP-
derived RUTF prototype formulation (~$0.70/kg) is likely to be
substantially cheaper, even after the addition of the micronutrient
premix. Importantly, the lower transport and importation costs
are also likely to result in a price advantage for locally produced
RUTF. The regional agriculture economy may also benefit due to
local purchase of the ingredients. However, more robust methods
for economic assessment of RUF formulations are needed to
support decision makers.
Future standard protocols for RUF design should address these
economic aspects, including validatedmethods to obtain food price
data in low-income countries for use in the LP model. In our study,
it was challenging to find price data for ingredients that reliably
represented seasonal fluctuations at national or regional levels.
Briend et al. (25) estimated the economic impact and efficacy of
novel nutrient-dense formulations against other current products,
but such analysis goes beyond the goal of our current study.
Some constraints were highlighted in applying LP to design
food formulations of this kind. The accuracy of the novel RUF
was highly dependent on the quality of the available FCD. Since
the 1970s, researchers have realized that most foods exhibit
variations in composition and that a single table value cannot
fully represent any particular food (38). Nutrient figures must
therefore be considered as estimates (38). Improvements in FCD
data collection and management have been proposed. For
example, the INFOODS (33) and Codex Alimentarius Web pages
(41) report information on standardized nutrient analyses, and
recent international protocols and software (42) try to harmonize
food names. Despite these initiatives, no FCD source, used for this
LP exercise, reported coefficients of variation or SD figures despite
their use being internationally recommended (38). Within
WFDAS, the same item descriptors were sometimes reported
more than once or did not specify the variety (e.g., in case of
sorghum, white or red varieties), emphasizing the importance of
the database item code for avoiding data selection errors.
In our study, lysine and tryptophan in soybean data from an
American database (36) were higher than inmerged non-American
databases (35). This might have overestimated the final RUTF
protein quality. However, the Kenyan manufacturer reported that
U.S. soybeans were often present on the local market and so may
be used in products manufactured in East Africa.
The oil descriptor used, palm oil, was different from the
actual commodity used, which was palm olein oil. Palm olein is
an industrially prepared fraction of palm oil. Therefore, it can be
speculated that its nutrient composition, mainly in terms of (n-3)
and (n-6) fatty acids, are different. Unfortunately, the laboratory
used in this study, and probably most industrial laboratories in
Africa, was not equipped to confirm the (n-3) and (n-6) fatty acid
LP estimates. Rancidity of these nutrients is a major risk for the
stability of food products with a high fat content. Therefore,
close monitoring of its shelf life is important. At the time of
writing this paper, the results from the RUTF shelf life study
were not yet available.
In conclusion, this paper describes a widely applicable method
for the rational design of therapeutic food products at minimum
cost. The study provided a prototype formulation, which met all
the predefined requirements, except for one relaxed by 0.2%, and
also suggested, as a lesson learnt, the need for improved methods
to determine the ingredient prices to use in the model. The RUTF
cost (based only on food ingredients) was approximately 4- to 5-
fold cheaper than the current standard product (food ingredients
and premix). Using the methods described here, public health nu-
tritionists and food technologists could apply these steps to design
other RUF formulations, such as ready-to-use supplementary or
complementary foods. However, the macronutrient contents of
LP prototypes always need to be confirmed by food composition
analysis and the finalized products trialed under field conditions
before they can be recommended for general use (39,43).
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Objective: To develop a method for determining the acceptability and safety of ready-to-use
therapeutic foods (RUTF) before clinical trialing. Acceptability was deﬁned using a combination
of three consumption, nine safety, and six preference criteria. These were used to compare a soy/
maize/sorghum RUTF (SMS-RUTFh), designed for the rehabilitation of human immunodeﬁciency
virus/tuberculosis (HIV/TB) wasted adults, with a peanut-butter/milk-powder paste (P-RUTF;
brand: Plumpy’nut) designed for pediatric treatment.
Methods: A cross-over, randomized, controlled trial was conducted in Kenya. Ten days of repeated
measures of product intake by 41 HIV/TB patients, >18 y old, body mass index (BMI) 18-24 kg$m2,
250 g were offered daily under direct observation as a replacement lunch meal. Consumption,
comorbidity, and preferences were recorded.
Results: The study arms had similar age, sex, marital status, initial BMI, and middle upper-arm
circumference. No carryover effect or serious adverse events were found. SMS-RUTFh energy
intake was not statistically different from the control, when adjusted for BMI on day 1, and the
presence of throat sores. General preference, taste, and sweetness scores were higher for
SMS-RUTFh compared to the control (P < 0.05). Most consumption, safety, and preference criteria
for SMS-RUTFh were satisﬁed except for the average number of days of nausea (0.16 versus 0.09 d)
and vomiting (0.04 versus 0.02 d), which occurred with a higher frequency (P < 0.05).
Conclusion: SMS-RUTFh appears to be acceptable and can be safely clinically trialed, if close
monitoring of vomiting and nausea is included. The method reported here is a useful and feasible
approach for testing the acceptability of ready-to-use foods in low income countries.
 2012 Elsevier Inc. All rights reserved.Introduction
Ready-to-use therapeutic foods (RUTF) are high-energy,
nutrient-dense products in which the powdered ingredients
are usually suspended in fat. They do not require any preparation
or the addition of water before ingestion [1] and can be stored
for long periods without refrigeration. They can be individually
packaged and can therefore be used effectively in situations with
non-optimal hygiene conditions [1]. RUTFs are popular in
feeding programs [2], including human immunodeﬁciency59.
ibari).
ll rights reserved.
et al., Development of a cr
12.04.016virus/tuberculosis (HIV/TB) interventions [1,3], because their use
has been associated with an increase in successful treatment
rates for severe acute malnutrition (SAM) when compared to
other conventional treatments [4]. However, at present, the high
price of RUTFs and their low regional availability hampers
widespread use [5].
RUTF were initially developed for pediatric nutritional reha-
bilitation and the United Nations currently recommends [2,6]
their use, at the community level, to help eradicate the one
million child deaths that occur every year due to SAM [6]. In
the next few years, $US2.6 billionwill be spent on SAM treatment
[4,7], and therefore, novel, cheaper, culturally acceptable, efﬁ-
cacious, and regionally manufactured products are already inoss-over randomized trial method to determine the acceptability
F. Dibari et al. / Nutrition xxx (2012) 1–62demand for this patient group [2]. RUTF have also been used in
feeding programs for HIV and TB patients and evidence from
low-resource settings [8–14] shows that HIV/TB wasting in
adults is still a public health issue in Sub-Saharan Africa, despite
the increasing access to antiretroviral therapy.
In such countries, HIV programs aiming for nutritional reha-
bilitation and/or nutrition support tend to use a few speciﬁc
types of food [10], usually either fortiﬁed blended foods [15] or
RUTFs [16]. The most common commercial brand of RUTF is
Plumpy’nut [17], which was designed for pediatric use and is the
only one that has been clinically tested in several different
studies [3,18–22]. In wasted adults, a number of factors have
been shown to reduce compliance with Plumpy’nut including
the taste of this pediatric formulation [23]. Moreover, the
micronutrient densities in Plumpy’nut might not be appropriate
for the needs of wasted adults with HIV/TB. For these reasons,
there is demand for the development of a novel RUTF for this
patient group.
Changes to the formulation of RUTF should be based on
clinical evidence derived from randomized controlled trials
(RCT) [24] but these are costly to implement. Therefore, robust
data on product acceptability are required before implementa-
tion of a RCT, and determining adequate consumption, safety,
and preference is a crucial early step in successful product
development. However, at present there is no internationally
endorsed protocol to assess the acceptability of products of
this kind.
Here, we present a method for testing the acceptability of
novel RUTF. To our knowledge, this is the ﬁrst trial in a devel-
oping country that tests the acceptability of this type of product
inwasted adults. The results of this randomized control study are
presented according to recommended guidelines for cross-over
trials [25].Materials and methods
Trial and control products
The control product (Plumpy’nut; Nutriset, Malaunay, France [17]) contains
peanut butter, milk powder, and a premix of vitamins and minerals and is
referred to here as P-RUTF. The trial RUTF (Valid Nutrition, Derry Duff, Ireland, at
Insta Ltd., Nairobi, Kenya) contained soybeans, maize, and sorghum, no micro-
nutrients premix, and is referred to here as SMS-RUTFh (“h” standing for adult
HIV/TB). Both products contained sugar (28 and 15 100 g1, respectively, for
P-RUTF and SMS-RUTFh) and their macronutrients (energy, protein, lipids)
closely met the United Nations requirements for RUTF (Table 1). Both their
consistencies were pastelike, but their tastes and colors were different. TheTable 1
Comparison of macronutrients in the two RUTFs
SMS-RUTFh
Ingredients: Soy beans, maize, sorghum, sugar, and oil




Energy, kJ$kg1 20 900 22 350
Protein, g$kg1 120 153
Protein/energy ratio, % 10 11
Lipid, g$kg1 310 336
Lipid/Energy ratio, % 56 56
(u-6) Fatty acids/energy ratio, % 9 n.a.
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another article (in preparation).Study population, recruitment, and setting
The study was carried out in two locations, 2 km from each other, in Homa
Bay, Kenya. The participants, enrolled after written informed consent, were
patients recruited from the District hospital, supported by the Ministry of Health
(MoH) and Medecins Sans Frontieres-France (MSF). The patients from the two
study groupsmet each other only at enrollment (day 1), and/or incidentally in the
routine medical hospital visits. The participants, HIV and/or TB infected, were
considered eligible if receiving antiretroviral therapy and/or TB treatment; age
18 y; and BMI between 18 and 24 kg$m2 (Table 2). The exclusion criteria
consisted of previous enrollment in a nutritional therapeutic program; oral
problems that prevented adequate swallowing (typical AIDS oral thrush was not
an exclusion criteria); and any speciﬁc food intolerance (e.g., peanut allergy).
Patients missing more than 3 d were considered defaulters.Study design
The study design was a two-arm cross-over randomized control trial. At
enrollment, the patients were given a number from 1 to 2, randomly generated
using an Excel spreadsheet (RAND function), that corresponded to one of the trial
groups. Each group received one of the two products during each phase (AB/BA
sequence). Under direct observation, during 2 wk (10 working days), water ad
libitum and 250 g of one of the two products were offered to the patients as
a replacement of the midday meal, with the message “please, eat as much as you
wish.” An extra 50 g was available on request. A maximum of 2 h was allowed to
consume the product, and no leftovers could be taken away. After 2 wk (phase 1),
the study was interrupted for 7 d (washout period) and then resumed for two
more weeks (phase 2).
The professional background of the research staff included nursing, nutrition,
and counseling. No one worked for the MoH or MSF, and the staff worked in
a different study group each day, interviewing randomly assigned patients (ratio
of staff members and patients: 1:3). In-depth questionnaires and focus group
guidelines were provided in both English and the local language (Dholuo), after
being anonymously back-translated. The packaging concealed the product
identiﬁcation.Study procedure and outcomes
To consider RUTFh acceptable and safe, it had to fulﬁll the following criteria
and subcriteria for consumption, safety, and preference (Tables 3–5).
Criterion 1: Consumption
The consumption criterion consisted of three subcriteria. The subcriteria
“average consumption”was satisﬁed if average SMS-RUTFh intakewasmore than
75% (187.5 g) of the offered amount within 1 h (criterion 1.1; Table 3), whereas
SMS-RUTFh “daily consumption”was met if its intake was higher than 75% of the
offered food for more than 75% of the days on the trial (criterion 1.2). Finally, the
“comparative energy intake” criterion (1.3) was satisﬁed if the average energy
intake per kilogram of body weight was signiﬁcantly higher than 75% of the
energy intake from the P-RUTF.P-RUTF References
Peanut butter, milk powder,
sugar and oil, vitamin and
mineral premix
n.a.
y results Diop et al.(2003) UN reference for pediatric
RUTF (2007)
[19] [6]
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Table 2
Characteristics of the participants at the start of the study (day 1), unless spec-
iﬁed otherwise
Group
1 (n ¼ 20) 2 (n ¼ 21)
Females, n (%) 17 (85.0) 15 (71.4)
Age,* y 34 (29; 42) 30 (27; 35)
Marital status, n (%)
Currently married 10 (50.0) 12 (57.1)
Never been married 1 (5.0) 3 (14.3)
Previously married and
now widower
9 (45.0) 6 (28.6)
BMI at enrollment,* kg$m2 20.3 (18.9; 22.1) 19.9 (19.1; 21.8)
MUAC at enrollment,* mm 260 (229; 274) 266 (248; 280)
Diet Diversity Scorey 7.5 (6.9; 8.2) 7.3 (6.7; 7.9)
Participants who had tasted P-RUTF at
least once before the trial, n (%)
20 (100) 21 (100)
* Median and inter-quartile range (IQR).
y Medians and IQR of four measures over 2 wk, two consecutive days per week
(phase 2 of the trial).
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SMS-RUTFh was considered acceptable from the safety point of view if
participants did not report any of ﬁve comorbidity eventsmore frequently than in
the control product (criteria 2.1-2.5; Table 4). This parameter was expressed as
the mean number of days in which morbidity events occurred during product
consumption (10 d or less). Before the acceptability trial, microbiologic testing of
SMS-RUTFh was performed. The results were in conformity with the United
Nations speciﬁcations for such products [6].
Criterion 3: Preference
A product was considered preferred if its score was higher than the alter-
native in the following aspects: general preference, color, taste, sweetness, and
texture (criteria 3.1-3.5; Table 5). At the end of the trial, each participant was
asked to select the most preferred product (criterion 3.6), and two focus groups
were held to investigate participants’ experiences and perceptions that other
methods may not have captured.
Data collection
Quantitative data were collected daily and included body weight, height, and
middle upper-arm circumference (MUAC), weight of RUTF intake (Salter scale
M021, max 500  5 g), 24-h recall of nine clinical events, and individual eating
duration. Body weight, MUAC, and height were collected daily, weekly, and at
baseline, respectively. Individual interviews of all participants used a ﬁve-point
Likert scale (with lower scores representing greater liking of a RUTF) [26], held
to evaluate the preference for each product. Focus groups (30 to 40 min long)
used preselected lists of discussion themes and the facilitators followed awritten
manual. Discussions undertaken in the local language were digitally recorded
and transcribed into English, and twice a week, a diet diversity score (DDS)
questionnaire (0-12 items type [27]) recorded the foods consumed at home.
Management of adverse events
Patients reporting any of the ﬁve clinical events for more than three
consecutive days would have been immediately referred to the local clinic and
withdrawn from the study if the cause was considered to be related to RUTF
intake.Table 3




Average consumption, g$d1 (95%CI) 232.5 (218.9; 2
Daily consumption,k % (95%CI) 86.1 (78.8; 93
Comparative energy intake kJ intake$kg body wt1$d1 (95%CI) 94.9 (81.5; 10
* Least-square means and 95% conﬁdence intervals.
y P value between SMS-RUTFh and threshold.
z P value between P-RUTF and threshold.
x The threshold is 0.75 times the 250 g initially provided.
k Percentage of days with consumption higher than 75% of the provided amount (2
{ The thresholds are 0.75 times the P-RUTF ﬁgures.
Please cite this article in press as: Dibari F, et al., Development of a cr
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A pediatric acceptability cross-over trial on RUTF [28] involved a sample size
of 31 children, during 2 d of RUTF feeding, to detect a signiﬁcant difference with
a and b errors of 0.05 and 0.95. Its power calculation, based on of RUTF daily
intake, considered 1 SD an acceptable difference to be detected. However,
because previous research on RUTF acceptability was not available in adults,
the nature of our study was exploratory. For this reason, when compared to the
Indian pediatric study, the sample size (n ¼ 50 including dropouts) and the
number of feeding days (10 repeated measures/RUTF/individual) were both
increased, but limited by the available budget.
Statistical methods
Student’s t test and regression models were used to test for differences
between continuous data. TheWilcoxon rank-sum (Mann-Whitney) test and sign
test were used for non-normally distributed, unpaired, continuous data, whereas
the Wilcoxon matched-pairs signed-rank test was used for non-normally
distributed, paired continuous data, including the Likert scale ﬁve-item score.
The double-sided Fisher exact test was used to compare categorical data, and
odds ratios and conﬁdence intervals were calculated. A linear regression model
compared the energy intake of the two products after adjusting for potential
confounders, including clinical events, socioeconomic data, and anthropometry
at enrollment. Logistic regression models explored if the preference for a product
could be inﬂuenced by group membership. Analysis of ordinal score for prefer-
ence criteria was based on logistic (not ordinal) regression, after regrouping the
data into two categories (scores 1 and score 2, 3, 4, or 5 of 5). This was because of
the instability of themodel, due to too fewcases when cross-tabulating outcomes
and predictors. When applicable, regression models beneﬁtted from the robust
standard error approach [29], so that the participant’s series of repeated
measurements were considered as individual clusters. Absence of a carryover
effect was checked before treatment-effect analysis, following a method
described elsewhere [30]. Statistical comparisons were two-tailed, and all testing
was conducted at a ¼ 0.05, on per protocol data. EpiData version 3.1 software
(Copenhagen, Denmark) was used for data entry and data analysis was under-
taken using Stata IC v.10.
Ethical issues
This acceptability and safety trial was embedded into a larger research
program that had ethical approval granted by the Kenyan Medical Research
Institute and National Ethical Review Committee (SSC No.1414) to test the clinical
effectiveness of SMS-RUTFh.
Results
Characteristics of the participants
On June 30, 2008, the study staff enrolled 51 patients (Fig. 1)
into a 5-wk trial. Two patients were excluded because they lived
too far. Twenty-four and 25 participants were randomly allo-
cated into groups 1 and 2, respectively. During the ﬁrst phase of
the trial, eight patients defaulted for more than 3 d and were
excluded. Two of them stopped coming after the second day of
the trial for unknown reasons and could not be traced. Sixtion* P Valuey P Valuez
¼ 381) P-RUTF (n ¼ 398) Threshold
B
46.1) 243.0 (230.9; 255.0) 187.5x <0.001 <0.001
.4) 87.7 (81.4; 94.0) 75.0 <0.001 <0.001
8.3) 102.4 (96.0; 108.7) 76.8 (72.0; 81.4){ <0.001 <0.001
50 g).
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Table 4
Safety criteria using 24-h morbidity recall in combined groups (n1 ¼ 20; n2 ¼ 21)
Criteria Number of days* during which morbidity
events occurred
P value
SMS-RUTFh (n ¼ 381) P-RUTF (n ¼ 398)
A B
C2.1: Nausea 0.16 (0.05; 0.47) 0.09 (0.05; 0.14) 0.04
C2.2: Vomiting 0.04 (0.01; 0.19) 0.02 (0.01; 0.04) 0.03
C2.3: Stomach pain 0.14 (0.05; 0.38) 0.16 (0.10; 0.25) NS
C2.4: Flatulence 0.13 (0.05; 0.36) 0.16 (0.09; 0.26) NS
C2.5: Diarrhea 0.36 (0.03; 0.70) 0.31 (0.13; 0.49) NS
NS, non-signiﬁcant
* Least-square mean and 95% conﬁdence interval.
F. Dibari et al. / Nutrition xxx (2012) 1–64patients dropped out because of reasons not associated with
product intake (transfer, other commitments). Forty-one
patients successfully completed the study.
At admission, gender, marital status, BMI, and MUAC (Table 2)
in the two groups were statistically similar. The DDS did not
highlight any statistical signiﬁcant difference in terms of kinds of
food intake at household level, between the two groups. No
difference was detected between the 2 wk DDS, nor within the
sameweek for the same patients (Table 6). No carryover regarding
amount and daily energy intake was reported (P > 0.05).
Measurement of acceptability
Measurement of consumption
Both average and daily consumptionmeasurementswere above
the threshold (P < 0.001; Table 3) for SMS-TUTFh, conﬁrming that
all the patients consumed more than 75% of SMS-RUTFh within an
hour (criterion 1.1); that acceptable consumption occurred onmore
than 75% of the trial days (criterion 1.2); and that its energy intake
was higher than 75% of the P-RUTF intake in the two groups
combined (P < 0.001) (criterion 1.3).
A linear regression model (robust standard error, 40-cluster
analysis; R2¼ 0.11; P¼ 0.01; N¼ 779) showed that the difference
between the energy intakes of the two products (SMS-RUTFh and
P-RUTF) was not statistically signiﬁcant (P¼ 0.06) when adjusted
for confounders identiﬁed by a stepwise analysis (initial BMI,
negatively correlated with energy intake, P ¼ 0.002; presence of
throat sores, negatively correlated, P ¼ 0.13). Other potential
confounders, which showed no or very small inﬂuence in the
explored model and were not included, were age, and days ofTable 5
Criteria for food preference (Likert score type*; ﬁve items) in the two groups
(n1 ¼ 20; n2 ¼ 21), expressed on the last days of phase 1 and 2 of the trial
Criteria SMS-RUTFh (n ¼ 39) P-RUTF (n ¼ 41) P value
C3.1: General preference
Median (IQR) 1 (1; 2) 2 (2; 3) <0.001
Mean (95%CI) 1.4 (1.2; 1.5) 2.4 (2.1; 2.8)
C3.2: Color
Median (IQR) 2 (1; 3) 2 (1; 3) NS
Mean (95%CI) 2.0 (1.6; 2.4) 2.1 (1.7; 2.4)
C3.3: Taste
Median (IQR) 1 (1; 2) 3 (2; 4) <0.001
Mean (95%CI) 1.5 (1.3; 1.8) 2.7 (2.3; 3.1)
C3.4: Sweetness
Median (IQR) 1 (1; 2) 3 (2; 4) <0.001
Mean (95%CI) 1.7 (1.3; 2.0) 2.3 (2.5; 3.3)
C3.5: Texture
Median (IQR) 2 (1; 4) 2 (1; 2) 0.02
Mean (95%CI) 2.3 (1.8; 2.7) 1.7 (1.4; 1.9)
NS, non-signiﬁcant
* The scores range from 1 (very good) to 5 (very bad).
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Evaluation of possible morbidity effects
Most types of morbidity did not differ according to product
consumption (Table 4). Also, the average number of days with
reported nausea and vomiting in participants consuming SMS-
RUTFh was low (0.16 and 0.04 d of illness; 381 repeated daily
measures). However, when applying robust standard error
analysis, the data showed that these morbidities were signiﬁ-
cantly more frequent than when subjects were consuming
P-RUTF (0.09 and 0.02; 398 repeated measures; P ¼ 0.04 and
0.03). Nausea or vomiting never occurred for more than three
consecutive days.
Measurement of patient’s preference
Results from the fortnight interviews indicated higher scores
for general preference, taste, and sweetness for SMS-RUTFh (crite-
rion 3.1, 3.3, and 3.4; P< 0.001; Table 5), whereas no product was
preferred in termsof color (criterion 3.2). SMS-RUTFh texturewas
less preferred than the control (criterion 3.5; P ¼ 0.02).
On the last day of the trial, thewhole sample (n¼ 41) failed to
identify a ﬁnal preference (criterion 3.6) for a speciﬁc product
(P ¼ 0.8). SMS-RUTFh and P-RUTF were preferred, respectively,
by 52% (95%CI: 36; 69) and 48% (32; 64) of the participants.
However for most patients, the preferred product was the one
allocated to them in the ﬁrst phase of the trial. For participants
starting phase 1 with product A, the odds to prefer product A
were 5.4 times (95% CI, 1.4-20.4) higher than for participants
starting product A in phase 2 (P ¼ 0.02).
The two focus groups organized on the last day supported the
ﬁndings from the quantitative data and also suggested that
“SMS-RUTFh texture needed to be reﬁned,” whereas “P-RUTF
tasted salty” and “provoked more cases of ﬂatulence.” Moreover
the patients were “not happy about changing the product from
phase 1 to 2, once they had got accustomed to the ﬁrst provided
product” and felt that “the products were increasing weight” and
physical “strength,” “reducing hunger feelings.” No morbidity
event was mentioned during the focus groups.
Discussion
The present study demonstrated that most prestated criteria
for acceptability of a novel RUF were satisﬁed, conﬁrmed the
utility of the proposed method and, at the same time, illustrated
lessons that will contribute to improving future trials of a similar
kind.
The acceptability of SMS-RUTFh
The ﬁndings of this study suggest that, in this participant
group, SMS-RUTFh intake was adequate, and it was preferred in
some regard to the current standard product. The patients could
consume most of the trial product provided throughout the
study, exceeding the selected threshold for adequate energy
intake based on the control RUTF. Despite the higher (8%) energy
density of P-RUTF, the energy intakes of the two products were
statistically similar when adjusted for possible confounders, but
the study might be underpowered to highlight a difference.
Among the identiﬁed confounders, it can be speculated that
throat sores reduce the swallowing capacity of the patients. A
qualitative study on the compliance of the use of P-RUTF ach-
ieved a similar conclusion [23]. In SAM patients, cases of swal-
lowing difﬁculty need to be detected early by medical staff andoss-over randomized trial method to determine the acceptability
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Fig. 1. Flow chart of the participants through the trial.
F. Dibari et al. / Nutrition xxx (2012) 1–6 5ideally addressed with appropriate in-patient care using thera-
peutic milk formulas (F75 and F100) [31]. As soon as the swal-
lowing capacity is restored, generally in a few days, RUTF-based
nutrition can be started and home-based care established.
The regression analysis found no evidence of increased
morbidity associated with SMS-RUTFh consumption for most
parameters. Although the frequencies of nausea and vomiting
were higher in SMS-RUTFh than in the control product, they
never affected participants for a prolonged period, and days of
illness appeared to be scattered randomly along the time course
of the trial. The regression models showed that the two comor-
bidities were not associated with a decreased energy intake. This
suggests that the cause(s) might be due to chance or unknown
factors, and that these and other events need close monitoring
during the clinical trial.
The score for general preference was higher for SMS-RUTFh
and its taste and sweetness were also preferred. However, its
texture was less liked than P-RUTF, and this suggested the needTable 6
Diet diversity score* in phase 2 of the trial
Week 1 2
Tuesday Thursday Tuesday Thursday
Group 1 (n ¼ 19) 7.4 (6.5; 8.2) 7.7 (6.9; 8.5) 7.4 (6.5; 8.3) 7.6 (7.0; 8.2)
Group 2 (n ¼ 21) 7.8 (7.1; 8.5) 6.7 (5.9; 7.6) 7.7 (6.8; 8.6) 6.9 (6.7; 7.7)
Groups combined 7.6 (7.1; 8.1) 7.2 (6.6; 7.8) 7.6 (6.9; 8.2) 7.2 (6.7; 7.7)
* Mean (95% conﬁdence intervals).
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The order the RUTFs were offered to the participants was
important. SMS-RUTFh consumption increased or decreased,
according to whether it was provided as the ﬁrst or second
product. That might be because it was difﬁcult for participants to
adapt to a novel product once they are accustomed to the
previous one.
Some constraints were highlighted. The participants of the
trial were enrolled in the MoH/MSF HIV program and had all
been exposed to P-RUTF. Information of this kind, acquired
before direct experience, could have shaped the food consump-
tion and preferences as suggested elsewhere [32].
Lesson learned about the method
This study highlighted important aspects in the application of
methods to assess RUF acceptability. Among these, the results
conﬁrmed that a combination of both quantitative and qualita-
tive measures is needed to capture the complex of factors inﬂu-
encing acceptability. The carryover effect analysis, recommended
in cross-over studies [25], showed that the washout period
(1 wk) was adequate and might be reduced for future trials.
The sample size (n ¼ 41) compares favorably with an Indian
study, whose sample size was powered for a difference of at least
1 SD. Determining the equivalence or non-inferiority of SMS-RUTFh
to the current standard product, rather than its statistical superi-
ority to prestated thresholds, represents an alternative study design
used to validate robustly a novel therapy [33] but requires a largeoss-over randomized trial method to determine the acceptability
F. Dibari et al. / Nutrition xxx (2012) 1–66sample size [34]. Other randomized trials [3,18,28], comparing
RUTF with alternative food-based therapies, did not apply these
methods. It is also important to note that the method described
here is designed to be used in conducting an acceptability trial that
precedes a RCT of clinical efﬁcacy.
The study had some constraints. Ten days of RUTF intake, in
eachphase of our study,might havebeen too short to simulate the
nutrition rehabilitation therapy in wasted adults (3 mo; MSF/
Kenya, personal communication, 2008). ThemainuseofRUTF is in
outpatient and exclusive feeding programs. The study patients,
instead, had access to the RUTF during only one daily meal, far
from their households, while theywere observed by the research
staff.
For reasons explained elsewhere35, the SMS-RUTF did not
contain the micronutrients premix, which might alter the ﬁnal
taste of the product and the ﬁndings of the trial. A taste
comparison between RUTF with and without premix therefore
must be carried out to conﬁrm these acceptability results.Conclusion
Despite constraints, this exploratory study demonstrated the
utility of this method and the acceptability of a novel, locally
produced, RUTF. Its safety, mainly from the points of view of
nausea and vomiting, should be monitored carefully. Lessons
about the method were learned from the implementation of the
study and should contribute to improving future trials.Acknowledgments
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